Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients

ABSTRACT

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

FIELD OF THE INVENTION

This invention relates to methods and uses involving lipid levels topredict and prevent severe cardiovascular disease-associated fatalcomplications. The invention thus provides a means to identify and treathigh-risk coronary artery disease patients. The methods includeanalyzing lipid levels of a biological sample, and comparing it to acontrol.

BACKGROUND OF THE INVENTION

Worldwide, cardiovascular diseases (CVD) are among the leading causes ofmortality and morbidity with ever-increasing prevalence. CVD is used toclassify numerous conditions that affect the heart, heart valves, blood,and vasculature of the body. One of these conditions is coronary arterydisease (CAD). Early targeted initiation of preventive measures ofCVD-related fatal complications, such as acute myocardial infarction(AMI) and death, would be of great benefit and can provide a majoropportunity in reducing mortality and morbidity in patients sufferingfrom CVD. To this end, accurate identification of individuals who are atrisk of developing CVD complications is essential. However, traditionalrisk assessment fails to recognize a substantial proportion of patientsat high risk while a large proportion of individuals are classified ashaving intermediate risk, leaving patient management uncertain.Additional strategies to further refine risk assessment of high-risk CVDare therefore highly needed. To this end, the inventors have evaluatedthe role of novel lipidomic biomarkers as a prognostic tool for fatalcardiovascular events in CVD patients.

Plasma or serum total cholesterol, LDL-cholesterol or HDL-cholesterolconcentrations have been used as gold standard biomarkers for CVD/CADrisk prediction. However, a number of coronary artery disease (CAD) oracute myocardial infarction (AMI) patients have LDL-C levels within therecommended range suggesting the need for additional diagnostic measuresof the residual risk. It is evident from earlier large scale populationstudies that these measurements associate with the CAD risk and CADendpoints such as AMI or cardiovascular death. Therefore, preventivetreatment strategies have so far been addressed to lower LDL-Cconcentrations (mainly by statin treatment) and more recently alsoattempts to raise HDL-C have been made (e.g., by CETP-inhibitors). Onthe other hand, it has also been observed that one half of the AMIpatients actually do have normal LDL cholesterol levels and that thereis a substantial residual risk in statin treated patients despite aLDL-C lowering. Furthermore, recent publications have demonstrated thatplasma levels of apolipoprotein B (apoB), the main surface protein onLDL particles, and LDL-C, the amount of cholesterol in those particles,are correlated and, considered separately, as positive risk factors.Plasma levels of apolipoprotein A₁, the main surface protein on HDLparticles, and HDL-C, the amount of cholesterol in those particles, arealso correlated with each other and, considered separately, as negativerisk factors. Importantly, for a given usual apoB, lower LDL-C has beenobserved to associate with a higher risk of AMI supporting the viewthat, on average, LDL particles with low cholesterol content perparticle (small, dense LDL particles) are particularly hazardous. Thus,it seems possible that LDL-C associates directly with the more dangerousmolecules carried by LDL-particle and that LDL-C is only an indirectmeasurement of the risk. Therefore, it is of importance to search formolecules e.g., certain lipid species that are directly related withhazardous (i.e., fatal) cardiovascular events.

Lipid metabolite imbalance is a probable cause of dyslipidemia and theensuing atherosclerosis manifested in its gravest form as the vulnerableatherosclerotic plaque. Atherosclerotic plaques are complex molecularformations that contain numerous lipids. However, there are otherfactors than lipid rich plaques or LDL cholesterol that make lipids anattractive group of molecules for CVD studies. Lipids are tightlyregulated which makes Lipidomic data robust and informative on thecurrent state of the studied organism. Also, lipids are one of theculmination points of a biological system, more the true outcome thanthe predictor. Combining Lipidomic data with appropriate biobankedclinical material presents a good opportunity for biomarker discovery.Moreover, lipidomics can be used as a gauge of efficacy and safety indrug development and evolving theragnostics. Lipidomic biomarkers areprime candidates for true companion diagnostics in the CVD area andpresent many opportunities for improved translational medicine as well.

The plaque building blocks and lipoprotein components that are thoughtto traffic lipids to the site of lesion formation can now be resolvedwith Lipidomic studies correlating lipid structure and composition tofunction and thereby disease pathogenesis. While the number of lipidmediators in the human body is overwhelming, their identification andquantification is facilitated by the advances in mass spectrometry andlipid biochemistry, which today enable the simultaneous high throughputidentification and quantification of hundreds of molecular lipid speciesin several lipid classes (Ejsing C S, et al: Global analysis of theyeast lipidome by quantitative shotgun mass spectrometry. Proc Natl AcadSci USA 2009, 106:2136-2141; Stahlman M, et al: High-throughput shotgunlipidomics by quadrupole time-of-flight mass spectrometry. J ChromatogrB Analyt Technol Biomed Life Sci 2009 Hiukka A, et al: ApoCIII-enrichedLDL in type 2 diabetes displays altered lipid composition, increasedsusceptibility for sphingomyelinase, and increased binding to biglycan.Diabetes 2009, 58:2018-2026; Linden D, et al: Liver-directedoverexpression of mitochondrial glycerol-3-phosphate acyltransferaseresults in hepatic steatosis, increased triacylglycerol secretion andreduced fatty acid oxidation. FASEB J2006, 20:434-443.) collectivelyreferred to as the lipidome. Lipidomic studies identify lipid cellulardistribution and describe their biochemical mechanisms, interactions anddynamics. Importantly, lipidomics quantifies the exact chemicalcomposition of lipidomes (Han X, Gross R W: Global analyses of cellularlipidomes directly from crude extracts of biological samples by ESI massspectrometry: a bridge to lipidomics. J Lipid Res 2003, 44:1071-1079).

Due to both high sensitivity and selectivity of lipidomics, even thesmallest sample amounts can be analyzed today. The bulk of the lipiddata in the art today presents lipids in a sum composition format, i.e.phosphatidylcholine (PC) 34:1 (Brugger B, et al: Quantitative analysisof biological membrane lipids at the low picomole level bynano-electrospray ionization tandem mass spectrometry. Proc Natl AcadSci USA 1997, 94:2339-2344) where the molecular lipid and the attachedfatty acid tails remain unidentified. The identification of molecularlipid species, e.g., PC 16:0/18:1 (Ekroos K, et al: Charting molecularcomposition of phosphatidylcholines by fatty acid scanning and ion trapMS3 fragmentation. J Lipid Res 2003, 44:2181-2192) is the main featureof advanced lipidomics, which delivers highly resolved molecular lipidspecies rather than summed fatty acid information. For example, theinformation of the type of fatty acids and their positions of attachmentto the glycerol backbone making up the particular PC molecule isrevealed. There are conventional techniques such as thin-layerchromatography combined with gas chromatography but they not onlyrequire considerably larger sample amounts and laborious samplepreparation, but they do not deliver the molecular lipid species.Despite multiple mass spectrometry techniques capable of characterizinglipid entities, most of them are still unable to deliver reliablehigh-quality quantitative data in terms of absolute or close-to absoluteconcentrations. In the context of the present invention, electrosprayionization mass spectrometry-based lipidomics is the preferredtechnology and can utilize both shotgun and targeted lipidomics forexhaustive deciphering and precise quantification of molecularlipidomes. The superior quality and specificity of shotgun and targetedlipidomics will meet stringent regulatory standards, such as goodlaboratory practice guidelines (GLP) when set-up in the properenvironment. Using these technologies quantification of up to twothousand molecular lipids is possible even in a high throughput format.

Lipidomics is a tool for differentiating patients based on theirmolecular lipid profiles. Personalized medicine and diagnostics enabledby lipidomics will facilitate the mission of the right individualreceiving the right drug at the right time and dose. Several worksemploying analytes consisting of lipids, proteins and hydrophilicmolecules among many others have been conducted to meet the needs ofpersonalized medicine. Recently, non-hypothesis-driven metabolomicscreenings have been used to identify novel CVD biomarkers.

For example, WO2004/038381 discloses a method for metabolomicallyfacilitating the diagnosis of a disease state of a subject, or forpredicting whether a subject is predisposed to having a disease statewherein the small molecule profile from a subject is obtained andcompared to a standard small molecule profile.

WO2008/148857 discloses a method to assess the risk of cardiovasculardisease in a patient (including atherosclerosis) by isolating the HDLfraction and sub-fraction from a blood sample of the patient. Thecomponents of the HDL fraction or sub-fraction to be measured wereSphingosine-1-Phosphate (SIP), sphingomyelin (SM) and Apolipoprotein A-I(apoA-1).

WO2008/11943 further discloses markers for detecting coronary arterydisease that can indicate a patient at risk of having or developingcoronary artery disease. These include 15 “first-choice” molecules whichwere: C18:3 Cholesterol ester, C32:1 Phosphatidylcholine, Alanine, Lipid(mainly VLDL), Lysine, Hexadecanoic acid, C36:2 Phosphatidylcholine,Formate, C32:2 Phosphatidylcholine, C18:2 (Linoleic Acid), Cholesterol,C 18:2 Lyso-phosphatidylcholine, C36:3 Phosphatidylcholine, C34:4Phosphatidylcholine and C34:3 Phosphatidylcholine.

Furthermore, US2007/0099242 describes a method to determine if a subjectis at risk to develop, or is suffering from cardiovascular disease. Themethod involves determining a change in the amount of a biomarker in thebiological sample or HDL sub-fraction thereof, compared to a controlsample, wherein the biomarker is at least one of Apolipoprotein C-IV(“ApoC-IV”), Paraoxonase 1 (“PON-1”), Complement Factor 3 (“C3”),Apolipoprotein A-IV (“ApoA-IV”), Apolipoprotein E (“ApoE”),Apolipoprotein LI (“ApoL1”), Complement Factor C4 (“C4”), ComplementFactor C4B1 (“C4B1”), Histone H2A, Apolipoprotein C-II (“ApoC-II”),Apolipoprotein M (“ApoM”), Vitronectin, Haptoglobin-related Protein andClusterin. The document also discloses a method for detecting thepresence of one or more atherosclerotic lesions wherein a change in theamount of a biomarker in the biological sample or HDL sub-fractionthereof is detected, compared to a control sample and wherein thebiomarker is selected from PON-1, C3, C4, ApoE, ApoM and C4B1. Allbiomarkers mentioned in this document are protein or lipoproteinbiomarkers.

From previous work it cannot be extrapolated that lipid analysis willyield by default a CVD biomarker predictive to the fatal outcomesassociated with CVD/CAD. The present invention identifies biomarkers ofhigh risk CVD by absolute, or close to absolute, quantification ofdefined molecular lipid species instead of profiling multiple analytesImportantly, while many of the existing biomarker candidates arecomposite fingerprints of multiple factors, the lipidomics approachherein shows value already at a level of single species or ratiosthereof.

In the present invention herein, lipid biomarker concentrations havebeen measured and quantified in patients with documented CAD who did notshow fatal outcomes during the follow-up period (3 years) and inhigh-risk CAD patients who died due to cardiovascular events during thefollow-up period. This invention thus enables accurate usage of thelipid-based biomarkers to identify high risk CVD/CAD patients. Anotherlayer of accuracy was reached through a careful patient selection sinceit is important to control for factors which may affect the lipidconcentration read-outs. Unlike the previous efforts described above, weused specific targeted platforms on a singular technology set-up toanalyze lipid species in particular.

The technology and the way it was applied in the context of theinventive teaching presented herein is set apart from similar efforts inthe field inter alia due to the following criteria. In samplepreparation, samples are strictly controlled and treated identically toavoid potential artifacts that could arise from improper handling. Inconnection with the present invention, samples were carefully thawedslowly on ice and directly thereafter subjected to a custom-madeautomated lipid extraction which possesses currently the highestprecision in liquid handling, therefore minimizing potential errors.Furthermore, sample freeze-thaw cycles were strictly controlled sincethis can dramatically affect the lipid stabilities. The automated lipidextraction is based on the method by Folch and colleagues (Folch J, etal: A simple method for the isolation and purification of total lipidsfrom animal tissues. J Biol Chem 1957, 226(1):497-509) which useschloroform and methanol. This method is preferred when a wide range,from polar to non-polar, of lipid classes are to be extracted withoptimal recoveries thus preventing the loss of lipid species. Lipidclass specific non-endogenous lipids, when applicable, were used asinternal standards to gain highest precision in identification(minimizing false positives) and quantification of monitored molecularlipid species. In this way absolute or semi-absolute amounts ofendogenous molecular lipids were determined with the highest precisionthat can be achieved with today's technologies. The endogenous lipidsand respective standards were monitored at the molecular lipid level. Inthis way, not only false positive identifications were minimized, butmolecular lipids could be precisely determined and quantified. Analysisquality was strictly controlled using a novel quality control system.This was mainly controlled by multiple internal standards (IS), externalstandards (ES), IS/ES ratios, and instrument control samples. Bystringently controlling these components, technical and biologicaloutliers were readily identified and rejected from further analysis. Toobtain best precision in sensitivity, selectivity and quantification foreach molecular lipid different targeted platforms were used. Some lipidsare best analyzed using high performance liquid chromatography (HPLC) orultra high performance liquid chromatography (UHPLC) combined with massspectrometry based multiple reaction monitoring (MRM) whereas others arebest analyzed by direct infusion in combination with massspectrometry-based precursor ion scanning and neutral loss scanningtechniques.

SUMMARY OF THE INVENTION

The present invention provides novel lipidomic markers for predictingand preventing severe CVD/CAD-associated complications, including AMIand death. These markers thus provide a means to identify and treathigh-risk coronary artery disease patients. Specifically, it has beenfound that the lipid molecules, lipid-lipid ratios and lipid-clinicalconcentration ratios provided herein, when displaying an increased ordecreased level—as the case may be—in samples from CAD patients, areuseful lipidomic markers for the methods and uses in accordance with thepresent invention. These sensitive and specific markers werespecifically tested to display superior diagnostic and prognostic valuecompared to the current clinically-used markers predictive for CVD/CADoutcomes. In fact, the currently available biomarkers such as LDL-C orHDL-C have only very limited or no value in predicting the CVD deathrisk in CAD patients. The present invention therefore represents asignificant advantage to other markers which are currently used todiagnose and/or predict CVD and CVD complications, which include LDL-C,total plasma/serum cholesterol and Apolipoprotein B and Al. Thus, thelipidomic markers provided herein allow better diagnosis of orassessment of the risk to develop major CVD complications such as AMI orCVD death.

In accordance with the present invention, methods are inter aliadisclosed herein for determining the risk of a patient to develop CVDcomplications, determining warning signs of CVD risks, (including death,myocardial infarction (MI), angina pectoris, transischemic attack (TIA)and stroke) in said patient.

Methods according to the invention typically comprise the steps of: a)providing a biological sample from a CAD subject; b) determining a lipidconcentration, lipid-lipid ratio, or lipid-clinical concentration ratioor (a) corresponding profile(s) from said sample (i.e., determininginformation on a lipidomic marker in accordance with the invention); andc) comparing said determined lipid concentration, lipid-lipid ratio, orlipid-clinical concentration ratio or said corresponding profile(s) tothe corresponding lipid concentration, lipid-lipid ratio, orlipid-clinical concentration ratio or the corresponding profile(s) in acontrol.

The control may be a sample from (a) CAD patient(s) with no history ofmajor CVD events. It may also be a sample that represents a combinationof samples from a CAD patient population with no history of major CVDevents. Alternatively, the control may be a set of data concerning alipidomic marker in accordance with the present invention, e.g.,information on the concentration of (a) lipid(s), lipid-lipid ratio(s),or lipid-clinical concentration ratio(s) in accordance with the presentinvention in a sample when taken from (a) CAD patient(s) with no historyof major CVD events, or in a combination of samples taken from a CADpatient population with no history of major CVD events. Saidinformation, and thus the corresponding set of data, may have beenpreviously determined, calculated or extrapolated, or may have yet to bedetermined, calculated or extrapolated, or may also be taken from theliterature.

As mentioned above, the lipidomic marker to be compared between thesubject sample and the control (or control sample) may be one or more ofthe lipid concentration(s), lipid-lipid ratio(s), or lipid-clinicalconcentration ratio(s) or combinations thereof, i.e., the correspondingprofile(s), as described and claimed herein. In this regard, the controlor control sample allows establishment of the lipidomic marker baselineor starting point.

In connection with all aspects and embodiments of the inventiondescribed and claimed herein, the determination of the lipidconcentration(s), the lipid-lipid ratio(s) or the lipid-clinicalconcentration ratio(s) is typically performed using an assay. Collectinginformation on a lipidomic marker (i.e., the concentration(s) of (a)lipid(s), lipid-lipid ratio(s), or lipid-clinical concentration ratio(s)or combinations thereof, i.e., corresponding profile(s)) from the sampleof a patient and, where appropriate, a corresponding control sample, canbe performed with various chemical and high-resolution analyticaltechniques. Suitable analytical techniques include, but are not limitedto, mass spectrometry and nuclear resonance spectroscopy. Anyhigh-resolution technique capable of resolving individual lipids orlipid classes and providing structural information of the same can beused to collect the information on the lipidomic marker in question,e.g., lipid profile from the biological sample. Collecting theinformation on the lipidomic marker with mass spectrometry (MS) is oneof the preferred embodiments of the current invention. The MS instrumentcan be coupled to a direct sample infusion method, such as a roboticnanoflow ion source device, or to a high performance separation methodsuch as high performance liquid chromatography (HPLC) or ultraperformance liquid chromatography (UPLC).

Again in accordance with all aspects and embodiments described andclaimed herein, both the sample from the subject and the control sampleis preferably a blood sample, more preferably a blood plasma sample, oralso preferably a blood serum sample. It may also be a fraction ofblood, blood plasma or blood serum, e.g., a lipoprotein fraction. Ablood sample can be prepared and plasma or serum, or fractions thereof,can be separated therefrom with techniques well known to the personskilled in the art. Alternatively, both the sample from the subject andthe control sample may also be a tissue sample, e.g., artery tissue,such as carotid artery tissue, or artery plaque material, such ascarotid artery plaque material.

The lipidomic markers of the present invention allow for prediction andprevention of fatal CVD complications. This will facilitate earlierintervention, less symptom development and suffering and decreasedmorbidity/mortality associated with CVD. Thus, the lipidomic markersdescribed and claimed herein allow for individual tailoring of drugintervention for patients being at risk to develop major CVDcomplications.

In other words, the present invention discloses diagnostic and/orpredictive lipid markers and lipid-lipid or lipid-clinical concentrationratios for use in predicting CVD complications such as AMI or CVD death.The invention uses the measurement of lipid concentrations, lipid-lipidand/or lipid-clinical concentration ratios to determine the risk of saidsubject to develop CVD complications such as AMI and/or CVD death. Thesubject may have previously suffered from a cardiovascular disease eventsuch as angina pectoris, myocardial infarction or stroke. The CVD may ormay not be a result of atherosclerosis.

Claim 1 (note claims only have preferred embodiments) Accordingly, inone aspect of the invention, a method is provided for determiningwhether a subject is at risk to develop one or more CVD complications,such as AMI or CVD death, said method comprising determining in a samplefrom said subject the concentration(s) of one or more lipid(s), wherein(an) increased or decreased concentration(s) in said sample, whencompared to a control sample, is (are) indicative of said subject havingan increased risk of developing one or more CVD complications, such asAMI or CVD death, wherein the one or more lipid(s) whose increase(s) inconcentration is (are) compared to the control is (are) selected from(Tables 4a and 7a):

Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/24:1), GlcCer(d18:1/18:0),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), PC O-32:0 (KDdiA-PC), PS O-16:0/18:2-alkenyl, PSO-16:1/18:2-alkyl, PS O-18:0/18:2-alkenyl (PS O-18:1/18:2-alkyl), PSO-18:2/16:0-alkenyl and Total LacCer; and wherein the one or morelipid(s) whose decrease(s) in concentration is (are) compared to thecontrol is (are) selected from (Tables 4a and 7a):CE 14:0, CE 16:0, CE 17:1, CE 20:3, Cer(d18:0/22:0), Cer(d18:0/24:0),LPC 18:1, PC 16:0/18:2, PC 16:0/20:3, PC 16:0/20:4, PC 16:0/22:6, PC18:0/18:1, PC 18:0/20:3, PC 18:0/20:4, PC 18:1/18:2, SM (d18:1/14:0)(d18:1/13:1-OH), SM (d18:1/23:0) (d18:1/22:1-OH), SM (d18:1/24:0)(d18:1/23:1-OH), Total CE, Total LPC and Total PC.

In a particular embodiment, a method is provided for determining whethera subject is at risk to develop one or more CVD complications, such asAMI or CVD death, wherein the subject is not undergoing statin treatmentand wherein said method comprises determining in a sample from saidsubject the concentration(s) of one or more lipid(s), wherein (an)increased or decreased concentration(s) in said sample, when compared toa control sample, is (are) indicative of said subject having anincreased risk of developing one or more CVD complications, such as AMIor CVD death, and wherein the one or more lipid(s) whose increase inconcentration is (are) compared to the control is (are) selected from(Tables 4b and 7b):

Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0),Cer(d18:1/24:1), Cer(d18:1/26:1), GlcCer(d18:1/18:0),GlcCer(d18:1/20:0), GlcCer(d18:1/24:1), GlcCer(d18:1/26:1),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), LacCer(d18:1/24:1), PC O-32:0 (KDdiA-PC), PSO-16:0/18:2-alkenyl, PS O-16:1/18:2-alkyl, PS O-18:2/16:0-alkenyl, TotalCer, Total DAG and Total LacCer;and wherein the one or more lipid(s) whose decrease(s) in concentrationis (are) compared to the control is (are) selected from (Tables 4b and7b):

CE 14:0, CE 17:1, CE 20:3, Cer(d18:0/24:0), LPC 18:1, PC 16:0/20:3, PC16:0/20:4, PC 18:0/20:4, PC O-40:3, SM (d18:1/14:0) (d18:1/13:1-OH),Total LPC and Total PC.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid(s) whoseincrease(s) in concentration is (are) compared to the control is (are)selected from (Table 10):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), PS O-18:2/16:0-alkenyl, PS O-16:1/18:2-alkyl, TotalCer, Total LacCer, GlcCer(d18:1/24:1), LacCer(d18:1/22:0) andCer(d18:1/18:0).

In another preferred embodiment, the one or more lipid(s) whosedecrease(s) in concentration is (are) compared to the control is (are)selected from (Table 10):

Total PC, PC 16:0/20:4, Cer(d18:0/24:0), Total LPC, CE 14:0, CE 20:3, CE17:1, PC 16:0/20:3, LPC 18:1, PC 18:0/20:3, PC 18:0/18:1 andCer(d18:0/22:0).

In a particularly preferred embodiment, the one or more lipid(s) whoseincrease(s) in concentration is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), LacCer(d18:1/22:0) and Cer(d18:1/18:0).

In another particularly preferred embodiment, the one or more lipid(s)whose decrease(s) in concentration is (are) compared to the control is(are) selected from (Table 13):

PC 16:0/20:4 and Cer(d18:0/24:0).

In an alternative embodiment, the present invention relates to a methodfor determining whether a subject is at risk to develop one or morecomplications such as AMI or CVD death, comprising determining in asample from said subject one or more lipid-lipid ratio(s), wherein (an)increased or decreased lipid-lipid ratio(s) in said sample, whencompared to a control sample, is (are) indicative of said subject havingan increased risk of developing one or more CVD complications, such asAMI or CVD death, wherein the one or more lipid-lipid ratio(s) whoseincrease(s) is (are) compared to the control is (are) selected from(Tables 5a and 8a):

CE 16:0/CE 18:3, CE 18:2/CE 18:3, CE 19:1/Cer(d18:0/22:0),Cer(d18:1/16:0)/LPC 18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC16:0, Cer(d18:1/18:0)/LPC 18:1, Cer(d18:1/18:0)/PC 16:0/18:1,Cer(d18:1/18:0)/PC 16:0/20:3, Cer(d18:1/18:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/Total LPC,Cer(d18:1/18:0)/Total PC, Cer(d18:1/20:0)/PC 16:0/18:1,Cer(d18:1/20:0)/PC 16:0/20:3, Cer(d18:1/20:0)/PC 16:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/Total PC, Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC16:0/20:3, Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/Total PC,Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC 18:2, Cer(d18:1/24:1)/PC16:0/18:1, Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/20:3,Cer(d18:1/24:1)/PC 18:0/20:4, Cer(d18:1/24:1)/SM (d18:1/24:0)(d18:1/23:1-OH), Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, Cer(d18:1/26:0)/PC O-40:0,GlcCer(d18:1/20:0)/PC 16:0/20:4, GlcCer(d18:1/20:0)/Total PC,GlcCer(d18:1/26:0)/Total CE, LacCer(d18:1/16:0)/Total LPC,LacCer(d18:1/18:0)/PC 16:0/18:1, LacCer(d18:1/18:0)/PC 16:0/20:3,LacCer(d18:1/18:0)/PC 18:0/18:1, LacCer(d18:1/18:0)/PC 18:0/20:3,LacCer(d18:1/18:0)/PC 18:1/18:1, LacCer(d18:1/18:0)/PC 18:1/18:2,LacCer(d18:1/18:0)/Total LPC, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/18:1, LacCer(d18:1/20:0)/PC 16:0/20:3,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3LacCer(d18:1/20:0)/PC 18:1/18:1, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/PC 18:2/18:2, LacCer(d18:1/20:0)/SM (d18:1/17:1-OH),LacCer(d18:1/20:0)/SM (d18:1/18:0), LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/22:0)/PC 16:0/20:3, LacCer(d18:1/22:0)/PC 16:0/20:4,LacCer(d18:1/22:0)/PC 18:0/20:3, LacCer(d18:1/22:0)/SM (d18:1/14:0)(d18:1/13:1-OH), LacCer(d18:1/22:0)/Total LPC, LacCer(d18:1/22:0)/TotalPC, LacCer(d18:1/24:0)/PC 16:0/20:3, LacCer(d18:1/24:0)/Total LPC,LacCer(d18:1/24:1)/Total LPC, LacCer(d18:1/24:1)/Total PC,LacCer(d18:1/24:1)/Total PC O, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC 16:0/18:2/Total PC, PC O-18:0/18:2-alkyl/PCO-36:5, PC O-32:0 (KDdiA-PC)/PC O-38:5, PS O-16:0/18:2-alkenyl/Total PSO, PS O-16:1/18:2-alkyl/Total PS O, PS O-18:0/18:2-alkenyl (PSO-18:1/18:2-alkyl)/Total PS O, PS O-18:2/16:0-alkenyl/Total PS O, TotalCer/Total PC, Total LacCer/Total PC and Total LacCer/Total PC O;and wherein the one or more lipid-lipid ratio(s) whose decrease(s) is(are) compared to the control is (are) selected from (Tables 5a and 8a):CE 14:0/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1), CE 16:1/CE 19:1, CE16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1),CE 16:1/GlcCer(d18:1/18:0), CE 16:1/GlcCer(d18:1/20:0), CE16:1/LacCer(d18:1/16:0), CE 16:1/LacCer(d18:1/18:0), CE16:1/LacCer(d18:1/20:0), CE 16:1/LacCer(d18:1/22:0), CE16:1/LacCer(d18:1/24:0), CE 16:1/PC 16:0/16:0, CE 16:1/Total LacCer, CE17:1/Cer(d18:1/24:1), CE 17:1/GlcCer(d18:1/24:1), CE17:1/LacCer(d18:1/18:0), CE 18:1/Total LacCer, CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/18:0), CE 18:3/GlcCer(d18:1/20:0), CE18:3/LacCer(d18:1/18:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:1-alkenyl (PSO-16:1/18:1-alkyl), CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalLacCer, CE 20:3/Cer(d18:1/24:1), CE 20:3/LacCer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/18:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/PSO-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl,Cer(d18:0/22:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/Cer(d18:1/20:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/GlcCer(d18:1/20:0), Cer(d18:0/24:0)/LacCer(d18:1/24:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/24:0)/SM (d18:1/17:0) (d18:1/16:1-OH),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Total Cer,Cer(d18:0/24:1)/Total CE, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0),GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/20:0), LPC16:0/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/24:1), LPC 16:0/TotalLacCer, LPC 18:1/LacCer(d18:1/20:0), LPC 18:2/LacCer(d18:1/20:0), LPC18:2/PS O-16:0/18:2-alkenyl, LPC 18:2/PS O-16:1/18:2-alkyl, PC16:0/20:3/PS O-16:0/18:2-alkenyl, PC 16:0/20:3/PS O-16:1/18:2-alkyl, PC18:1/18:2/PS O-16:0/18:2-alkenyl, PC 18:1/18:2/PS O-16:1/18:2-alkyl, SM(d18:1/24:0) (d18:1/23:1-OH)/Total Cer and Total LPC/Total LacCer.

In an alternative embodiment, the present invention relates to a methodfor determining whether a subject is at risk to develop one or morecomplications such as AMI or CVD death, wherein the subject is notundergoing statin treatment and wherein said method comprisesdetermining in a sample from said subject one or more lipid-lipidratio(s), wherein (an) increased or decreased lipid-lipid ratio(s) insaid sample, when compared to a control sample, is (are) indicative ofsaid subject having an increased risk of developing one or more CVDcomplications, such as AMI or CVD death, wherein the one or morelipid-lipid ratio(s) whose increase(s) is (are) compared to the controlis (are) selected from (Tables 5b and 8b):

CE 16:0/CE 18:3, CE 18:0/CE 18:3, CE 18:2/CE 18:3, Cer(d18:1/16:0)/LPC18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/PC 16:0/18:1, Cer(d18:1/18:0)/PC 16:0/20:3,Cer(d18:1/18:0)/PC 16:0/20:4, Cer(d18:1/18:0)/PC 18:0/18:1,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/PC 18:1/18:1,Cer(d18:1/18:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/18:0)/SM(d18:1/17:2-OH), Cer(d18:1/18:0)/SM (d18:1/18:1), Cer(d18:1/18:0)/TotalCE, Cer(d18:1/18:0)/Total LPC, Cer(d18:1/18:0)/Total PC,Cer(d18:1/20:0)/PC 16:0/18:1, Cer(d18:1/20:0)/PC 16:0/20:3,Cer(d18:1/20:0)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 18:0/18:1,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/20:0)/TotalLPC, Cer(d18:1/20:0)/Total PC, Cer(d18:1/20:0)/Total PC O,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC 16:0/20:3,Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/22:0)/Total PC, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/PC 16:0/18:1, Cer(d18:1/24:1)/PC 16:0/18:2,Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/18:2,Cer(d18:1/24:1)/PC 18:0/20:3, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/24:1)/PC 18:1/18:1, Cer(d18:1/24:1)/PC 18:1/18:2,Cer(d18:1/24:1)/PC O-40:3, Cer(d18:1/24:1)/SM (d18:1/17:1-OH),Cer(d18:1/24:1)/SM (d18:1/18:0), Cer(d18:1/24:1)/SM (d18:1/23:0)(d18:1/22:1-OH), Cer(d18:1/24:1)/SM (d18:1124:0) (d18:1/23:1-OH),Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, GlcCer(d18:1/26:0)/Total CE,GlcCer(d18:1/26:1)/Total CE, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/20:3, LacCer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3,LacCer(d18:1/20:0)/PC 18:0/20:4, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/SM (d18:1/17:1-OH), LacCer(d18:1/20:0)/SM(d18:1/18:0), LacCer(d18:1/20:0)/Total CE, LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/24:0)/Total LPC, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC O-32:0 (KDdiA-PC)/Total PC O, PSO-16:0/18:2-alkenyl/Total PC, PS O-16:0/18:2-alkenyl/Total PC O, PSO-16:0/18:2-alkenyl/Total PS O, PS O-16:1/18:2-alkyl/Total PC, PSO-16:1/18:2-alkyl/Total PC O, PS O-16:1/18:2-alkyl/Total PS O, PSO-18:2116:0-alkenyl/Total PC O, PS O-18:2/16:0-alkenyl/Total PS O, SM(d18:1/17:0) (d18:1/16:1-OH)/Total PC O, Total Cer/Total PC, TotalDAG/Total LPC, Total DAG/Total PC, Total DAG/Total PC O and TotalLacCer/Total PC;and wherein the one or more lipid-lipid ratio(s) whose decrease(s) is(are) compared to the control is (are) selected from (Tables 5b and 8b):CE 14:0/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/24:1), CE 14:0/Total DAG, CE15:0/Cer(d18:1/20:0), CE 16:0/Cer(d18:1/18:0), CE 16:0/Cer(d18:1/24:1),CE 16:1/CE 19:1, CE 16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE16:1/Cer(d18:1/24:1), CE 16:1/GlcCer(d18:1/24:1), CE16:1/LacCer(d18:1/18:0), CE 16:1/LacCer(d18:1/24:0), CE 16:1/TotalLacCer, CE 17:1/Cer(d18:1/18:0), CE 17:1/Cer(d18:1/24:1), CE18:2/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/20:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalDAG, CE 18:3/Total LacCer, CE 20:3/Cer(d18:1/24:1), CE20:3/LacCer(d18:1/20:0), CE 20:4/Cer(d18:1/18:0), CE20:4/Cer(d18:1/24:1), CE 20:4/GlcCer(d18:1/20:0), CE20:4/GlcCer(d18:1/24:1), CE 20:4/LacCer(d18:1/20:0), CE20:5/LacCer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/22:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/22:0)/Total CE, Cer(d18:0/22:0)/Total DAG,Cer(d18:0/22:0)/Total GlcCer, Cer(d18:0/24:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/Cer(d18:1/20:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Total Cer,DAG 16:0/18:1/Total DAG, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), LPC16:0/LacCer(d18:1/24:0), LPC 18:1/LacCer(d18:1/20:0), LPC18:2/LacCer(d18:1/20:0), PC 16:0/20:3/PS O-16:0/18:2-alkenyl, PC16:0/20:3/PS O-16:1/18:2-alkyl, PC 16:0/20:4/PS O-16:0/18:2-alkenyl, PC16:0/20:4/PS O-16:1/18:2-alkyl, PC 16:0/20:4/Total DAG, PC 18:0/20:3/PSO-16:0/18:2-alkenyl, PC 18:0/20:3/PS O-16:1/18:2-alkyl, PC 18:0/20:3/PSO-18:2/16:0-alkenyl, PC 18:0/20:4/PS O-16:0/18:2-alkenyl, PC18:0/20:4/PS O-16:1/18:2-alkyl, PC 18:1/18:2/PS O-16:0/18:2-alkenyl, PC18:1/18:2/PS O-16:1/18:2-alkyl, PC 18:1/18:2/Total Cer, PC O-40:3/PSO-18:2/16:0-alkenyl, SM (d18:1/23:0) (d18:1/22:1-OH)/Total DAG, SM(d18:1/24:0) (d18:1/23:1-OH)/Total Cer, Total CE/Total DAG and TotalLPC/Total LacCer.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-lipid ratio(s)whose increase is (are) compared to the control is (are) selected from(Table 11):

GlcCer(d18:1/26:1)/Total CE, Cer(d18:1/24:1)/Total PC,Cer(d18:1/24:1)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 16:0/20:3, Total Cer/Total PC, Total LacCer/TotalPC, LacCer(d18:1/20:0)/PC 18:1/18:2, PS O-16:0/18:2-alkenyl/Total PS O,Cer(d18:1/18:0)/PC 16:0/20:4, LacCer(d18:1/20:0)/Total LPC andLacCer(d18:1/20:0)/PC 16:0/20:4;

In another preferred embodiment, the one or more lipid-lipid ratio(s)whose decrease is (are) compared to the control is (are) selected from(Table 11):

Cer(d18:0/24:0)/Cer(d18:1/24:1), Cer(d18:0/22:0)/Cer(d18:1/24:1), DAG16:0/18:1/Total DAG, Cer(d18:0/24:0)/Cer(d18:1/22:0),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Total Cer, Cer(d18:0/24:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), TotalLPC/Total LacCer and GlcCer(d18:1/26:0)/LacCer(d18:1/22:0).

In a particularly preferred embodiment, the one or more lipid-lipidratio(s) whose increase is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/24:1)/PC 16:0/20:4, LacCer(d18:1/20:0)/PC 16:0/20:3, PSO-16:0/18:2-alkenyl/Total PS O and Cer(d18:1/18:0)/PC 16:0/20:4;and the one or more lipid-lipid ratio(s) whose decrease is (are)compared to the control is (are) selected from (Table 13):GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), DAG 16:0/18:1/Total DAG,Cer(d18:0/24:0)/Total Cer, Total LPC/Total LacCer,GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl andCer(d18:0/24:0)/LacCer(d18:1/24:0);

In yet another alternative embodiment the present invention relates to amethod for determining whether a subject is at risk to develop one ormore CVD complications, such as AMI or CVD death, comprising determiningin a sample from said subject one or more lipid-clinical concentrationratio(s), wherein (an) increased or decreased lipid-clinicalconcentration ratio(s) in said sample, when compared to a controlsample, is (are) indicative of said subject having an increased risk ofdeveloping one or more CVD complications, such as AMI or CVD death,wherein the one or more lipid-clinical concentration ratio(s) whoseincrease is (are) compared to the control is (are) selected from (Tables6a and 9a):

Cer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), Cer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/total-c/HDL-c, Cer(d18:1/24:1)/triglycerides(EDTA) (mg/dL), GlcCer(d18:1/24:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/18:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/18:0)/total-c/HDL-c, LacCer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total-c/HDL-c, LacCer(d18:1/22:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/24:0)/apoA1/apoB,LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-32:0 (KDdiA-PC)/apolipoprotein A-I (mg/dL), PC O-32:0(KDdiA-PC)/triglycerides (EDTA) (mg/dL), PC O-34:1/triglycerides (EDTA)(mg/dL), PS O-16:0/18:1-alkenyl (PS O-16:1/18:1-alkyl)/triglycerides(EDTA) (mg/dL), PS O-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/HDL cholesterol (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/triglycerides (EDTA) (mg/dL), TotalCer/apolipoprotein A-I (mg/dL), Total Cer/total cholesterol (EDTA)(mg/dL), Total Cer/triglycerides (EDTA) (mg/dL), TotalGlcCer/apolipoprotein B (mg/dL), Total GlcCer/total cholesterol (EDTA)(mg/dL), Total LacCer/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein B (mg/dL), Total LacCer/total cholesterol (EDTA)(mg/dL) and Total LacCer/triglycerides (EDTA) (mg/dL);and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from (Tables6a and 9a):CE 14:0/apolipoprotein B (mg/dL), CE 14:0/LDL cholesterol (EDTA)(mg/dL), CE 14:0/LDL-c/HDL-c, CE 14:0/total cholesterol (EDTA) (mg/dL),CE 14:0/total-c/HDL-c, CE 16:1/apolipoprotein B (mg/dL), CE 16:1/HDLcholesterol (EDTA) (mg/dL), CE 16:1/LDL cholesterol (EDTA) (mg/dL), CE16:1/total cholesterol (EDTA) (mg/dL), CE 17:1/LDL-c/HDL-c, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:3/apolipoprotein B (mg/dL), CE 20:3/LDL-c/HDL-c, CE20:3/total-c/HDL-c, CE 20:5/apolipoprotein B (mg/dL), CE 20:5/HDLcholesterol (EDTA) (mg/dL), CE 20:5/LDL cholesterol (EDTA) (mg/dL),Cer(d18:0/22:0)/apolipoprotein B (mg/dL), Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/apolipoprotein A-I(mg/dL), Cer(d18:0/24:0)/apolipoprotein B (mg/dL), Cer(d18:0/24:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:0/24:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total cholesterol(EDTA) (mg/dL), Cer(d18:0/24:0)/total-c/HDL-c, LPC 18:2/apoA1/apoB, LPC18:2/apolipoprotein B (mg/dL), LPC 18:2/HDL cholesterol (EDTA) (mg/dL),LPC 18:2/LDL cholesterol (EDTA) (mg/dL), LPC 18:2/LDL-c/HDL-c, LPC18:2/total cholesterol (EDTA) (mg/dL), PC 16:0/20:3/apolipoprotein B(mg/dL), PC 16:0/20:3/HDL cholesterol (EDTA) (mg/dL), PC16:0/20:3/LDL-c/HDL-c, PC 16:0/20:3/total-c/HDL-c, PC16:0/20:4/apolipoprotein A-I (mg/dL), PC 16:0/20:4/apolipoprotein B(mg/dL), PC 16:0/20:4/LDL cholesterol (EDTA) (mg/dL), PC16:0/20:4/LDL-c/HDL-c, PC 16:0120:4/total cholesterol (EDTA) (mg/dL), PC16:0/20:4/total-c/HDL-c, PC 18:0/18:1/LDL-c/HDL-c, PC18:0/20:3/LDL-c/HDL-c, PC 18:0/20:3/total-c/HDL-c, PC18:0/20:4/apoA1/apoB, Total LPC/LDL-c/HDL-c, Total LPC/total-c/HDL-c,Total PC/apolipoprotein B (mg/dL), Total PC/LDL-c/HDL-c, Total PC/totalcholesterol (EDTA) (mg/dL) and Total PC/total-c/HDL-c.

In yet another alternative embodiment the present invention relates to amethod for determining whether a subject is at risk to develop one ormore CVD complications, such as AMI or CVD death, wherein the subject isnot undergoing statin treatment and wherein said method comprisesdetermining in a sample from said subject one or more lipid-clinicalconcentration ratio(s), wherein (an) increased or decreasedlipid-clinical concentration ratio(s) in said sample, when compared to acontrol sample, is (are) indicative of said subject having an increasedrisk of developing one or more of CVD complications, such as AMI or CVDdeath, wherein the one or more lipid-clinical concentration ratio(s)whose increase is (are) compared to the control is (are) selected from(Tables 6b and 9b):

Cer(d18:1/16:0)/apolipoprotein A-I (mg/dL), Cer(d18:1/16:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/16:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), Cer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:1/20:0)/total-c/HDL-c, Cer(d18:1/20:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/22:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/24:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:0)/apolipoprotein B (mg/dL), Cer(d18:1/24:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total cholesterol(EDTA) (mg/dL), Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL),GlcCer(d18:1/20:0)/apolipoprotein B (mg/dL), GlcCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), GlcCer(d18:1/24:1)/apolipoprotein B (mg/dL),GlcCer(d18:1/26:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-34:1/apolipoprotein B (mg/dL), PSO-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), Total Cer/apolipoproteinA-I (mg/dL), Total Cer/apolipoprotein B (mg/dL), Total Cer/LDLcholesterol (EDTA) (mg/dL), Total Cer/total cholesterol (EDTA) (mg/dL),Total DAG/apolipoprotein A-I (mg/dL), Total DAG/triglycerides (EDTA)(mg/dL), Total GlcCer/apolipoprotein B (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), Total LacCer/apolipoprotein B (mg/dL)and Total LacCer/total cholesterol (EDTA) (mg/dL).and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from (Tables6b and 9b):CE 14:0/apoA1/apoB, CE 14:0/apolipoprotein B (mg/dL), CE14:0/LDL-c/HDL-c, CE 14:0/total-c/HDL-c, CE 16:1/apoA1/apoB, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:5/triglycerides (EDTA) (mg/dL), Cer(d18:0/24:0)/apolipoprotein B(mg/dL), Cer(d18:0/24:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:0/24:0)/total-c/HDL-c, PC 18:0/20:4/apoA1/apoB, PCO-38:6/apolipoprotein A-I (mg/dL), Total LPC/apoA1/apoB and TotalPC/apolipoprotein A-I (mg/dL).

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-clinicalconcentration ratio(s) whose increase is (are) compared to the controlis (are) selected from (Table 12):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/apolipoprotein A-1 (mg/dL),Total Cer/apolipoprotein A-I (mg/dL), Total LacCer/apolipoprotein A-I(mg/dL), Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL) and Cer(d18:1/24:1)/apolipoprotein B (mg/dL).

In another preferred embodiment, the one or more lipid-clinicalconcentration ratio(s) whose decrease is (are) compared to the controlis (are) selected from (Table 12): Cer(d18:0/24:0)/apolipoprotein B(mg/dL), Cer(d18:0/24:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:0/24:0)/apolipoprotein B (mg/dL), PC 16:0/20:4/apolipoprotein B(mg/dL) and Cer(d18:0/24:0)/apolipoprotein A-I (mg/dL).

In a particularly preferred embodiment, the lipid-clinical concentrationratio whose increase is compared to the control is (are) selected from(Table 13):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein

A-I (mg/dL), LacCer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL) andCer(d18:1/18:0)/apolipoprotein A-I (mg/dL).

For the purposes of the invention, and particularly for lipid-clinicalconcentration ratios, an Apolipoprotein A-I measurement mayalternatively be an Apolipoprotein A-II measurement.

claim 2 (note claims only have preferred embodiments) In another aspectthe present invention relates to a method for evaluating theeffectiveness of a treatment of CVD and/or one or more of itscomplications, such as AMI or CVD death, in a subject, comprisingdetermining in a sample from said subject the concentration(s) of one ormore lipid(s), wherein (an) increased or decreased concentration(s) insaid sample, when compared to a control sample, is (are) indicative ofeffectiveness of said treatment, wherein the one or more lipid(s) whoseincrease(s) in concentration is (are) compared to the control is (are)selected from (Table 4a and 7a):

Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/24:1), GlcCer(d18:1/18:0),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), PC O-32:0 (KDdiA-PC), PS O-16:0/18:2-alkenyl, PSO-16:1/18:2-alkyl, PS O-18:0/18:2-alkenyl (PS O-18:1/18:2-alkyl), PSO-18:2/16:0-alkenyl and Total LacCer;and wherein the one or more lipid(s) whose decrease(s) in concentrationis (are) compared to the control is (are) selected from (Table 4a and7a):CE 14:0, CE 16:0, CE 17:1, CE 20:3, Cer(d18:0/22:0), Cer(d18:0/24:0),LPC 18:1, PC 16:0/18:2, PC 16:0/20:3, PC 16:0/20:4, PC 16:0/22:6, PC18:0/18:1, PC 18:0/20:3, PC 18:0/20:4, PC 18:1/18:2, SM (d18:1/14:0)(d18:1/13:1-OH), SM (d18:1/23:0) (d18:1/22:1-OH), SM (d18:1/24:0)(d18:1/23:1-OH), Total CE, Total LPC and Total PC.

In a particular embodiment, the present invention relates to a methodfor evaluating the effectiveness of a treatment of CVD and/or one ormore of its complications, such as AMI or CVD death, in a subject,wherein the subject is not undergoing statin treatment and wherein saidmethod comprises, determining in a sample from said subject theconcentration(s) of one or more lipid(s), wherein (an) increased ordecreased concentration(s) in said sample, when compared to a controlsample, is (are) indicative of effectiveness of said treatment, whereinthe one or more lipid(s) whose increase(s) in concentration is (are)compared to the control is (are) selected from (Table 4b and 7b):

Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0),Cer(d18:1/24:1), Cer(d18:1/26:1), GlcCer(d18:1/18:0),GlcCer(d18:1/20:0), GlcCer(d18:1/24:1), GlcCer(d18:1/26:1),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), LacCer(d18:1/24:1), PC O-32:0 (KDdiA-PC), PSO-16:0/18:2-alkenyl, PS O-16:1/18:2-alkyl, PS O-18:2/16:0-alkenyl, TotalCer, Total DAG and Total LacCer;and wherein the one or more lipid(s) whose decrease(s) in concentrationis (are) compared to the control is (are) selected from (Table 4b and7b):

CE 14:0, CE 17:1, CE 20:3, Cer(d18:0/24:0), LPC 18:1, PC 16:0/20:3, PC16:0/20:4, PC 18:0/20:4, PC O-40:3, SM (d18:1/14:0) (d18:1/13:1-OH),Total LPC and Total PC.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid(s) whoseincrease in concentration is (are) compared to the control is (are)selected from (Table 10):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), PS O-18:2/16:0-alkenyl, PS O-16:1/18:2-alkyl, TotalCer, Total LacCer, GlcCer(d18:1/24:1), LacCer(d18:1/22:0) andCer(d18:1/18:0).

In another preferred embodiment, the one or more lipid(s) whose decreasein concentration is (are) compared to the control is (are) selected from(Table 10): Total PC, PC 16:0/20:4, Cer(d18:0/24:0), Total LPC, CE 14:0,CE 20:3, CE 17:1, PC 16:0/20:3, LPC 18:1, PC 18:0/20:3, PC 18:0/18:1 andCer(d18:0/22:0).

In a particularly preferred embodiment, the one or more lipid(s) whoseincrease in concentration is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), LacCer(d18:1/22:0) and Cer(d18:1/18:0);

and the one or more lipid(s) whose decrease in concentration is (are)compared to the control is (are) selected from (Table 13): PC 16:0/20:4and Cer(d18:0/24:0).

In another alternative embodiment the invention relates to a method forevaluating the effectiveness of a treatment of CVD and/or one or more ofits complications, such as AMI or CVD death, in a subject, comprisingdetermining in a sample from said subject one or more lipid-lipidratio(s), wherein (an) increased or decreased lipid-lipid ratio(s) insaid sample, when compared to a control sample, is (are) indicative ofeffectiveness of said treatment, wherein the one or more lipid-lipidratio(s) whose increase(s) is (are) compared to the control is (are)selected from (Tables 5a and 8a):

CE 16:0/CE 18:3, CE 18:2/CE 18:3, CE 19:1/Cer(d18:0/22:0),Cer(d18:1/16:0)/LPC 18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC16:0, Cer(d18:1/18:0)/LPC 18:1, Cer(d18:1/18:0)/PC 16:0/18:1,Cer(d18:1/18:0)/PC 16:0/20:3, Cer(d18:1/18:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/Total LPC,Cer(d18:1/18:0)/Total PC, Cer(d18:1/20:0)/PC 16:0/18:1,Cer(d18:1/20:0)/PC 16:0/20:3, Cer(d18:1/20:0)/PC 16:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/Total PC, Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC16:0/20:3, Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/Total PC,Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC 18:2, Cer(d18:1/24:1)/PC16:0/18:1, Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/20:3,Cer(d18:1/24:1)/PC 18:0/20:4, Cer(d18:1/24:1)/SM (d18:1/24:0)(d18:1/23:1-OH), Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, Cer(d18:1/26:0)/PC O-40:0,GlcCer(d18:1/20:0)/PC 16:0/20:4, GlcCer(d18:1/20:0)/Total PC,GlcCer(d18:1/26:0)/Total CE, LacCer(d18:1/16:0)/Total LPC,LacCer(d18:1/18:0)/PC 16:0/18:1, LacCer(d18:1/18:0)/PC 16:0/20:3,LacCer(d18:1/18:0)/PC 18:0/18:1, LacCer(d18:1/18:0)/PC 18:0/20:3,LacCer(d18:1/18:0)/PC 18:1/18:1, LacCer(d18:1/18:0)/PC 18:1/18:2,LacCer(d18:1/18:0)/Total LPC, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/18:1, LacCer(d18:1/20:0)/PC 16:0/20:3,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3LacCer(d18:1/20:0)/PC 18:1/18:1, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/PC 18:2/18:2, LacCer(d18:1/20:0)/SM (d18:1/17:1-OH),LacCer(d18:1/20:0)/SM (d18:1/18:0), LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/22:0)/PC 16:0/20:3, LacCer(d18:1/22:0)/PC 16:0/20:4,LacCer(d18:1/22:0)/PC 18:0/20:3, LacCer(d18:1/22:0)/SM (d18:1/14:0)(d18:1/13:1-OH), LacCer(d18:1/22:0)/Total LPC, LacCer(d18:1/22:0)/TotalPC, LacCer(d18:1/24:0)/PC 16:0/20:3, LacCer(d18:1/24:0)/Total LPC,LacCer(d18:1/24:1)/Total LPC, LacCer(d18:1/24:1)/Total PC,LacCer(d18:1/24:1)/Total PC O, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC 16:0/18:2/Total PC, PC O-18:0/18:2-alkyl/PCO-36:5, PC O-32:0 (KDdiA-PC)/PC O-38:5, PS O-16:0/18:2-alkenyl/Total PSO, PS O-16:1/18:2-alkyl/Total PS O, PS O-18:0/18:2-alkenyl (PSO-18:1/18:2-alkyl)/Total PS O, PS O-18:2/16:0-alkenyl/Total PS O, TotalCer/Total PC, Total LacCer/Total PC and Total LacCer/Total PC O;and wherein one or more lipid-lipid ratio(s) whose decrease is (are)compared to the control is (are) selected from (Tables 5a and 8a):CE 14:0/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1), CE 16:1/CE 19:1, CE16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1),CE 16:1/GlcCer(d18:1/18:0), CE 16:1/GlcCer(d18:1/20:0), CE16:1/LacCer(d18:1/16:0), CE 16:1/LacCer(d18:1/18:0), CE16:1/LacCer(d18:1/20:0), CE 16:1/LacCer(d18:1/22:0), CE16:1/LacCer(d18:1124:0), CE 16:1/PC 16:0/16:0, CE 16:1/Total LacCer, CE17:1/Cer(d18:1/24:1), CE 17:1/GlcCer(d18:1/24:1), CE17:1/LacCer(d18:1/18:0), CE 18:1/Total LacCer, CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/18:0), CE 18:3/GlcCer(d18:1/20:0), CE18:3/LacCer(d18:1/18:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:1-alkenyl (PSO-16:1/18:1-alkyl), CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalLacCer, CE 20:3/Cer(d18:1/24:1), CE 20:3/LacCer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/18:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/PSO-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl,Cer(d18:0/22:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/Cer(d18:1/20:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/GlcCer(d18:1/20:0), Cer(d18:0/24:0)/LacCer(d18:1/24:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/24:0)/SM (d18:1/17:0) (d18:1/16:1-OH),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Total Cer,Cer(d18:0/24:1)/Total CE, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0),GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/20:0), LPC16:0/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/24:1), LPC 16:0/TotalLacCer, LPC 18:1/LacCer(d18:1/20:0), LPC 18:2/LacCer(d18:1/20:0), LPC18:2/PS O-16:0/18:2-alkenyl, LPC 18:2/PS O-16:1/18:2-alkyl, PC16:0/20:3/PS O-16:0/18:2-alkenyl, PC 16:0/20:3/PS O-16:1/18:2-alkyl, PC18:1/18:2/PS O-16:0/18:2-alkenyl, PC 18:1/18:2/PS O-16:1/18:2-alkyl, SM(d18:1/24:0) (d18:1/23:1-OH)/Total Cer and Total LPC/Total LacCer.

In another alternative embodiment the invention relates to a method forevaluating the effectiveness of a treatment of CVD and/or one or more ofits complications, such as AMI or CVD death, in a subject, wherein thesubject is not undergoing statin treatment and wherein said methodcomprises comprising determining in a sample from said subject one ormore lipid-lipid ratio(s), wherein (an) increased or decreasedlipid-lipid ratio(s) in said sample, when compared to a control sample,is (are) indicative of effectiveness of said treatment, wherein the oneor more lipid-lipid ratio(s) whose increase(s) is (are) compared to thecontrol is (are) selected from (Tables 5b and 8b):

CE 16:0/CE 18:3, CE 18:0/CE 18:3, CE 18:2/CE 18:3, Cer(d18:1/16:0)/LPC18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/PC 16:0/18:1, Cer(d18:1/18:0)/PC 16:0/20:3,Cer(d18:1/18:0)/PC 16:0/20:4, Cer(d18:1/18:0)/PC 18:0/18:1,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/PC 18:1/18:1,Cer(d18:1/18:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/18:0)/SM(d18:1/17:2-OH), Cer(d18:1/18:0)/SM (d18:1/18:1), Cer(d18:1/18:0)/TotalCE, Cer(d18:1/18:0)/Total LPC, Cer(d18:1/18:0)/Total PC,Cer(d18:1/20:0)/PC 16:0/18:1, Cer(d18:1/20:0)/PC 16:0/20:3,Cer(d18:1/20:0)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 18:0/18:1,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/20:0)/TotalLPC, Cer(d18:1/20:0)/Total PC, Cer(d18:1/20:0)/Total PC O,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC 16:0/20:3,Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/22:0)/Total PC, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/PC 16:0/18:1, Cer(d18:1/24:1)/PC 16:0/18:2,Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/18:2,Cer(d18:1/24:1)/PC 18:0/20:3, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/24:1)/PC 18:1/18:1, Cer(d18:1/24:1)/PC 18:1/18:2,Cer(d18:1/24:1)/PC O-40:3, Cer(d18:1/24:1)/SM (d18:1/17:1-OH),Cer(d18:1/24:1)/SM (d18:1/18:0), Cer(d18:1/24:1)/SM (d18:1/23:0)(d18:1/22:1-OH), Cer(d18:1/24:1)/SM (d18:1/24:0) (d18:1/23:1-OH),Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, GlcCer(d18:1/26:0)/Total CE,GlcCer(d18:1/26:1)/Total CE, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/20:3, LacCer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3,LacCer(d18:1/20:0)/PC 18:0/20:4, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/SM (d18:1/17:1-OH), LacCer(d18:1/20:0)/SM(d18:1/18:0), LacCer(d18:1/20:0)/Total CE, LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/24:0)/Total LPC, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC O-32:0 (KDdiA-PC)/Total PC O, PSO-16:0/18:2-alkenyl/Total PC, PS O-16:0/18:2-alkenyl/Total PC O, PSO-16:0/18:2-alkenyl/Total PS O, PS O-16:1/18:2-alkyl/Total PC, PSO-16:1/18:2-alkyl/Total PC O, PS O-16:1/18:2-alkyl/Total PS O, PSO-18:2/16:0-alkenyl/Total PC O, PS O-18:2/16:0-alkenyl/Total PS O, SM(d18:1/17:0) (d18:1/16:1-OH)/Total PC O, Total Cer/Total PC, TotalDAG/Total LPC, Total DAG/Total PC, Total DAG/Total PC O and TotalLacCer/Total PC;and wherein the one or more lipid-lipid ratio(s) whose decrease(s) is(are) compared to the control is (are) selected from (Tables 5b and 8b):CE 14:0/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/24:1), CE 14:0/Total DAG, CE15:0/Cer(d18:1/20:0), CE 16:0/Cer(d18:1/18:0), CE 16:0/Cer(d18:1/24:1),CE 16:1/CE 19:1, CE 16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE16:1/Cer(d18:1/24:1), CE 16:1/GlcCer(d18:1/24:1), CE16:1/LacCer(d18:1/18:0), CE 16:1/LacCer(d18:1/24:0), CE 16:1/TotalLacCer, CE 17:1/Cer(d18:1/18:0), CE 17:1/Cer(d18:1/24:1), CE18:2/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/20:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalDAG, CE 18:3/Total LacCer, CE 20:3/Cer(d18:1/24:1), CE20:3/LacCer(d18:1/20:0), CE 20:4/Cer(d18:1/18:0), CE20:4/Cer(d18:1/24:1), CE 20:4/GlcCer(d18:1/20:0), CE20:4/GlcCer(d18:1/24:1), CE 20:4/LacCer(d18:1/20:0), CE20:5/LacCer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/22:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl,

Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl, Cer(d18:0/22:0)/Total CE,Cer(d18:0/22:0)/Total DAG, Cer(d18:0/22:0)/Total GlcCer,Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/Cer(d18:1/20:0),Cer(d18:0/24:0)/Cer(d18:1/24:1), Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/PS O-16:1/18:2-alkyl, Cer(d18:0/24:0)/Total CE,Cer(d18:0/24:0)/Total Cer, DAG 16:0/18:1/Total DAG,GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), LPC 16:0/LacCer(d18:1/24:0), LPC18:1/LacCer(d18:1/20:0), LPC 18:2/LacCer(d18:1/20:0), PC 16:0/20:3/PSO-16:0/18:2-alkenyl, PC 16:0/20:3/PS O-16:1/18:2-alkyl, PC 16:0/20:4/PSO-16:0/18:2-alkenyl, PC 16:0/20:4/PS O-16:1/18:2-alkyl, PC16:0/20:4/Total DAG, PC 18:0/20:3/PS O-16:0/18:2-alkenyl, PC18:0/20:3/PS O-16:1/18:2-alkyl, PC 18:0/20:3/PS O-18:2/16:0-alkenyl, PC18:0/20:4/PS O-16:0/18:2-alkenyl, PC 18:0/20:4/PS O-16:1/18:2-alkyl, PC18:1/18:2/PS O-16:0/18:2-alkenyl, PC 18:1/18:2/PS O-16:1/18:2-alkyl, PC18:1/18:2/Total Cer, PC O-40:3/PS O-18:2/16:0-alkenyl, SM (d18:1/23:0)(d18:1/22:1-OH)/Total DAG, SM (d18:1/24:0) (d18:1/23:1-OH)/Total Cer,Total CE/Total DAG and Total LPC/Total LacCer.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-lipid ratio(s)whose increase is (are) compared to the control is (are) selected from(Table 11):

GlcCer(d18:1/26:1)/Total CE, Cer(d18:1/24:1)/Total PC,Cer(d18:1/24:1)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 16:0/20:3, Total Cer/Total PC, Total LacCer/TotalPC, LacCer(d18:1/20:0)/PC 18:1/18:2, PS O-16:0/18:2-alkenyl/Total PS O,Cer(d18:1/18:0)/PC 16:0/20:4, LacCer(d18:1/20:0)/Total LPC andLacCer(d18:1/20:0)/PC 16:0/20:4.

In another preferred embodiment, the one or more lipid-lipid ratio(s)whose decrease is (are) compared to the control is (are) selected from(Table 11):

Cer(d18:0/24:0)/Cer(d18:1/24:1), Cer(d18:0/22:0)/Cer(d18:1/24:1), DAG16:0/18:1/Total DAG, Cer(d18:0/24:0)/Cer(d18:1/22:0),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Total Cer, Cer(d18:0/24:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), TotalLPC/Total LacCer and GlcCer(d18:1/26:0)/LacCer(d18:1/22:0).

In a particularly preferred embodiment, the one or more lipid-lipidratio(s) whose increase is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/24:1)/PC 16:0/20:4, LacCer(d18:1/20:0)/PC 16:0/20:3, PSO-16:0/18:2-alkenyl/Total PS O and Cer(d18:1/18:0)/PC 16:0/20:4;and the one or more lipid-lipid ratio(s) whose decrease is (are)compared to the control is (are) selected from (Table 13):

GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), DAG 16:0/18:1/Total DAG,

Cer(d18:0/24:0)/Total Cer, Total LPC/Total LacCer,GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl andCer(d18:0/24:0)/LacCer(d18:1/24:0).

In yet another alternative embodiment the invention relates to a methodfor evaluating the effectiveness of a treatment of CVD and/or one ormore of its complications, such as AMI or CVD death, in a subject,comprising determining in a sample from said subject one or morelipid-clinical concentration ratio(s), wherein (an) increased ordecreased lipid-clinical concentration ratio(s) in said sample, whencompared to a control sample, is (are) indicative of effectiveness ofsaid treatment, wherein the one or more lipid-clinical concentrationratio(s) whose increase(s) is (are) compared to the control is (are)selected from (Tables 6a and 9a):

Cer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), Cer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/total-c/HDL-c, Cer(d18:1/24:1)/triglycerides(EDTA) (mg/dL), GlcCer(d18:1/24:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/18:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/18:0)/total-c/HDL-c, LacCer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total-c/HDL-c, LacCer(d18:1/22:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/24:0)/apoA1/apoB,LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-32:0 (KDdiA-PC)/apolipoprotein A-I (mg/dL), PC O-32:0(KDdiA-PC)/triglycerides (EDTA) (mg/dL), PC O-34:1/triglycerides (EDTA)(mg/dL), PS O-16:0/18:1-alkenyl (PS O-16:1/18:1-alkyl)/triglycerides(EDTA) (mg/dL), PS O-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/HDL cholesterol (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/triglycerides (EDTA) (mg/dL), TotalCer/apolipoprotein A-I (mg/dL), Total Cer/total cholesterol (EDTA)(mg/dL), Total Cer/triglycerides (EDTA) (mg/dL), TotalGlcCer/apolipoprotein B (mg/dL), Total GlcCer/total cholesterol (EDTA)(mg/dL), Total LacCer/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein B (mg/dL), Total LacCer/total cholesterol (EDTA)(mg/dL) and Total LacCer/triglycerides (EDTA) (mg/dL);and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from Tables6a and 9a:CE 14:0/apolipoprotein B (mg/dL), CE 14:0/LDL cholesterol (EDTA)(mg/dL), CE 14:0/LDL-c/HDL-c, CE 14:0/total cholesterol (EDTA) (mg/dL),CE 14:0/total-c/HDL-c, CE 16:1/apolipoprotein B (mg/dL), CE 16:1/HDLcholesterol (EDTA) (mg/dL), CE 16:1/LDL cholesterol (EDTA) (mg/dL), CE16:1/total cholesterol (EDTA) (mg/dL), CE 17:1/LDL-c/HDL-c, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:3/apolipoprotein B (mg/dL), CE 20:3/LDL-c/HDL-c, CE20:3/total-c/HDL-c, CE 20:5/apolipoprotein B (mg/dL), CE 20:5/HDLcholesterol (EDTA) (mg/dL), CE 20:5/LDL cholesterol (EDTA) (mg/dL),Cer(d18:0/22:0)/apolipoprotein B (mg/dL), Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/apolipoprotein A-I(mg/dL), Cer(d18:0/24:0)/apolipoprotein B (mg/dL), Cer(d18:0/24:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:0/24:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total cholesterol(EDTA) (mg/dL), Cer(d18:0/24:0)/total-c/HDL-c, LPC 18:2/apoA1/apoB, LPC18:2/apolipoprotein B (mg/dL), LPC 18:2/HDL cholesterol (EDTA) (mg/dL),LPC 18:2/LDL cholesterol (EDTA) (mg/dL), LPC 18:2/LDL-c/HDL-c, LPC18:2/total cholesterol (EDTA) (mg/dL), PC 16:0/20:3/apolipoprotein B(mg/dL), PC 16:0/20:3/HDL cholesterol (EDTA) (mg/dL), PC16:0/20:3/LDL-c/HDL-c, PC 16:0/20:3/total-c/HDL-c, PC16:0/20:4/apolipoprotein A-I (mg/dL), PC 16:0/20:4/apolipoprotein B(mg/dL), PC 16:0/20:4/LDL cholesterol (EDTA) (mg/dL), PC16:0/20:4/LDL-c/HDL-c, PC 16:0/20:4/total cholesterol (EDTA) (mg/dL), PC16:0/20:4/total-c/HDL-c, PC 18:0/18:1/LDL-c/HDL-c, PC18:0/20:3/LDL-c/HDL-c, PC 18:0/20:3/total-c/HDL-c, PC18:0/20:4/apoA1/apoB, Total LP C/LDL-c/HDL-c, Total LPC/total-c/HDL-c,Total PC/apolipoprotein B (mg/dL), Total PC/LDL-c/HDL-c, Total PC/totalcholesterol (EDTA) (mg/dL) and Total PC/total-c/HDL-c.

In yet another alternative embodiment the invention relates to a methodfor evaluating the effectiveness of a treatment of CVD and/or one ormore of its complications, such as AMI or CVD death, in a subject,wherein the subject is not undergoing statin treatment and wherein saidmethod comprises determining in a sample from said subject one or morelipid-clinical concentration ratio(s), wherein (an) increased ordecreased lipid-clinical concentration ratio(s) in said sample, whencompared to a control sample, is (are) indicative of effectiveness ofsaid treatment, wherein the one or more lipid-clinical concentrationratio(s) whose increase(s) is (are) compared to the control is (are)selected from (Tables 6b and 9b):

Cer(d18:1/16:0)/apolipoprotein A-I (mg/dL), Cer(d18:1/16:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/16:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), C er(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:1/20:0)/total-c/HDL-c, Cer(d18:1/20:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/22:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/24:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:0)/apolipoprotein B (mg/dL), Cer(d18:1/24:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total cholesterol(EDTA) (mg/dL), Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL),GlcCer(d18:1/20:0)/apolipoprotein B (mg/dL), GlcCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), GlcCer(d18:1/24:1)/apolipoprotein B (mg/dL),GlcCer(d18:1/26:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-34:1/apolipoprotein B (mg/dL), PSO-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), Total Cer/apolipoproteinA-I (mg/dL), Total Cer/apolipoprotein B (mg/dL), Total Cer/LDLcholesterol (EDTA) (mg/dL), Total Cer/total cholesterol (EDTA) (mg/dL),Total DAG/apolipoprotein A-I (mg/dL), Total DAG/triglycerides (EDTA)(mg/dL), Total GlcCer/apolipoprotein B (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), Total LacCer/apolipoprotein B (mg/dL)and Total LacCer/total cholesterol (EDTA) (mg/dL).and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from (Tables6b and 9b):CE 14:0/apoA1/apoB, CE 14:0/apolipoprotein B (mg/dL), CE14:0/LDL-c/HDL-c, CE 14:0/total-c/HDL-c, CE 16:1/apoA1/apoB, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:5/triglycerides (EDTA) (mg/dL), Cer(d18:0/24:0)/apolipoprotein B(mg/dL), Cer(d18:0/24:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:0/24:0)/total-c/HDL-c, PC 18:0/20:4/apoA1/apoB, PCO-38:6/apolipoprotein A-I (mg/dL), Total LPC/apoA1/apoB and TotalPC/apolipoprotein A-I (mg/dL).

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-clinicalconcentration ratio(s) whose increase is (are) compared to the controlis (are) selected from (Table 12):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), Total Cer/apolipoproteinA-I (mg/dL), Total LacCer/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL) and Cer(d18:1/24:1)/apolipoprotein B (mg/dL).

In another preferred embodiment, the one or more lipid-clinicalconcentration ratio(s) whose decrease is (are) compared to the controlis (are) selected from (Table 12):

Cer(d18:0/24:0)/apolipoprotein B (mg/dL), Cer(d18:0/24:0)/totalcholesterol (EDTA) (mg/dL), Cer(d18:0/24:0)/apolipoprotein B (mg/dL), PC16:0/20:4/apolipoprotein B (mg/dL) and Cer(d18:0/24:0)/apolipoproteinA-I (mg/dL).

In a particularly preferred embodiment, the lipid-clinical concentrationratio(s) whose increased is (are) compared to the control are selectedfrom (Table 13):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDL cholesterol(EDTA) (mg/dL) and Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL).

For the purposes of the invention, and particularly for lipid-clinicalconcentration ratios, an Apolipoprotein A-I measurement mayalternatively be an Apolipoprotein A-II measurement.

Claim 3 (note claims only have preferred embodiments) In yet anotheraspect the invention relates to a method of choosing an appropriatetreatment of CVD and/or one or more of its complications, such as AMI orCVD death, in a subject, comprising determining in a sample from saidsubject the concentration of one or more lipid(s), wherein (an)increased or decreased concentration(s) in said sample, when compared toa control sample, is (are) indicative of said subject being in need oftreatment or a change in, or supplementation of, an already administeredtreatment, wherein the one or more lipid(s) whose increase(s) inconcentration is (are) compared to the control is (are) selected from(Tables 4a and 7a):

Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/24:1), GlcCer(d18:1/18:0),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), PC O-32:0 (KDdiA-PC), PS O-16:0/18:2-alkenyl, PSO-16:1/18:2-alkyl, PS O-18:0/18:2-alkenyl (PS O-18:1/18:2-alkyl), PSO-18:2/16:0-alkenyl and Total LacCer;and wherein the one or more lipid(s) whose decrease(s) in concentrationis (are) compared to the control is (are) selected from (Tables 4a and7a):CE 14:0, CE 16:0, CE 17:1, CE 20:3, Cer(d18:0/22:0), Cer(d18:0/24:0),LPC 18:1, PC 16:0/18:2, PC 16:0/20:3, PC 16:0/20:4, PC 16:0/22:6, PC18:0/18:1, PC 18:0/20:3, PC 18:0/20:4, PC 18:1/18:2, SM (d18:1/14:0)(d18:1/13:1-OH), SM (d18:1/23:0) (d18:1/22:1-OH), SM (d18:1/24:0)(d18:1/23:1-OH), Total CE, Total LPC and Total PC.

In yet another aspect the invention relates to a method of choosing anappropriate treatment of CVD and/or one or more of its complications,such as AMI or CVD death, in a subject, wherein the subject is notundergoing statin treatment and wherein said method comprisesdetermining in a sample from said subject the concentration of one ormore lipid(s), wherein (an) increased or decreased concentration(s) insaid sample, when compared to a control sample, is (are) indicative ofsaid subject being in need of treatment or a change in, orsupplementation of, an already administered treatment, wherein the oneor more lipid(s) whose increase(s) in concentration is (are) compared tothe control is (are) selected from (Tables 4b and 7b):

Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0),Cer(d18:1/24:1), Cer(d18:1/26:1), GlcCer(d18:1/18:0),GlcCer(d18:1/20:0), GlcCer(d18:1/24:1), GlcCer(d18:1/26:1),LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0),LacCer(d18:1/24:0), LacCer(d18:1/24:1), PC O-32:0 (KDdiA-PC), PSO-16:0/18:2-alkenyl, PS O-16:1/18:2-alkyl, PS O-18:2/16:0-alkenyl, TotalCer, Total DAG and Total LacCer;and wherein the one or more lipid(s) whose decrease(s) in concentrationis (are) compared to the control is (are) selected from (Tables 4b and7b):

CE 14:0, CE 17:1, CE 20:3, Cer(d18:0/24:0), LPC 18:1, PC 16:0/20:3, PC16:0/20:4, PC 18:0/20:4, PC O-40:3, SM (d18:1/14:0) (d18:1/13:1-OH),Total LPC and Total PC.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid(s) whoseincrease in concentration is (are) compared to the control is (are)selected from (Table 10):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), PS O-18:2/16:0-alkenyl, PS O-16:1/18:2-alkyl, TotalCer, Total LacCer, GlcCer(d18:1/24:1), LacCer(d18:1/22:0) andCer(d18:1/18:0).

In another preferred embodiment, the one or more lipid(s) whose decreasein concentration is (are) compared to the control is (are) selected from(Table 10):

Total PC, PC 16:0/20:4, Cer(d18:0/24:0), Total LPC, CE 14:0, CE 20:3, CE17:1, PC 16:0/20:3, LPC 18:1, PC 18:0/20:3, PC 18:0/18:1 andCer(d18:0/22:0).

In a particularly preferred embodiment, the one or more lipid(s) whoseincrease in concentration is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), LacCer(d18:1/22:0) and Cer(d18:1/18:0);

and the one or more lipid(s) whose decrease in concentration is (are)compared to the control is (are) selected from (Table 13): PC 16:0/20:4and Cer(d18:0/24:0).

In an alternative embodiment the invention relates to a method ofchoosing an appropriate treatment of CVD and/or one or more of itscomplications, such as AMI or CVD death, in a subject, comprisingdetermining in a sample from said subject one or more lipid-lipidratio(s), wherein (an) increased or decreased lipid-lipid ratio(s) insaid sample, when compared to a control sample, is (are) indicative ofsaid subject being in need of treatment or a change in, orsupplementation of, an already administered treatment, wherein the oneor more lipid-lipid ratio(s) whose increase(s) is (are) compared to thecontrol is (are) selected from (Tables 5a and 8a):

CE 16:0/CE 18:3, CE 18:2/CE 18:3, CE 19:1/Cer(d18:0/22:0),Cer(d18:1/16:0)/LPC 18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC16:0, Cer(d18:1/18:0)/LPC 18:1, Cer(d18:1/18:0)/PC 16:0/18:1,Cer(d18:1/18:0)/PC 16:0/20:3, Cer(d18:1/18:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/Total LPC,Cer(d18:1/18:0)/Total PC, Cer(d18:1/20:0)/PC 16:0/18:1,Cer(d18:1/20:0)/PC 16:0/20:3, Cer(d18:1/20:0)/PC 16:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/Total PC, Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC16:0/20:3, Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/Total PC,Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC 18:2, Cer(d18:1/24:1)/PC16:0/18:1, Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/20:3,Cer(d18:1/24:1)/PC 18:0/20:4, Cer(d18:1/24:1)/SM (d18:1/24:0)(d18:1/23:1-OH), Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, Cer(d18:1/26:0)/PC O-40:0,GlcCer(d18:1/20:0)/PC 16:0/20:4, GlcCer(d18:1/20:0)/Total PC,GlcCer(d18:1/26:0)/Total CE, LacCer(d18:1/16:0)/Total LPC,LacCer(d18:1/18:0)/PC 16:0/18:1, LacCer(d18:1/18:0)/PC 16:0/20:3,LacCer(d18:1/18:0)/PC 18:0/18:1, LacCer(d18:1/18:0)/PC 18:0/20:3,LacCer(d18:1/18:0)/PC 18:1/18:1, LacCer(d18:1/18:0)/PC 18:1/18:2,LacCer(d18:1/18:0)/Total LPC, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/18:1, LacCer(d18:1/20:0)/PC 16:0/20:3,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3LacCer(d18:1/20:0)/PC 18:1/18:1, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/PC 18:2/18:2, LacCer(d18:1/20:0)/SM (d18:1/17:1-OH),LacCer(d18:1/20:0)/SM (d18:1/18:0), LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/22:0)/PC 16:0/20:3, LacCer(d18:1/22:0)/PC 16:0/20:4,LacCer(d18:1/22:0)/PC 18:0/20:3, LacCer(d18:1/22:0)/SM (d18:1/14:0)(d18:1113:1-OH), LacCer(d18:1/22:0)/Total LPC, LacCer(d18:1/22:0)/TotalPC, LacCer(d18:1/24:0)/PC 16:0/20:3, LacCer(d18:1/24:0)/Total LPC,LacCer(d18:1/24:1)/Total LPC, LacCer(d18:1/24:1)/Total PC,LacCer(d18:1/24:1)/Total PC O, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC 16:0/18:2/Total PC, PC O-18:0/18:2-alkyl/PCO-36:5, PC O-32:0 (KDdiA-PC)/PC O-38:5, PS O-16:0/18:2-alkenyl/Total PSO, PS O-16:1/18:2-alkyl/Total PS O, PS O-18:0/18:2-alkenyl (PSO-18:1/18:2-alkyl)/Total PS O, PS O-18:2/16:0-alkenyl/Total PS O, TotalCer/Total PC, Total LacCer/Total PC and Total LacCer/Total PC O;and wherein one or more lipid-lipid ratio(s) whose decrease is (are)compared to the control is (are) selected from (Tables 5a and 8a):CE 14:0/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1), CE 16:1/CE 19:1, CE16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1),CE 16:1/GlcCer(d18:1/18:0), CE 16:1/GlcCer(d18:1/20:0), CE16:1/LacCer(d18:1/16:0), CE 16:1/LacCer(d18:1/18:0), CE16:1/LacCer(d18:1/20:0), CE 16:1/LacCer(d18:1/22:0), CE16:1/LacCer(d18:1/24:0), CE 16:1/PC 16:0/16:0, CE 16:1/Total LacCer, CE17:1/Cer(d18:1/24:1), CE 17:1/GlcCer(d18:1/24:1), CE17:1/LacCer(d18:1/18:0), CE 18:1/Total LacCer, CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/18:0), CE 18:3/GlcCer(d18:1/20:0), CE18:3/LacCer(d18:1/18:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:1-alkenyl (PSO-16:1/18:1-alkyl), CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalLacCer, CE 20:3/Cer(d18:1/24:1), CE 20:3/LacCer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/18:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/PSO-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl,Cer(d18:0/22:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/Cer(d18:1/20:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/GlcCer(d18:1/20:0), Cer(d18:0/24:0)/LacCer(d18:1/24:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/24:0)/SM (d18:1/17:0) (d18:1/16:1-OH),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Total Cer,Cer(d18:0/24:1)/Total CE, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0),GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/20:0), LPC16:0/LacCer(d18:1/22:0), LPC 16:0/LacCer(d18:1/24:1), LPC 16:0/TotalLacCer, LPC 18:1/LacCer(d18:1/20:0), LPC 18:2/LacCer(d18:1/20:0), LPC18:2/PS O-16:0/18:2-alkenyl, LPC 18:2/PS O-16:1/18:2-alkyl, PC16:0/20:3/PS O-16:0/18:2-alkenyl, PC 16:0/20:3/PS O-16:1/18:2-alkyl, PC18:1/18:2/PS O-16:0/18:2-alkenyl, PC 18:1/18:2/PS O-16:1/18:2-alkyl, SM(d18:1/24:0) (d18:1/23:1-OH)/Total Cer and Total LPC/Total LacCer.

In an alternative embodiment the invention relates to a method ofchoosing an appropriate treatment of CVD and/or one or more of itscomplications, such as AMI or CVD death, in a subject, wherein thesubject is not undergoing statin treatment and wherein said methodcomprises determining in a sample from said subject one or morelipid-lipid ratio(s), wherein (an) increased or decreased lipid-lipidratio(s) in said sample, when compared to a control sample, is (are)indicative of said subject being in need of treatment or a change in, orsupplementation of, an already administered treatment, wherein the oneor more lipid-lipid ratio(s) whose increase(s) is (are) compared to thecontrol is (are) selected from (Tables 5b and 8b):

CE 16:0/CE 18:3, CE 18:0/CE 18:3, CE 18:2/CE 18:3, Cer(d18:1/16:0)/LPC18:1, Cer(d18:1/16:0)/Total PC, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/PC 16:0/18:1, Cer(d18:1/18:0)/PC 16:0/20:3,Cer(d18:1/18:0)/PC 16:0/20:4, Cer(d18:1/18:0)/PC 18:0/18:1,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/18:0)/PC 18:1/18:1,Cer(d18:1/18:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/18:0)/SM(d18:1/17:2-OH), Cer(d18:1/18:0)/SM (d18:1/18:1), Cer(d18:1/18:0)/TotalCE, Cer(d18:1/18:0)/Total LPC, Cer(d18:1/18:0)/Total PC,Cer(d18:1/20:0)/PC 16:0/18:1, Cer(d18:1/20:0)/PC 16:0/20:3,Cer(d18:1/20:0)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 18:0/18:1,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/20:0)/PC 18:1/18:1,Cer(d18:1/20:0)/SM (d18:1/14:0) (d18:1/13:1-OH), Cer(d18:1/20:0)/TotalLPC, Cer(d18:1/20:0)/Total PC, Cer(d18:1/20:0)/Total PC O,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/22:0)/PC 16:0/20:3,Cer(d18:1/22:0)/PC 16:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/22:0)/Total PC, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/PC 16:0/18:1, Cer(d18:1/24:1)/PC 16:0/18:2,Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:4,Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/18:2,Cer(d18:1/24:1)/PC 18:0/20:3, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/24:1)/PC 18:1/18:1, Cer(d18:1/24:1)/PC 18:1/18:2,Cer(d18:1/24:1)/PC O-40:3, Cer(d18:1/24:1)/SM (d18:1/17:1-OH),Cer(d18:1/24:1)/SM (d18:1/18:0), Cer(d18:1/24:1)/SM (d18:1/23:0)(d18:1/22:1-OH), Cer(d18:1/24:1)/SM (d18:1124:0) (d18:1/23:1-OH),Cer(d18:1/24:1)/Total CE, Cer(d18:1/24:1)/Total LPC,Cer(d18:1/24:1)/Total PC, GlcCer(d18:1/26:0)/Total CE,GlcCer(d18:1/26:1)/Total CE, LacCer(d18:1/18:0)/Total PC,LacCer(d18:1/20:0)/PC 16:0/20:3, LacCer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 18:0/18:1, LacCer(d18:1/20:0)/PC 18:0/20:3,LacCer(d18:1/20:0)/PC 18:0/20:4, LacCer(d18:1/20:0)/PC 18:1/18:2,LacCer(d18:1/20:0)/SM (d18:1/17:1-OH), LacCer(d18:1/20:0)/SM(d18:1/18:0), LacCer(d18:1/20:0)/Total CE, LacCer(d18:1/20:0)/Total LPC,LacCer(d18:1/20:0)/Total PC, LacCer(d18:1/20:0)/Total SM,LacCer(d18:1/24:0)/Total LPC, PC 16:0/16:0/PC 16:0/20:4, PC16:0/16:0/Total PC, PC O-32:0 (KDdiA-PC)/Total PC O, PSO-16:0/18:2-alkenyl/Total PC, PS O-16:0/18:2-alkenyl/Total PC O, PSO-16:0/18:2-alkenyl/Total PS O, PS O-16:1/18:2-alkyl/Total PC, PSO-16:1/18:2-alkyl/Total PC O, PS O-16:1/18:2-alkyl/Total PS O, PSO-18:2/16:0-alkenyl/Total PC O, PS O-18:2/16:0-alkenyl/Total PS O, SM(d18:1/17:0) (d18:1/16:1-OH)/Total PC O, Total Cer/Total PC, TotalDAG/Total LPC, Total DAG/Total PC, Total DAG/Total PC O and TotalLacCer/Total PC;and wherein the one or more lipid-lipid ratio(s) whose decrease(s) is(are) compared to the control is (are) selected from (Tables 5b and 8b):CE 14:0/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/24:1), CE 14:0/Total DAG, CE15:0/Cer(d18:1/20:0), CE 16:0/Cer(d18:1/18:0), CE 16:0/Cer(d18:1/24:1),CE 16:1/CE 19:1, CE 16:1/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/20:0), CE16:1/Cer(d18:1/24:1), CE 16:1/GlcCer(d18:1/24:1), CE16:1/LacCer(d18:1/18:0), CE 16:1/LacCer(d18:1/24:0), CE 16:1/TotalLacCer, CE 17:1/Cer(d18:1/18:0), CE 17:1/Cer(d18:1/24:1), CE18:2/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/16:0),CE 18:3/Cer(d18:1/18:0), CE 18:3/Cer(d18:1/20:0), CE18:3/Cer(d18:1/22:0), CE 18:3/Cer(d18:1/24:0), CE 18:3/Cer(d18:1/24:1),CE 18:3/GlcCer(d18:1/20:0), CE 18:3/LacCer(d18:1/20:0), CE18:3/LacCer(d18:1/22:0), CE 18:3/LacCer(d18:1/24:0), CE 18:3/PC16:0/16:0, CE 18:3/PC O-34:1, CE 18:3/PS O-16:0/18:2-alkenyl, CE 18:3/PSO-16:1/18:2-alkyl, CE 18:3/Total CE, CE 18:3/Total Cer, CE 18:3/TotalDAG, CE 18:3/Total LacCer, CE 20:3/Cer(d18:1/24:1), CE20:3/LacCer(d18:1/20:0), CE 20:4/Cer(d18:1/18:0), CE20:4/Cer(d18:1/24:1), CE 20:4/GlcCer(d18:1/20:0), CE20:4/GlcCer(d18:1/24:1), CE 20:4/LacCer(d18:1/20:0), CE20:5/LacCer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/22:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Cer(d18:1/24:1),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/22:0)/Total CE, Cer(d18:0/22:0)/Total DAG,Cer(d18:0/22:0)/Total GlcCer, Cer(d18:0/24:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/Cer(d18:1/20:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl, Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Total Cer,DAG 16:0/18:1/Total DAG, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), LPC16:0/LacCer(d18:1/24:0), LPC 18:1/LacCer(d18:1/20:0), LPC18:2/LacCer(d18:1/20:0), PC 16:0/20:3/PS O-16:0/18:2-alkenyl, PC16:0/20:3/PS O-16:1/18:2-alkyl, PC 16:0/20:4/PS O-16:0/18:2-alkenyl, PC16:0/20:4/PS O-16:1/18:2-alkyl, PC 16:0/20:4/Total DAG, PC 18:0/20:3/PSO-16:0/18:2-alkenyl, PC 18:0/20:3/PS O-16:1/18:2-alkyl, PC 18:0/20:3/PSO-18:2/16:0-alkenyl, PC 18:0/20:4/PS O-16:0/18:2-alkenyl, PC18:0/20:4/PS O-16:1/18:2-alkyl, PC 18:1/18:2/PS O-16:0/18:2-alkenyl, PC18:1/18:2/PS O-16:1/18:2-alkyl, PC 18:1/18:2/Total Cer, PC O-40:3/PSO-18:2/16:0-alkenyl, SM (d18:1/23:0) (d18:1/22:1-OH)/Total DAG, SM(d18:1/24:0) (d18:1/23:1-OH)/Total Cer, Total CE/Total DAG and TotalLPC/Total LacCer.

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-lipid ratio(s)whose increase is (are) compared to the control is (are) selected from(Table 11):

GlcCer(d18:1/26:1)/Total CE, Cer(d18:1/24:1)/Total PC,Cer(d18:1/24:1)/PC 16:0/20:4, Cer(d18:1/20:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/PC 16:0/20:3, Total

Cer/Total PC, Total LacCer/Total PC, LacCer(d18:1/20:0)/PC 18:1118:2, PSO-16:0/18:2-alkenyl/Total PS O, Cer(d18:1/18:0)/PC 16:0/20:4,LacCer(d18:1/20:0)/Total LPC and LacCer(d18:1/20:0)/PC 16:0/20:4;

In another preferred embodiment, the one or more lipid-lipid ratio(s)whose decrease is (are) compared to the control is (are) selected from(Table 11):

Cer(d18:0/24:0)/Cer(d18:1/24:1), Cer(d18:0/22:0)/Cer(d18:1/24:1), DAG16:0/18:1/Total DAG, Cer(d18:0/24:0)/Cer(d18:1/22:0),Cer(d18:0/24:0)/Total CE, Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Total Cer, Cer(d18:0/24:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/LacCer(d18:1/24:0), Cer(d18:0/22:0)/Cer(d18:1/18:0),Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/Cer(d18:1/20:0),Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl, Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), TotalLPC/Total LacCer and GlcCer(d18:1/26:0)/LacCer(d18:1/22:0).

In a particularly preferred embodiment, the one or more lipid-lipidratio(s) whose increase is (are) compared to the control is (are)selected from (Table 13):

Cer(d18:1/24:1)/PC 16:0/20:4, LacCer(d18:1/20:0)/PC 16:0/20:3, PSO-16:0/18:2-alkenyl/Total PS O and Cer(d18:1/18:0)/PC 16:0/20:4;and the one or more lipid-lipid ratio(s) whose decrease is (are)compared to the control is (are) selected from (Table 13):GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), DAG 16:0/18:1/Total DAG,Cer(d18:0/24:0)/Total Cer, Total LPC/Total LacCer,GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl andCer(d18:0/24:0)/LacCer(d18:1/24:0).

In yet another embodiment the invention relates to a method of choosingan appropriate treatment of CVD and/or one or more of its complications,such as AMI or CVD death, in a subject, comprising determining in asample from said subject one or more lipid-clinical concentrationratio(s), wherein (an) increased or decreased lipid-clinicalconcentration ratio(s) in said sample, when compared to a controlsample, is (are) indicative of said subject being in need of treatmentor a change in, or supplementation of, an already administeredtreatment, wherein the one or more lipid-clinical concentration ratio(s)whose increase is (are) compared to the control is (are) selected from(Tables 6a and 9a):

Cer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), Cer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/total-c/HDL-c, Cer(d18:1/24:1)/triglycerides(EDTA) (mg/dL), GlcCer(d18:1/24:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/18:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/18:0)/total-c/HDL-c, LacCer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total-c/HDL-c, LacCer(d18:1/22:0)/triglycerides(EDTA) (mg/dL), LacCer(d18:1/24:0)/apoA1/apoB,LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-32:0 (KDdiA-PC)/apolipoprotein A-I (mg/dL), PC O-32:0(KDdiA-PC)/triglycerides (EDTA) (mg/dL), PC O-34:1/triglycerides (EDTA)(mg/dL), PS O-16:0/18:1-alkenyl (PS O-16:1/18:1-alkyl)/triglycerides(EDTA) (mg/dL), PS O-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/HDL cholesterol (EDTA) (mg/dL), PSO-18:2/16:0-alkenyl/triglycerides (EDTA) (mg/dL), TotalCer/apolipoprotein A-I (mg/dL), Total Cer/total cholesterol (EDTA)(mg/dL), Total Cer/triglycerides (EDTA) (mg/dL), TotalGlcCer/apolipoprotein B (mg/dL), Total GlcCer/total cholesterol (EDTA)(mg/dL), Total LacCer/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein B (mg/dL), Total LacCer/total cholesterol (EDTA)(mg/dL) and Total LacCer/triglycerides (EDTA) (mg/dL);and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from (Tables6a and 9a):CE 14:0/apolipoprotein B (mg/dL), CE 14:0/LDL cholesterol (EDTA)(mg/dL), CE 14:0/LDL-c/HDL-c, CE 14:0/total cholesterol (EDTA) (mg/dL),CE 14:0/total-c/HDL-c, CE 16:1/apolipoprotein B (mg/dL), CE 16:1/HDLcholesterol (EDTA) (mg/dL), CE 16:1/LDL cholesterol (EDTA) (mg/dL), CE16:1/total cholesterol (EDTA) (mg/dL), CE 17:1/LDL-c/HDL-c, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:3/apolipoprotein B (mg/dL), CE 20:3/LDL-c/HDL-c, CE20:3/total-c/HDL-c, CE 20:5/apolipoprotein B (mg/dL), CE 20:5/HDLcholesterol (EDTA) (mg/dL), CE 20:5/LDL cholesterol (EDTA) (mg/dL),Cer(d18:0/22:0)/apolipoprotein B (mg/dL), Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/apolipoprotein A-I(mg/dL), Cer(d18:0/24:0)/apolipoprotein B (mg/dL), Cer(d18:0/24:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:0/24:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total cholesterol(EDTA) (mg/dL), Cer(d18:0/24:0)/total-c/HDL-c, LPC 18:2/apoA1/apoB, LPC18:2/apolipoprotein B (mg/dL), LPC 18:2/HDL cholesterol (EDTA) (mg/dL),LPC 18:2/LDL cholesterol (EDTA) (mg/dL), LPC 18:2/LDL-c/HDL-c, LPC18:2/total cholesterol (EDTA) (mg/dL), PC 16:0/20:3/apolipoprotein B(mg/dL), PC 16:0/20:3/HDL cholesterol (EDTA) (mg/dL), PC16:0/20:3/LDL-c/HDL-c, PC 16:0/20:3/total-c/HDL-c, PC16:0/20:4/apolipoprotein A-I (mg/dL), PC 16:0/20:4/apolipoprotein B(mg/dL), PC 16:0/20:4/LDL cholesterol (EDTA) (mg/dL), PC16:0/20:4/LDL-c/HDL-c, PC 16:0/20:4/total cholesterol (EDTA) (mg/dL), PC16:0/20:4/total-c/HDL-c, PC 18:0/18:1/LDL-c/HDL-c, PC18:0/20:3/LDL-c/HDL-c, PC 18:0/20:3/total-c/HDL-c, PC18:0/20:4/apoA1/apoB, Total LPC/LDL-c/HDL-c, Total LPC/total-c/HDL-c,Total PC/apolipoprotein B (mg/dL), Total PC/LDL-c/HDL-c, Total PC/totalcholesterol (EDTA) (mg/dL) and Total PC/total-c/HDL-c.

In yet another embodiment the invention relates to a method of choosingan appropriate treatment of CVD and/or one or more of its complications,such as AMI or CVD death, in a subject, wherein the subject is notundergoing statin treatment and wherein said method comprisesdetermining in a sample from said subject one or more lipid-clinicalconcentration ratio(s), wherein (an) increased or decreasedlipid-clinical concentration ratio(s) in said sample, when compared to acontrol sample, is (are) indicative of said subject being in need oftreatment or a change in, or supplementation of, an already administeredtreatment, wherein the one or more lipid-clinical concentration ratio(s)whose increase is (are) compared to the control is (are) selected from(Tables 6b and 9b):

Cer(d18:1/16:0)/apolipoprotein A-I (mg/dL), Cer(d18:1/16:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/16:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein B (mg/dL), Cer(d18:1/18:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/18:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/triglycerides(EDTA) (mg/dL), Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/20:0)/apolipoprotein B (mg/dL), Cer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:1/20:0)/total-c/HDL-c, Cer(d18:1/20:0)/triglycerides (EDTA)(mg/dL), Cer(d18:1/22:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/22:0)/apolipoprotein B (mg/dL), Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/22:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL),Cer(d18:1/24:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:0)/apolipoprotein B (mg/dL), Cer(d18:1/24:0)/LDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:0)/total cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein B (mg/dL), Cer(d18:1/24:1)/HDLcholesterol (EDTA) (mg/dL), Cer(d18:1/24:1)/LDL cholesterol (EDTA)(mg/dL), Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total cholesterol(EDTA) (mg/dL), Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL),GlcCer(d18:1/20:0)/apolipoprotein B (mg/dL), GlcCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), GlcCer(d18:1/24:1)/apolipoprotein B (mg/dL),GlcCer(d18:1/26:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/18:0)/apolipoprotein B (mg/dL), LacCer(d18:1/18:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/apoA1/apoB,LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein B (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL), LacCer(d18:1/20:0)/LDL-c/HDL-c, LacCer(d18:1/20:0)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/20:0)/total-c/HDL-c,LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL),LacCer(d18:1/22:0)/apoA1/apoB, LacCer(d18:1/22:0)/apolipoprotein A-I(mg/dL), LacCer(d18:1/22:0)/apolipoprotein B (mg/dL),LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL),LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL),LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/24:1)/apolipoprotein B (mg/dL), LacCer(d18:1/24:1)/totalcholesterol (EDTA) (mg/dL), LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL), PC O-34:1/apolipoprotein B (mg/dL), PSO-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL), PSO-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL), Total Cer/apolipoproteinA-I (mg/dL), Total Cer/apolipoprotein B (mg/dL), Total Cer/LDLcholesterol (EDTA) (mg/dL), Total Cer/total cholesterol (EDTA) (mg/dL),Total DAG/apolipoprotein A-I (mg/dL), Total DAG/triglycerides (EDTA)(mg/dL), Total GlcCer/apolipoprotein B (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), Total LacCer/apolipoprotein B (mg/dL)and Total LacCer/total cholesterol (EDTA) (mg/dL).and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease is (are) compared to the control is (are) selected from (Tables6b and 9b):CE 14:0/apoA1/apoB, CE 14:0/apolipoprotein B (mg/dL), CE14:0/LDL-c/HDL-c, CE 14:0/total-c/HDL-c, CE 16:1/apoA1/apoB, CE18:3/apoA1/apoB, CE 18:3/apolipoprotein A-I (mg/dL), CE18:3/apolipoprotein B (mg/dL), CE 18:3/HDL cholesterol (EDTA) (mg/dL),CE 18:3/LDL cholesterol (EDTA) (mg/dL), CE 18:3/LDL-c/HDL-c, CE18:3/total cholesterol (EDTA) (mg/dL), CE 18:3/total-c/HDL-c, CE20:5/triglycerides (EDTA) (mg/dL), Cer(d18:0/24:0)/apolipoprotein B(mg/dL), Cer(d18:0/24:0)/total cholesterol (EDTA) (mg/dL),Cer(d18:0/24:0)/total-c/HDL-c, PC 18:0/20:4/apoA1/apoB, PCO-38:6/apolipoprotein A-I (mg/dL), Total LPC/apoA1/apoB and TotalPC/apolipoprotein A-I (mg/dL).

In a preferred embodiment (for subjects that are either undergoing ornot undergoing statin treatment), the one or more lipid-clinicalconcentration ratio(s) whose increase is (are) compared to the controlis (are) selected from (Table 12):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), Total Cer/apolipoproteinA-I (mg/dL), Total LacCer/apolipoprotein A-I (mg/dL),Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL),LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDLcholesterol (EDTA) (mg/dL) and Cer(d18:1/24:1)/apolipoprotein B (mg/dL).

In another preferred embodiment, the one or more lipid-clinicalconcentration ratio(s) whose decrease is (are) compared to the controlis (are) selected from (Table 12):

Cer(d18:0/24:0)/apolipoprotein B (mg/dL), Cer(d18:0/24:0)/totalcholesterol (EDTA) (mg/dL), Cer(d18:0/24:0)/apolipoprotein B (mg/dL), PC16:0/20:4/apolipoprotein B (mg/dL) and Cer(d18:0/24:0)/apolipoproteinA-I (mg/dL).

In a particularly preferred embodiment, the one or more lipid-clinicalconcentration ratio(s) whose increase is (are) compared to the controlis (are) selected from (Table 13):

Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL),Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDL cholesterol(EDTA) (mg/dL) and Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL).

For the purposes of the invention, and particularly for lipid-clinicalconcentration ratios, an Apolipoprotein A-I measurement mayalternatively be an Apolipoprotein A-II measurement.

Claim 5 In one embodiment of the invention, the treatment theeffectiveness of which is to be evaluated or which is to be chosen asappropriate in accordance with the methods described and claimed herein,is a lipid modifying treatment.

Claim 7 For the purposes of the invention, at least one lipidconcentration, lipid-lipid ratio or lipid-clinical concentration ratiofrom Tables 4-13, or combinations thereof, may be determined to assesswhether the patient is at risk to develop one or more of CVDcomplications such as AMI or CVD death; to evaluate the effectiveness ofthe treatment of CVD and/or one or more of its complications, such asAMI or CVD death in a subject; or to choose an appropriate treatment ofCVD and/or one or more of its complications, such as AMI or CVD death ina subject. However, it is also possible, and may be advantageous, todetermine at least 2, at least 3, at least 4, at least 5, at least 6, atleast 7, or at least 8 lipid concentrations, lipid-lipid ratios orlipid-clinical concentration ratios from Tables 4-13, or combinationsthereof, in this regard. Where more than one lipidomic markers aredetermined and used for the assessment, it may be advantageous that aspecific lipid concentration, lipid-lipid ratio, lipid-clinicalconcentration ratio or combination thereof, is given greater weight thanothers in the above-mentioned assessment, evaluation or choice.

Preferred embodiments of the invention are methods wherein the one ormore lipid(s) or lipid ratio(s), or combination thereof, comprise(s):(particularly preferred lipid species and ratios in claim 6)Cer(d18:1/20:0), LacCer(d18:1/20:0), Cer(d18:1/24:1),LacCer(d18:1/24:1), LacCer(d18:1/22:0), Cer(d18:1/18:0), PC 16:0/20:4,Cer(d18:0/24:0), Cer(d18:1/24:1)/PC 16:0/20:4, LacCer(d18:1/20:0)/PC16:0/20:3, PS O-16:0/18:2-alkenyl/Total PS O, Cer(d18:1/18:0)/PC16:0/20:4, GlcCer(d18:1/26:0)/LacCer(d18:1/20:0), DAG 16:0/18:1/TotalDAG, Cer(d18:0/24:0)/Total Cer, Total LPC/Total LacCer,GlcCer(d18:1/26:0)/LacCer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/24:1),Cer(d18:0/24:0)/Cer(d18:1/18:0), Cer(d18:0/24:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/24:0)/Cer(d18:1/22:0), Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl,Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl,Cer(d18:0/24:0)/LacCer(d18:1/24:0), Cer(d18:1/20:0)/apolipoprotein A-I(mg/dL), Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL),LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL), TotalLacCer/apolipoprotein A-I (mg/dL), LacCer(d18:1/20:0)/HDL cholesterol(EDTA) (mg/dL) and Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL).

In the context of the present invention, CVD is typically characterizedby coronary artery disease, peripheral artery disease, a stroke and/orCVD death. The CVD in the subject whose sample is analyzed in accordancewith the invention may be atherosclerosis-induced. However, theinvention also embodies methods involving subjects who are at risk ofdeveloping CVD, but who may or may not have atherosclerosis.

In a further embodiment, the methods of the invention may furthercomprise determining the serum level of total cholesterol, low-densitylipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol(HDL-C), Apolipoprotein B (ApoB) and/or Apolipoprotein C-III in thesubject's sample. In one embodiment of the invention, the subject doesnot have elevated serum levels of one or more of total cholesterol,low-density lipoprotein cholesterol (LDL-C), Apolipoprotein C-III orApolipoprotein B (ApoB), or a decreased serum level of HDL-cholesterol(HDL-C).

As mentioned above, for the purposes of the present invention, a controlsample may be obtained from (a) CAD patient(s) or a group of CADpatients that has/have remained free of any major CVD complicationse.g., by mixing a variety of samples from said population. If a group ofCAD patients is used then several lipid profiles from a population arecombined and the lipidomic marker is created from this combination. Thelevels or amounts of the individual lipids or the lipid-lipid ratios orlipid-clinical concentration ratios in the sample from a subject arecompared to the levels or amounts of the lipids or lipid ratios in thecontrol for determining the risk of one or more of CVD complications,such as AMI or CVD death, in said subject.

The invention encompasses the analysis of lipid concentrations,lipid-lipid ratios and/or lipid-clinical concentration ratios in samplesfrom a subject that has been or is being treated with one or morestatins and/or any other HMG-CoA reductase inhibitor.

Alternatively, the invention encompasses the analysis of lipidconcentrations, lipid-lipid ratios and/or lipid-clinical concentrationratios in samples from a subject that has not yet undergone statintherapy or therapy with any other HMG-CoA reductase inhibitor.

In accordance with the aspects and embodiments of the inventiondescribed and claimed herein, the statin may be one selected from thegroup consisting of atorvastatin, cerivastatin, fluvastatin, fluvastatinXL, lovastatin, pitavastatin, pravastatin, rosuvastatin, andsimvastatin.

Collecting information on a lipidomic marker or a lipidomic profile froma subject's biological sample can be performed via various chemical andhigh resolution analytical techniques. Suitable analytical techniquesinclude but are not limited to mass spectrometry and nuclear resonancespectroscopy. Any high resolution technique capable of resolvingindividual lipids or lipid classes and providing structural informationof the same can be used to collect the lipid profile from the biologicalsample. For methods of the present invention the level of the lipid isdetermined by using mass spectrometry, nuclear magnetic resonancespectroscopy, fluorescence spectroscopy or dual polarisationinterferometry, a high performance separation method such as HPLC orUPLC and/or an immunoassay such as an ELISA. According to an alternativeor further embodiment an analyte in a sample can be detected and/orquantified by combining the analyte with a binding moiety capable ofspecifically binding the analyte. The binding moiety can include, forexample, a member of a ligand-receptor pair, i.e., a pair of moleculescapable of having a specific binding interaction. The binding moiety canalso include, for example, a member of a specific binding pair, such asantibody-antigen, enzyme-substrate, nucleic acid-based ligands, otherprotein ligands, or other specific binding pairs known in the art. In apreferred embodiment, the lipidomic profile is collected with massspectrometry (MS), wherein the MS instrument may be coupled to directinfusion methods and high performance separation methods such as HPLC orHPLC. The amount of the individual lipids or lipid classes in thecollected lipidomic profile is used when comparing the collected lipidprofile to a control.

The methods of the present invention may be used for determining a riskof said patient to develop CVD complications, particularly severe CVDcomplications such as death and myocardial infarction (MI), includingacute myocardial infarction (AMI).

In one embodiment of the invention, a method for treating or preventingCVD complications, such as AMI or CVD death, in a subject in needthereof is provided. The method comprises administering atherapeutically effective dose of a drug capable of modulating one ormore of the lipid concentration(s), lipid-lipid ratio(s) orlipid-clinical concentration ratio(s) described in Tables 4-13, whereinthe dose is such that said one or more lipid concentration(s),lipid-lipid ratio(s) or lipid-clinical concentration ratio(s) in asample of said subject does not significantly change when compared to(a) corresponding lipid concentration(s), (a) corresponding lipid-lipidratio(s) or (a) corresponding lipid-clinical concentration ratio(s) in acontrol, e.g., a control sample. In a preferred embodiment, the drug isa statin or another HMG CoA reductase inhibitor. Particularly preferredstatins in this regard are atorvastatin, cerivastatin, fluvastatin,fluvastatin XL, lovastatin, pitavastatin, pravastatin, rosuvastatin orsimvastatin. In another preferred embodiment, the drug is niacin(nicotinic acid); a cholesterol absorption inhibitor, such as ezetimibeor SCH-48461; a cholesteryl ester transfer protein (CETP) inhibitor,such as torcetrapib, anacetrapib or JTT-705; a bile acids sequestrant,such as colesevelam, cholestyramine and colestipol; or a fibrate, suchas fenofibrate, gemfibrozil, clofibrate, and bezafibrate. Alternatively,it may also be a phytosterol.

Also embodied by the present invention is a lipid as described herein,e.g. a lipid from any of Tables 4, 7, 10 or 13, for use in preventing ortreating a subject at risk to develop CVD complications such as AMI orCVD death, wherein the said lipid is to be taken as a dietary supplementor a medicament. A corresponding method of treatment is likewiseencompassed. Likewise, the invention also encompasses a modulator foruse for modulating a lipid concentration, lipid-lipid ratio orlipid-clinical concentration ratio as described herein, e.g., in Tables4-13, in a subject at risk to develop CVD and/or one or more of itscomplications such as AMI or CVD death. A corresponding method oftreatment is likewise encompassed. In a further embodiment, the saidmodulator is a small molecule, an antisense RNA, a small interfering RNA(siRNA) or a natural or modified lipid.

In one embodiment of the present invention, an antibody against any oneof the lipids in Tables 4-13 is used for predicting one or more CVDcomplications such as AMI or CVD death. In another embodiment of theinvention, the antibody may be used for preventing or treating one ormore of the above complications in a subject.

Any of the methods, drugs, lipids or antibodies of the present inventionmay be used for a subject which is at risk to develop or has sufferedfrom one or more CVD complications such as acute myocardial infarctionand/or a cardiovascular death. For the purposes of the invention, CVDcomplication(s) includes severe CVD complication(s), particularly death.

Also encompassed by the present invention is a kit for predicting CVDcomplications or for performing any of the methods or uses of thepresent invention, wherein the kit comprises a lipid standard chosenfrom the lipids in Tables 4, 7, 10 or 13, one or more control lipidomicmarkers, an antibody against one of the said lipids, and reagents forperforming the method.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1.

This FIGURE demonstrates the importance of molecular lipid measurements.Two examples are given in this FIGURE to illustrate that two closelyrelated molecular lipids may have a very different or even oppositeeffect on CVD complications. First quadrangles are used to indicate twoLactosylceramides (LacCer). LacCer (18:1/20:0) is a significantpredictor for CVD Death, while closely related LacCer (18:1/16:0) hasonly limited or no value as a risk predictor. Second example proves thatthat two lipid species from the same lipid class may have even anopposite effect on CVD events. PC (18:0/20:4) proved to be a protectivelipid against CVD death while PC (16:0/16:0) seems to increase CVDcomplications.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Coronary vascular disease/cardiovascular disease (CVD) has its generalmeaning in the art and is used to classify numerous conditions thataffect the heart, heart valves, blood, and vasculature of the body,including CAD. In the present invention the terms CVD and CAD may beused interchangeably. Cardiovascular diseases include endothelialdysfunction, coronary artery disease, angina pectoris, myocardialinfarction, atherosclerosis, congestive heart failure, hypertension,cerebrovascular disease, stroke, transient ischemic attacks, deep veinthrombosis, peripheral artery disease, cardiomyopathy, arrhythmias,aortic stenosis, and aneurysm. Such diseases frequently involveatherosclerosis. In a preferred embodiment of the invention, thecardiovascular disease is a cardiovascular disease associated withatherosclerosis.

CAD is coronary artery disease, AMI is acute myocardial infarction, ACSis acute coronary syndrome, CAC is coronary artery calcification, RCT isreverse cholesterol transport, LDL is low density lipoprotein, HDL ishigh density lipoprotein, LDL-C is low density lipoprotein cholesterol,HDL-C is high density lipoprotein cholesterol, ApoA is Apolipoprotein A,ApoB is Apolipoprotein B, ApoC is apolipoprotein C, MS is massspectrometry, HPLC is high performance liquid chromatography, and UPLCis ultra performance liquid chromatography.

As used herein, “a subject” includes all mammals, including withoutlimitation humans, but also non-human primates, dogs, cats, horses,sheep, goats, cows, rabbits, pigs and rodents.

A “sample” is defined as any biological sample obtained from a subjector a group or population of subjects. For the purposes of the presentinvention, the biological sample may be whole blood, blood serum, orblood plasma. It may also be a tissue sample. However, a preferredembodiment is wherein the biological sample is plasma or serum. Taking ablood sample of a patient is a part of normal clinical practice. Theblood sample can be taken in connection with e.g. measuring thecholesterol levels in the patients. The collected blood sample can beprepared and serum or plasma can be separated with techniques well knownto a person skilled in the art. Vena blood samples can be collected frompatients using a needle and a BD Vacutainer® Plastic Tubes orVacutainer® Plus Plastic Tubes (BD Vacutainer® SST™ Tubes containspray-coated silia and a polymer gel for serum separation). Serum can beseparated by centrifugation at 1300 RCF for 10 min at room temperatureand stored in small plastic tubes at −80° C.

For the purposes of the present invention, lipids from the Lipidomicanalysis were named according to the following nomenclature: CE ischolesteryl ester, Cer is ceramide, DAG is diacylglycerol, PC O isether-linked PC, GD is disialogangliosides, GlcCer is galactosyl- andglucosylceramides, GM is monosialogangliosides, LacCer islactosylceramides, LPC is lysophosphatidylcholine, PC isPhosphatidylcholine, PE is Phosphatidylethanolamine, PI isPhosphatidylinositol, SM is Sphingomyelin, SIP issphingosine-1-phosphate.

The nomenclature X:Y indicates, X number of total carbon atoms in thefatty acid(s) portions of the molecule, and Y the total number of doublebonds in the fatty acid portion(s) of the molecule.

The nomenclature A/B indicates, for a molecule of DAG and PC, A and Btypes of fatty acid moieties attached to the glycerol backbone of themolecule.

The nomenclature (dC/A) indicates, for a molecule of Cer, GlcCer, LacCerand SM, C the type of long-chain base with an amide-linked, A, fattyacid moiety.

The wording “compared to a control sample” as used herein will beunderstood to include embodiments where control samples are actuallyanalyzed in respect of a lipidomic marker of interest, i.e., in respectof the concentration of one or more of the lipid(s), the lipid-lipidratios, or the lipid-clinical concentration ratios or combinationsthereof as specifically described herein in connection with the variousaspects and embodiments of the present invention. It will beappreciated, however, that the above wording also includes embodimentswhere the corresponding information on said lipidomic marker in saidcontrol sample is merely taken from the literature, or has beenpreviously determined, calculated or extrapolated, or is yet to bedetermined, calculated or extrapolated.

As used herein, the term “antibody” includes monoclonal and polyclonalantibodies, whole antibodies, antibody fragments, and antibodysub-fragments that exhibit specific binding to a said lipid. Thus,suitable “antibodies” can be whole immunoglobulins of any class, e.g.,IgG, IgM, IgA, IgD, IgE, chimeric antibodies or hybrid antibodies withdual or multiple antigen or epitope specificities, or fragments, e.g.,F(ab′)₂, Fab′, Fab and the like, including hybrid fragments, andadditionally includes any immunoglobulin or any natural, synthetic orgenetically engineered protein that acts like an antibody by binding toa specific antigen to form a complex. The term “antibody” encompassesantigen-binding fragments of antibodies (e.g., single chain antibodies,Fab fragments, F(ab)₂, a Fd fragment, a Fv fragment and dAb fragments)as well as complete antibodies. For example, Fab molecules can beexpressed and assembled in a genetically transformed host like E. coli.A lambda vector system is available thus to express a population ofFab's with a potential diversity equal to or exceeding that of subjectgenerating the predecessor antibody. See Huse W D, et al., Science 1989,246:1275-81. Such Fab's are included in the definition of “antibody.”The ability of a given molecule, including an antibody fragment orsub-fragment, to act like an antibody and specifically bind to aspecific antigen can be determined by binding assays known in the art,for example, using the antigen of interest as the binding partner.

Antibodies against lipids in accordance with the present invention maybe prepared by methods well known to those skilled in the art. Forexample, mice may be immunized with a lipid with adjuvant. Splenocytesare harvested as a pool from the mice that were administered 3immunizations at 2-week intervals with test bleeds performed onalternate weeks for serum antibody titers. Splenocytes are prepared as 3aliquots that are either used immediately in fusion experiments orstored in liquid nitrogen for use in future fusions.

Fusion experiments are then performed according to the procedure ofStewart & Fuller, J. Immunol. Methods 1989, 123:45-53. Supernatants fromwells with growing hybrids are screened by enzyme-linked immunosorbentassay (ELISA) for monoclonal antibody (MAb) secretors on 96-well ELISAplates coated with the said lipid. ELISA positive cultures are cloned bylimiting dilutions, typically resulting in hybridomas established fromsingle colonies after 2 serial cloning experiments.

EXAMPLES Example 1 Materials and Methods

This study is a sub-cohort of the LURK study that is a large scaleprospective study on cardiovascular epidemiology. LURIC databasecontains clinical information over 3000 patients including baselinecoronary angiography, clinically used biomarker data and also e.g. CVDmortality data for the follow-up period (3 years). In this biomarkerstudy the inventors compared CAD cases (n=62) that died during thefollow-up due to CVD with patients (n=173) having a stable CAD. Subjectswith a significant atherosclerosis level in the angiogram but no CVDrelated death during the follow-up were used as controls, while the casegroup had similarly a significant atherosclerosis based on theangiography at baseline and in addition they died during the follow-updue to acute cardiovascular events. A statistical analysis was performedseparately also for cases (n=48) and controls (n=124) that were nottreated with statins. The clinical characteristics are described inTable 1.

TABLE 1 Background characteristics for LURIC patients analyzed withlipidomics Variable Controls (n = 173) Cases (n = 62) Age (average) 6067 LDL-C (mg/dL) 122 117.5 HDL-C (mg/dL) 37.2 35.3 DM2 patients 62 (36%)36 (58%) Hypertensive patients 101 (58%)  39 (63%) Lipid lowering users49 (28%) 14 (23%) Smokers (active or quit less than 3 46 (27%)  8 (13%)years before sampling)

Definition of Cases: All cases had a significant vessel disease (>=20%stenosis) in coronary angiogram and they all died due to CVD during thefollow-up.

Definition of Controls: All controls had a significant vessel disease(>=20% stenosis) in coronary angiogram, but they did not die due to CVDduring the follow-up.

Example 2 Analytical Methods Mass Spectrometry Driven Lipidomics

Direct infusion coupled to tandem mass spectrometry, i.e. shotgunlipidomics, and two liquid chromatography tandem mass spectrometry(LC-MS/MS) approaches, i.e. ceramide and cerebroside lipidomics andganglioside lipidomics, were used to identify lipid biomarkers forcoronary artery disease (CVD) risk by analyzing molecular lipid speciesin human serum, plasma, and carotid artery plaques. The applied methodswere optimized especially for quantification of molecular cholesterylesters (CE), phosphatidylcholines (PC), lysophosphatidylcholines (LPC)and other lysophospholipids (LPL), ether-linked phosphatidylcholines (PCO) and other ether-linked phospholipids (PL O), phosphatidylserines(PS), phosphatidylethanolamines (PE), phosphatidylglycerols (PG),phosphatidylinositols (PI), phosphatidic acids (PA), diacylglycerols(DAG), ceramides (Cer), glucosylceramides (GlcCer) and lactosylceramides(LacCer).

The following materials were used according to the methods. HPLC orLC-MS grade of chloroform, methanol, water, acetonitrile, formic acid,methanol, isopropanol, ammonium acetate, acetic acid, potassium chlorideand butylated hydroxytoluene (BHT) were purchased from Sigma-Aldrich(St. Louis, Mo., USA).

HPLC column (Acquity BEH C18, 2.1×50 mm id. 1.7 μm) was purchased fromWaters (Milford, Mass., USA). HPLC pre-column (Widepore C18 4×2.0 mm)was purchased from Phenomenex (Torrance, Calif., USA). All labware usedfor the extraction were resistant to chloroform. Aerosol resistantfilter tips (Molecular BioProducts) and Eppendorf 2 ml safe-lock tubes,96-well twin.tec PCR plates, and Pierce-it-lite thermo-sealing foilswere purchased from VWR International (West Chester, Pa., USA). CO-REFilter Tips and 96-well 2 ml Whatman Uniplates were purchased fromHamilton Robotics (Bonaduz, Switzerland). Synthetic lipid standards werepurchased from Avanti Polar Lipids (Alabaster, Ala., USA) and fromMatreya (Pleasant Gap, PA, USA).

Lipids were extracted in chloroform:methanol according to the followingprotocols. Samples were spiked with known amounts of non-endogenoussynthetic internal standards for data normalization and endogenous lipidquantification. In shotgun lipidomics analysis; LPC 17:0, PC 17:0/17:0,PA 17:0/17:0, PE 17:0/17:0, PG 17:0/17:0, PS 17:0/17:0, DAG 17:0/17:0,D6-CE 18:0, in ceramide and cerebroside lipidomics; Cer d18:1/17:0,D3-LacCer d18:1/16:0, and D3-GlcCer d18:1/16:0, were used as internalstandards. Post-extract spiked non-endogenous synthetic externalstandards were used for quality controlling. Stock solutions ofstandards were prepared by dissolving appropriately weighed amounts ofeach standard in chloroform:methanol (2:1, V:V) to achieve a finalconcentration of 500 μM. An internal standard mixture containing each ofthe standard stock was created and used in lipid extraction.

Samples and quality control samples for each extraction batch werethawed on ice. The carotid artery plaque samples were weighed on ice byusing a cryo-box and homogenized in ice-cold 70% methanol in water. TheMixer Mill 301 Teflon adapters were kept at −20° C. Homogenization wasperformed at 15-25 Hz for 2-15 minutes with Mixer Mill 301 (Retch GmbH,Germany).

Lipid extraction of human samples was carried out in automated fashionusing a Hamilton MICROLAB STAR system (Hamilton Robotics, Switzerland).Well-mixed samples were aliquoted into a 96-well 2 ml Whatman Uniplatecontaining ice-cold methanol and 0.1% BHT. 5 μl of serum and plasma and30 μl of carotid artery plaques were used for shotgun- and ceramide andcerebroside lipidomics and 100 μl of serum and plasma and 200 μl ofcarotid artery plaques was used for ganglioside lipidomics. The sampleswere mixed thoroughly after each step in the extraction protocol. Theextraction proceeded at room temperature by adding an appropriate volumeof internal standard mixture and chloroform, and methanol and water inthe case of ganglioside lipidomics. In shotgun and ceramide andcerebroside lipidomics, the organic phase separation was facilitated byadding 20 mM acetic acid and centrifuging the plate for 5 min at 500×g.The organic phase was transferred into a new 96-well 2 ml WhatmanUniplate. The remaining water-containing phase was washed by addingappropriate volume of chloroform followed by centrifugation. The twoorganic phases were pooled and evaporated under N₂ until dryness. Thelipid extracts were then re-dissolved in chloroform:methanol (1:2, v:v)including the addition of the synthetic external standard. Inganglioside lipidomics, after thorough mixing the supernatant wascollected after 30 min centrifugation at 2000×g. The remaining pelletwas re-extracted with appropriate volume of water andchloroform:methanol (1:2, v:v) and the supernatant was collected in thesame way as above. The pooled supernatant was subjected to solventpartitioning by addition of water and inversion of the sample tubes. Theupper phase was collected after 30 min centrifugation at 2000×g. Thelower phase was thoroughly re-extracted with potassium chloride and theproduced upper phase was collected as mentioned above. The upper phaseswere pooled and evaporated under N₂ until dryness. The lipid extractswere then re-dissolved in chloroform:methanol (1:2, v:v). The extractswere stored in 2 ml safe-lock Eppendorf tubes at −20° C. prior to MSanalysis. Required volumes of lipid extracts were aliquoted into anEppendorf 96-well twin.tec PCR plate and the plate was heat-sealed withaluminum foil to avoid evaporation.

In shotgun lipidomics, lipid extracts were analyzed on a hybrid triplequadrupole/linear ion trap mass spectrometer (QTRAP 5500, AB Sciex)equipped with a robotic nanoflow ion source (NanoMate HD, AdvionBiosciences). The instruments were operated in positive and negative ionmodes. In positive ion the spray voltage was set to 1.0 to 1.4 kV and innegative ion mode to −1.0 to −1.4 kV. A gas pressure of 0.3-0.8 psi wasused and the interface heater was set at 60° C. The collision energy(CE) and declustering potential (DP) was optimized for each lipid classusing synthetic standards. The mass spectrometer was operated in unitresolution mode using a scan speed of 200 Da/s. Molecular lipids wereanalyzed in both positive and negative ion modes using multipleprecursor ion scanning (MPIS) and neutral loss scanning (NLS). The usedprecursor ion and neutral loss scans in positive mode and negative modeare summarized in Table 2.

TABLE 2 Shotgun lipidomics. Lipid Class Characteristic Fragment PIS orNL [M + H]⁺ (m/z) PC/SM/LPC Phosphorylcholine 184.1 DAG FA 14:1 283.25DAG FA 14:0 285.25 DAG FA 16:2 309.25 DAG FA 16:1 311.25 DAG FA 16:0313.25 DAG FA 17:0 327.25 DAG FA 18:3 335.25 DAG FA 18:2 337.25 DAG FA18:1 339.25 DAG FA 18:0 341.25 DAG FA 20:5 359.25 DAG FA 20:4 361.25 DAGFA 20:3 363.25 DAG FA 20:2 365.25 DAG FA 20:1 367.25 CE Cholestadiene369.35 d6-CE d6-Cholestadiene 375.35 DAG FA 22:6 385.30 DAG FA 22:5387.30 DAG FA 22:4 389.30 DAG FA 22:3 391.30 PE/PE-Ophosphorylethanolamine NL 141.0 PS phosphorylserine NL 185.0 PGphosphorylglycerol +NH₄ NL 189.0 PI phosphorylinositol +NH₄ NL 277.1 PISor NL [M − H]⁻ (m/z) PA/PG/PS/PI Glycerophosphate −H₂0 153.000 PC/LPCPhosphorylcholine 168.000 PA/PG/PS/PI/PC/LPC FA 10:1 169.100PA/PG/PS/PI/PC/LPC FA 10:0 171.100 PA/PG/PS/PI/PC/LPC FA 11:1 183.100PA/PG/PS/PI/PC/LPC FA 11:0 185.200 PE dilyso PE −H₂0 196.000PA/PG/PS/PI/PC/LPC FA 12:1 197.200 PA/PG/PS/PI/PC/LPC FA 12:0 199.200PA/PG/PS/PI/PC/LPC FA 13:1 211.200 PA/PG/PS/PI/PC/LPC FA 13:0 213.200PA/PG/PS/PI/PC/LPC FA 14:2 223.200 PA/PG/PS/PI/PC/LPC FA 14:1 225.200PA/PG/PS/PI/PC/LPC FA 14:0 227.200 PA/PG/PS/PI/PC/LPC FA 15:2, O-16:2237.200 PA/PG/PS/PI/PC/LPC FA 15:1, O-16:1 239.200 PI PI-H₂O 241.000PA/PG/PS/PI/PC/LPC FA 15:0 241.200 PA/PG/PS/PI/PC/LPC FA 16:2 251.200PA/PG/PS/PI/PC/LPC FA 16:1 253.200 PA/PG/PS/PI/PC/LPC FA 16:0 255.200PA/PG/PS/PI/PC/LPC FA 20:5-CO₂ 257.200 PC/LPC D3-FA 16:0 258.200PA/PG/PS/PI/PC/LPC FA 20:4-CO₂ 259.200 PA/PG/PS/PI/PC/LPC FA 17:2265.200 PA/PG/PS/PI/PC/LPC O-18:2 265.300 PA/PG/PS/PI/PC/LPC FA 17:1267.200 PA/PG/PS/PI/PC/LPC FA 17:0 269.300 PA/PG/PS/PI/PC/LPC FA 18:3277.200 PA/PG/PS/PI/PC/LPC FA 18:2 279.200 PA/PG/PS/PI/PC/LPC FA 18:1281.300 PA/PG/PS/PI/PC/LPC FA 18:0 283.300 PA/PG/PS/PI/PC/LPC FA22:5-CO₂ 285.300 PA/PG/PS/PI/PC/LPC FA 22:4-CO₂ 287.300PA/PG/PS/PI/PC/LPC FA 19:2 293.300 PA/PG/PS/PI/PC/LPC FA 19:1 295.300PA/PG/PS/PI/PC/LPC FA 19:0 297.300 PA/PG/PS/PI/PC/LPC FA 20:5 301.200PA/PG/PS/PI/PC/LPC FA 20:4 303.200 PA/PG/PS/PI/PC/LPC FA 20:3 305.200PA/PG/PS/PI/PC/LPC FA 20:2 307.300 PA/PG/PS/PI/PC/LPC FA 20:1 309.300PA/PG/PS/PI/PC/LPC FA 20:0 311.300 PA/PG/PS/PI/PC/LPC FA 22:6 327.200PA/PG/PS/PI/PC/LPC FA 22:5 329.200 PA/PG/PS/PI/PC/LPC FA 22:4 331.300PA/PG/PS/PI/PC/LPC FA 22:3 333.300 PA/PG/PS/PI/PC/LPC FA 22:2 335.300PA/PG/PS/PI/PC/LPC FA 22:1 337.300 PA/PG/PS/PI/PC/LPC FA 22:0 339.300SGalCer HSO₄ 96.9 PS Serine −H₂O NL 87.1

In ceramide and cerebroside lipidomics, the high performance liquidchromatography (HPLC) analyses were conducted in the following way.Chromatographic apparatus consisted of a CTC HTC PAL autosampler (CTCAnalytics AG, Switzerland), a Rheos Allegro UHPLC pump (Flux InstrumentsAG, Switzerland), an external column heater set to 60° C. for ceramideand cerebroside lipidomics and 45° C. for ganglioside lipidomics, andthe Acquity BEH C18 column with an in-line pre-column. The extractedsamples, 10 μl of each, were injected into the pre-column followed bythe analytical column and delivered to the mass spectrometer at a flowrate of 500 μl/min In ceramide and cerebroside lipidomics, A gradientwas used for lipid analyte separation with solvent A comprising 10 mMammonium acetate in HPLC grade water containing 0.1% formic acid andsolvent B of 10 mM ammonium acetate in acetonitrile:isopropanol (4:3,V:V) containing 0.1% formic acid. The gradient was constructed in thefollowing way: 0 min—65% B; 2 min—65% B; 2.5 min—75% B; 17.5 min—100% B;22.5 min—100% B; 22.6 min—65% B; 25 min—65% B.

The lipid extracts were analyzed by HPLC-MS/MS. The MS analysis wasperformed on a hybrid triple quadrupole/linear ion trap massspectrometer equipped with the Turbo V™ Ion Source (4000 QTRAP, ABSciex). The instrument was operating in positive and negative ion modes.The ion source voltage was set to 5500V for ceramide and cerebrosidelipidomics and to −4500V for ganglioside lipidomics, and sourcetemperature at 400° C. The collision energy (CE) and declusteringpotential (DP) was optimized for each lipid class using syntheticstandards. A 20 sec dwell time was applied for each scan. Multiplereaction monitoring (MRM) scan mode was used. MRM transitions for eachlipid species are summarized in table 3.

TABLE 3 Ceramide and cerebroside lipidomics. Lipid [M + H]⁺ (m/z)Product [M + H]⁺ (m/z) Cer(d18:0/16:0) 540.5 266.25 Cer(d18:0/18:0)568.6 266.25 Cer(d18:0/20:0) 596.6 266.25 Cer(d18:0/22:0) 624.6 266.25Cer(d18:0/24:0) 652.7 266.25 Cer(d18:0/24:1) 650.6 266.25Cer(d18:0/26:0) 680.7 266.25 Cer(d18:0/26:1) 678.7 266.25Cer(d18:1/16:0) 538.5 264.25 Cer(d18:1/18:0) 566.5 264.25Cer(d18:1/20:0) 594.6 264.25 Cer(d18:1/22:0) 622.6 264.25Cer(d18:1/24:0) 650.6 264.25 Cer(d18:1/24:1) 648.6 264.25Cer(d18:1/26:0) 678.7 264.25 Cer(d18:1/26:1) 676.7 264.25GlcCer(d18:0/16:0) 702.6 266.25 GlcCer(d18:0/18:0) 730.6 266.25GlcCer(d18:0/20:0) 758.6 266.25 GlcCer(d18:0/22:0) 786.7 266.25GlcCer(d18:0/24:0) 814.7 266.25 GlcCer(d18:0/24:1) 812.7 266.25GlcCer(d18:0/26:0) 842.7 266.25 GlcCer(d18:0/26:1) 840.7 266.25GlcCer(d18:1/16:0) 700.6 264.25 GlcCer(d18:1/18:0) 728.6 264.25GlcCer(d18:1/20:0) 756.6 264.25 GlcCer(d18:1/22:0) 784.7 264.25GlcCer(d18:1/24:0) 812.7 264.25 GlcCer(d18:1/24:1) 810.7 264.25GlcCer(d18:1/26:0) 840.7 264.25 GlcCer(d18:1/26:1) 838.7 264.25LacCer(d18:1/16:0) 862.6 264.25 LacCer(d18:1/18:0) 890.7 264.25LacCer(d18:1/20:0) 918.7 264.25 LacCer(d18:1/22:0) 946.7 264.25LacCer(d18:1/24:0) 974.7 264.25 LacCer(d18:1/24:1) 972.7 264.25LacCer(d18:1/26:0) 1002.8 264.25 LacCer(d18:1/26:1) 1000.8 264.25LacCer(d18:0/16:0) 864.6 266.25 LacCer(d18:0/18:0) 892.7 266.25LacCer(d18:0/20:0) 920.7 266.25 LacCer(d18:0/22:0) 948.7 266.25LacCer(d18:0/24:0) 976.7 266.25 LacCer(d18:0/24:1) 974.7 266.25LacCer(d18:0/26:0) 1004.8 266.25 LacCer(d18:0/26:1) 1002.8 266.25Cer(d18:1/16:0)-OH 554.5 264.25 Cer(d18:1/18:0)-OH 582.5 264.25Cer(d18:1/20:0)-OH 610.6 264.25 Cer(d18:1/22:0)-OH 638.6 264.25Cer(d18:1/24:0)-OH 666.6 264.25 Cer(d18:1/24:1)-OH 664.6 264.25Cer(d18:1/26:0)-OH 694.7 264.25 Cer(d18:1/26:1)-OH 692.7 264.25 ISD3-LacCer d18:1/16:0 865.6 264.25 IS D3-GluCer d18:1/16:0 703.7 264.25IS Cer d18:1/17:0 552.5 264.25 ES Cer d17:1/18:0 552.5 250.25

The data processing was done in the following way. Initially theretention time (in LC mode) and identification of each peak was doneusing endogenous standards and by Information Dependent Acquisition(IDA) experiments where applicable. The raw data were processedaccording to peak detected and retention time (in LC mode) in automatedfashion. A stringent cutoff was applied for separating background noisefrom actual lipid peaks. Each sample was controlled and only acceptedwhen fulfilling the stringent acceptance criteria. Peak area counts(cps) of detected peaks were converted into a list of correspondinglipid names. Lipids were normalized to their respective internalstandard and sample volume or tissue weight to retrieve theirconcentrations.

Several quality controls were used in the lipidomic analyses. Acalibration line using synthetic or isolated standards was obtainedprior to sample analysis. Synthetic standards were chosen based onapplication and had similar properties to the endogenous lipids oranalyte(s) of interest. The calibration line consisted of a minimum offive standards points covering the expected quantification range. Asample extracted without standard and standards extracted with nomatrix, were included with the calibration line.

The calibration line was used to determine the dynamic quantificationrange for each lipid class monitored, e.g., the linear quantificationlimits. As the internal standards used behave in the same way asendogenous lipids they were used for quantifying endogenous lipidspecies. The calibration lines were based on the same internal standardsthat were used for quantification of the endogenous lipids.

In each sample extracted for lipids, the ratio of synthetic internalstandards (IS) to corresponding post-extract spiked external standard(ES) was determined. The peak area (cps) ratio of internal to externalstandard (IS/ES) was used for calculating the Coefficient of Variation(CV) across all samples. The IS/ES ratio enabled the calculation oflipid extraction recovery.

Instrument control (IC) was included at the start, middle and end ofeach run. IC sample analyzed was an extracted reference plasma sampleand a set of standards to monitor the instrument's performance, i.e.,the intra- and inter-assay variation.

For each platform, a stringent cutoff was applied for separatingbackground noise from actual lipid peaks. Each sample was controlled andonly accepted when fulfilling the stringent acceptance criteria. Massesand counts of detected peaks were converted into a list of correspondinglipid names. Lipids were normalized to their respective internalstandard and sample volume to retrieve their concentrations.

Statistical Analyses

Percentage changes in lipid concentrations between control and casegroups were calculated as follows:

100*(AVG[C] in case group−AVG[C] in control group)/AVG[C] in controlgroup

Statistical significance was assigned based on standard t-test p-values.

In addition, ROC curves were used for finding lipid molecules andconcentration cutoffs that separate the best cases from controls.Selectivity is calculated as a number of correctly identified casesdivided by the total number of cases. Specificity is calculated as anumber of correctly identified controls divided by the total number ofcontrols. Selectivity and specificity was calculated for each lipidconcentration, lipid to lipid ratio and ratio of lipid to clinicalconcentrations.

Example 3 Ethics

The LURIC study was approved by the ethics review committee at the“Landesärztekammer Rheinland-Pfalz” (Mainz, Germany). Written informedconsent was obtained from each of the participants.

Results

In this LURIC study sub-cohort, the traditional biomarkers includingLDL-cholesterol and HDL-cholesterol concentrations were practicallyidentical in both groups and therefore were not predictive ofCVD-related mortality in this study.

Multiple lipidomic markers appeared as significant predictors of CVDdeath (Tables 4-13). A total of 151 molecular lipids were quantified.The significant predictors were selected based on the top fiftycandidates from each category, when available. The biomarker candidatesbased on molecular lipid concentrations are presented in Tables 4, 7, 10and 13. The candidates were selected according to the followingcriteria: t-test p-value ≦0.05 or sensitivity ≧60% and specificity ≧60%.From traditional clinical chemistry only apolipoprotein A1 and totalcholesterol reached statistical significance with p-value lower than0.05, but % change was less than 10% between controls and cases, otherclinical values did not show any statistical significance. Thepredictive value of new lipidomic biomarkers was increased when theirlevels were expressed as distinct lipid-lipid ratios or lipid-clinicalratios (e.g. LDL-C or HDL-C). The top biomarker candidates are presentedin Table 13. Top candidates from each category, when available, wereselected based on the following selection criteria: t-test p-value ≦0.05and sensitivity ≧60% and specificity ≧60%.

Importance of Detailed Molecular Lipid Analyses

Recent evolvement of mass spectrometry driven lipid analysis approacheshas made it possible to resolve complex lipidomes to their molecularlipid species level at high-throughput and quality required for analysesof clinical cohorts. As a result of the high sensitivity and selectivityof the methods, a lipidome-wide analysis of minute sample amounts hasbecome feasible. Present technologies are capable of identifying lipidswith different sum compositions, i.e. phosphatidylcholine (PC) 34:1, butmore important is the identification of molecular lipid species, e.g. PC16:0/18:1. In the latter analysis, information of the type of fattyacids and their positions attached to the glycerol backbone making upthe particular PC molecule is retrieved.

The seminal work of Shinzawa-Itoh and colleagues showed by highlysophisticated experiments that the oxygen transfer mechanism incytochrome c oxidase requires a specific phosphatidylglycerol molecularlipid with palmitate and vaccenate at the sn-1 and sn-2 positionsrespectively on the glycerol backbone (Shinzawa-Itoh K, Aoyama H,Muramoto K et al: Structures and physiological roles of 13 integrallipids of bovine heart cytochrome c oxidase. EMBO J 2007, 26:1713-1725).In line with other studies, this undoubtedly indicates that the lipidstructure is an essential determinant of the biological effect.Therefore, molecular lipidomics is an essential for biomarker discovery.FIG. 1 illustrates the importance of molecular lipid data by comparingthe biomarker value of two PC and LacCer molecules in predicting CVDmortality in the LURIC cohort. The data reveals that whileLacCer(d18:1/20:0) is a significant CVD predictor, LacCer(d18:1/18:16:0) has low biomarker potential. In addition, two PCmolecules PC (18:0/20:4) and PC (18:0/16:0) have even opposite effectson CVD complications. Thus, it is always necessary to identify andquantify all lipid species for lipid classes of interest including butnot limited to cholesterol esters, different phopsholipid classes,ceramides, cerebro sides (lactosylceramides, glycosylceramides), andgangliosides.

TABLE 4 Significant lipids in LURIC study sorted by p-value. Lipidnames, p-values and % change for negative correlation are presented.Table 4a shows significant lipids from all study subjects. Thesignificant lipids from subjects not undergoing statin treatment arelisted in table 4b. Percentage Lipid name p-value change 4a) Significantlipids in LURIC study sorted by p-value from all study subjects.Positive correlation LacCer(d18:1/20:0) 0.00008 29.52421LacCer(d18:1/22:0) 0.00046 22.75541 LacCer(d18:1/18:0) 0.00094 26.78692Cer(d18:1/18:0) 0.00177 23.30373 Cer(d18:1/20:0) 0.00302 17.32385LacCer(d18:1/24:1) 0.00361 24.72456 PS O-18:2/16:0-alkenyl 0.0057149.89286 PS O-16:0/18:2-alkenyl 0.00670 49.99084 PS O-16:1/18:2-alkyl0.00670 49.99084 Cer(d18:1/24:1) 0.01142 14.88898 Total LacCer 0.0166913.83938 PS O-18:0/18:2-alkenyl 0.02899 40.93773 (PS O-18:1/18:2-alkyl)LacCer(d18:1/24:0) 0.04425 15.80958 PC O-32:0 (KDdiA-PC) 0.0454617.40815 GlcCer(d18:1/18:0) 0.04913 12.83156 Negative correlation TotalPC 0.00011 −16.07367 PC 16:0/20:4 0.00077 −18.06547 Total LPC 0.00126−17.02070 CE 14:0 0.00181 −22.73309 PC 16:0/20:3 0.00191 −18.78110Cer(d18:0/24:0) 0.00254 −27.27562 PC 18:0/20:4 0.00303 −16.02110 CE 20:30.00312 −19.02446 CE 17:1 0.00694 −16.90145 PC 18:0/20:3 0.00726−17.20664 PC 18:0/18:1 0.00765 −18.18002 Cer(d18:0/22:0) 0.01158−22.37263 PC 16:0/22:6 0.01180 −16.65050 LPC 18:1 0.01457 −14.45827 SM(d18:1/23:0) (d18:1/22:1-OH) 0.01920 −14.02360 CE 16:0 0.02427 −10.63490Total CE 0.02745 −11.83333 SM (d18:1/24:0) (d18:1/23:1-OH) 0.02784−13.83715 PC 18:1/18:2 0.03666 −10.83371 4b) Significant lipids in LURICstudy sorted by p-value from subjects not undergoing statin treatment.Positive correlation Cer(d18:1/20:0) 0.00004 28.00357 Cer(d18:1/18:0)0.00009 34.32550 LacCer(d18:1/20:0) 0.00010 32.91154 Cer(d18:1/24:1)0.00039 23.37606 LacCer(d18:1/22:0) 0.00048 25.61851 LacCer(d18:1/18:0)0.00144 29.19850 LacCer(d18:1/24:1) 0.00199 29.83279 PSO-18:2/16:0-alkenyl 0.00432 33.81177 Cer(d18:1/22:0) 0.00473 18.32126 PSO-16:0/18:2-alkenyl 0.00590 32.17190 PS O-16:1/18:2-alkyl 0.0059032.17190 Total DAG 0.00794 31.67365 Cer(d18:1/16:0) 0.00952 16.71359Total Cer 0.00932 15.44601 Total LacCer 0.01105 16.00541LacCer(d18:1/24:0) 0.01989 19.85622 GlcCer(d18:1/20:0) 0.02288 17.74772PC O-32:0 (KDdiA-PC) 0.02467 22.23265 GlcCer(d18:1/18:0) 0.0258416.12961 GlcCer(d18:1/24:1) 0.03290 18.89331 GlcCer(d18:1/26:1) 0.0470217.52675 Cer(d18:1/26:1) 0.04802 13.59618 Negative correlation Total PC0.00921 −12.44220 CE 14:0 0.01090 −21.01258 CE 20:3 0.02157 −16.03606 CE17:1 0.02204 −15.93952 PC 16:0/20:4 0.02256 −14.96966 PC 18:0/20:40.03376 −13.60917 Cer(d18:0/24:0) 0.03376 −21.87004 Total LPC 0.03443−12.91576 PC 16:0/20:3 0.04337 −13.43056

TABLE 5 Table of significant lipid to lipid ratios in LURIC study sortedby p-value. Lipid names, p-values, % change both for positive andnegative correlation are presented. Table 5a shows significant lipidsfrom all study subjects. The significant lipids from subjects notundergoing statin treatment are listed in table 5b. Percentage Lipidname/lipid name p-value change 5a) Significant lipid to lipid ratios inLURIC study sorted by p-value from all study subjects. Positivecorrelation GlcCer(d18:1/26:0)/Total CE 0.0000000 12.8050228GlcCer(d18:1/26:1)/Total CE 0.0000000 29.5576923 PSO-16:0/18:2-alkenyl/Total PS O 0.0000000 26.0723978 PSO-16:1/18:2-alkyl/Total PS O 0.0000000 26.0723978 PSO-18:2/16:0-alkenyl/Total PS O 0.0000000 28.7826715Cer(d18:1/24:1)/Total PC 0.0000000 38.6612692 PC 16:0/16:0/Total PC0.0000000 26.1328496 LacCer(d18:1/20:0)/Total PC 0.0000000 55.3076855Cer(d18:1/24:1)/PC 16:0/20:4 0.0000000 52.6701270 Cer(d18:1/20:0)/TotalPC 0.0000000 40.0940286 LacCer(d18:1/18:0)/Total PC 0.0000000 53.5855166Cer(d18:1/18:0)/Total PC 0.0000000 48.2586905 Cer(d18:1/18:0)/PC16:0/20:4 0.0000000 65.7060860 Cer(d18:1/24:1)/PC 16:0/18:1 0.000000034.2415459 PS O-18:0/18:2-alkenyl 0.0000000 18.7146206 (PSO-18:1/18:2-alkyl)/Total PS O Total LacCer/Total PC 0.0000001 40.0389043Cer(d18:1/24:1)/PC 16:0/20:3 0.0000001 39.6033049 Cer(d18:1/22:0)/TotalPC 0.0000001 31.3604924 Cer(d18:1/20:0)/PC 16:0/20:4 0.000000155.6619154 LacCer(d18:1/22:0)/Total PC 0.0000001 48.7385500LacCer(d18:1/20:0)/PC 16:0/20:3 0.0000001 57.2475183 Cer(d18:1/18:0)/PC16:0/20:3 0.0000002 53.4975004 LacCer(d18:1/20:0)/PC 18:0/20:3 0.000000256.3125345 LacCer(d18:1/18:0)/PC 18:0/20:3 0.0000002 58.4642532Cer(d18:1/22:0)/PC 16:0/20:4 0.0000002 42.5755107 LacCer(d18:1/20:0)/PC18:0/18:1 0.0000004 50.6042672 Cer(d18:1/24:1)/LPC 18:1 0.000000437.9852355 LacCer(d18:1/20:0)/PC 16:0/18:1 0.0000004 46.3528827LacCer(d18:1/20:0)/PC 18:1/18:1 0.0000004 49.6378601 Cer(d18:1/18:0)/PC16:0/18:1 0.0000004 42.1348344 Cer(d18:1/18:0)/PC 18:0/20:4 0.000000555.4207048 Cer(d18:1/24:1)/PC 18:0/20:4 0.0000005 40.7129933Cer(d18:1/20:0)/PC 16:0/20:3 0.0000005 44.8451813 LacCer(d18:1/18:0)/PC18:0/18:1 0.0000006 50.0860210 Cer(d18:1/20:0)/PC 16:0/18:1 0.000000635.2897482 LacCer(d18:1/20:0)/PC 18:1/18:2 0.0000007 47.4807020Cer(d18:1/24:1)/Total LPC 0.0000007 37.5873387 Total Cer/Total PC0.0000007 28.8638001 Cer(d18:1/20:0)/PC 18:0/20:4 0.0000007 46.2204972LacCer(d18:1/18:0)/PC 18:1/18:1 0.0000007 47.3110220LacCer(d18:1/18:0)/PC 16:0/20:3 0.0000007 55.5925567LacCer(d18:1/24:1)/Total PC 0.0000008 56.5726916 Cer(d18:1/24:1)/PC18:0/18:1 0.0000008 38.3563305 Cer(d18:1/24:1)/PC 18:0/20:3 0.000001339.6802706 LacCer(d18:1/22:0)/PC 16:0/20:4 0.0000013 57.8428560LacCer(d18:1/18:0)/PC 16:0/18:1 0.0000014 45.2070855LacCer(d18:1/22:0)/PC 18:0/20:3 0.0000014 50.7183795 Cer(d18:1/20:0)/PC18:1/18:1 0.0000016 40.1833717 LacCer(d18:1/18:0)/PC 18:1/18:2 0.000001746.5169450 Cer(d18:1/22:0)/PC 16:0/20:3 0.0000018 33.7513783 Negativecorrelation Cer(d18:0/22:0)/Total CE 0.0000000 −11.7767698Cer(d18:0/24:0)/Total CE 0.0000000 −18.9531828 Cer(d18:0/24:1)/Total CE0.0000000 −1.2444181 CE 18:3/Cer(d18:1/24:1) 0.0000000 −35.9591235Cer(d18:0/24:0)/Cer(d18:1/24:1) 0.0000004 −36.1288066 CE 18:3/Total Cer0.0000021 −30.3105704 CE 18:3/PC 16:0/16:0 0.0000028 −30.4716021 CE18:3/LacCer(d18:1/20:0) 0.0000028 −44.3063424 CE 20:3/Cer(d18:1/24:1)0.0000034 −28.1216690 CE 18:3/PS O-16:0/18:2-alkenyl 0.0000036−38.5094276 CE 18:3/PS O-16:1/18:2-alkyl 0.0000036 −38.5094276 CE18:3/Total LacCer 0.0000037 −34.1308012 CE 18:3/Cer(d18:1/20:0)0.0000037 −33.6203392 LPC 18:2/LacCer(d18:1/20:0) 0.0000040 −41.6604394Cer(d18:0/24:0)/Total Cer 0.0000049 −31.4531758Cer(d18:0/24:0)/Cer(d18:1/18:0) 0.0000052 −40.2960344 Cer(d18:0/24:0)/PSO-16:0/18:2-alkenyl 0.0000059 −40.8329837 Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl 0.0000059 −40.8329837 Cer(d18:0/22:0)/Cer(d18:1/24:1)0.0000064 −32.1886967 Cer(d18:0/24:0)/LacCer(d18:1/24:0) 0.0000067−37.0287234 Cer(d18:0/22:0)/Cer(d18:1/18:0) 0.0000071 −36.5400374 CE14:0/Cer(d18:1/24:1) 0.0000076 −29.9054883 CE 18:3/Cer(d18:1/16:0)0.0000079 −32.5598715 CE 18:3/Cer(d18:1/18:0) 0.0000082 −38.1543108Cer(d18:0/24:0)/Cer(d18:1/20:0) 0.0000087 −35.4631184 CE18:3/GlcCer(d18:1/20:0) 0.0000087 −36.4665498 CE 18:3/Cer(d18:1/22:0)0.0000101 −30.6595286 Cer(d18:0/24:0)/Cer(d18:1/22:0) 0.0000105−32.4086711 Cer(d18:0/22:0)/PS O-16:0/18:2-alkenyl 0.0000114 −37.4226868Cer(d18:0/22:0)/PS O-16:1/18:2-alkyl 0.0000114 −37.4226868 CE 18:3/PCO-34:1 0.0000122 −33.4941413 CE 18:3/Total CE 0.0000151 −20.2882080 PC16:0/20:3/PS O-16:0/18:2-alkenyl 0.0000154 −29.5280580 PC 16:0/20:3/PSO-16:1/18:2-alkyl 0.0000154 −29.5280580 PC 18:1/18:2/PSO-16:0/18:2-alkenyl 0.0000155 −23.7129392 PC 18:1/18:2/PSO-16:1/18:2-alkyl 0.0000155 −23.7129392 Cer(d18:0/22:0)/Cer(d18:1/20:0)0.0000165 −31.5266149 CE 18:3/LacCer(d18:1/22:0) 0.0000174 −37.1525849LPC 18:2/PS O-16:0/18:2-alkenyl 0.0000175 −30.3450779 LPC 18:2/PSO-16:1/18:2-alkyl 0.0000175 −30.3450779 CE 17:1/Cer(d18:1/24:1)0.0000186 −24.8594478 CE 16:0/Cer(d18:1/24:1) 0.0000188 −19.2509390 CE18:3/GlcCer(d18:1/18:0) 0.0000221 −35.5601491 CE 18:3/LacCer(d18:1/18:0)0.0000326 −37.4416706 CE 18:3/PS O-16:0/18:1-alkenyl 0.0000326−34.1672013 (PS O-16:1/18:1-alkyl) CE 18:3/Cer(d18:1/24:0) 0.0000331−27.4645341 Cer(d18:0/22:0)/Cer(d18:1/22:0) 0.0000377 −28.0899033 LPC16:0/LacCer(d18:1/20:0) 0.0000391 −35.6188222Cer(d18:0/24:0)/Cer(d18:1/16:0) 0.0000446 −34.6695918 Total LPC/TotalLacCer 0.0000469 −26.0881987 5b) Significant lipid to lipid ratios inLURIC study sorted by p-value from subjects not undergoing statintreatment Positive correlation GlcCer(d18:1/26:0)/Total CE 0.00000013.329316 GlcCer(d18:1/26:1)/Total CE 0.000000 35.356592 PSO-16:0/18:2-alkenyl/Total PS O 0.000000 26.426208 PSO-16:1/18:2-alkyl/Total PS O 0.000000 26.426208 PSO-18:2/16:0-alkenyl/Total PS O 0.000000 29.590682 Cer(d18:1/24:1)/TotalPC 0.000000 43.040800 Cer(d18:1/24:1)/PC 16:0/20:4 0.000000 59.876132Cer(d18:1/24:1)/PC 18:0/20:4 0.000000 46.504629 Cer(d18:1/20:0)/Total PC0.000000 46.216544 PC 16:0/16:0/Total PC 0.000000 28.139641 TotalDAG/Total LPC 0.000000 57.426180 Cer(d18:1/18:0)/PC 16:0/20:4 0.00000073.073704 Cer(d18:1/18:0)/Total PC 0.000000 53.769121Cer(d18:1/22:0)/Total PC 0.000000 34.704834 Cer(d18:1/22:0)/PC 16:0/20:40.000000 47.860118 Cer(d18:1/20:0)/PC 16:0/20:4 0.000000 64.045788LacCer(d18:1/20:0)/Total PC 0.000000 55.686130 Cer(d18:1/18:0)/PC18:0/20:4 0.000000 61.943925 Cer(d18:1/20:0)/PC 18:0/20:4 0.00000053.941480 Cer(d18:1/24:1)/PC 16:0/18:1 0.000000 35.646899Cer(d18:1/24:1)/PC 16:0/20:3 0.000000 44.382440 Cer(d18:1/18:0)/PC16:0/20:3 0.000001 61.224227 Cer(d18:1/20:0)/PC 16:0/20:3 0.00000152.891307 Cer(d18:1/24:1)/PC 18:0/18:1 0.000001 42.115354Cer(d18:1/22:0)/PC 18:0/20:4 0.000001 36.949978 Cer(d18:1/20:0)/PC18:0/18:1 0.000004 47.396000 SM (d18:1/17:0) (d18:1/16:1-OH)/Total PC O0.000004 39.660537 PC O-32:0 (KDdiA-PC)/Total PC O 0.000005 46.418572Cer(d18:1/20:0)/PC 16:0/18:1 0.000005 37.704904 Cer(d18:1/24:1)/LPC 18:10.000005 40.092181 Cer(d18:1/24:1)/PC 18:1/18:1 0.000005 38.720001Cer(d18:1/18:0)/PC 16:0/18:1 0.000006 44.307054 LacCer(d18:1/18:0)/TotalPC 0.000006 50.539560 Cer(d18:1/20:0)/PC 18:1/18:1 0.000006 44.664936Cer(d18:1/18:0)/PC 18:0/18:1 0.000006 54.563687 LacCer(d18:1/20:0)/PC18:0/20:4 0.000007 66.072520 Cer(d18:1/24:1)/PC 18:0/20:3 0.00000744.320399 LacCer(d18:1/20:0)/PC 16:0/20:3 0.000008 56.972652Cer(d18:1/22:0)/PC 16:0/20:3 0.000008 37.291136 PC 16:0/16:0/PC16:0/20:4 0.000009 42.512740 PS O-16:0/18:2-alkenyl/Total PC 0.00000953.059092 PS O-16:1/18:2-alkyl/Total PC 0.000009 53.059092LacCer(d18:1/20:0)/PC 18:0/20:3 0.000009 55.403274 Total Cer/Total PC0.000011 29.949121 Total LacCer/Total PC 0.000012 37.815865 TotalDAG/Total PC 0.000012 57.897424 Cer(d18:1/18:0)/PC 18:1/18:1 0.00001249.427440 LacCer(d18:1/20:0)/PC 18:1/18:2 0.000013 48.432788 TotalDAG/Total PC O 0.000014 52.258466 Cer(d18:1/24:1)/Total LPC 0.00001438.684740 Negative correlation Cer(d18:0/22:0)/Total CE 0.000000−6.628640 Cer(d18:0/24:0)/Total CE 0.000000 −13.307278 DAG16:0/18:1/Total DAG 0.000000 −17.305276 CE 18:3/Cer(d18:1/24:1) 0.000000−37.975733 CE 16:0/Cer(d18:1/24:1) 0.000001 −23.257135Cer(d18:0/24:0)/Cer(d18:1/24:1) 0.000003 −36.760563 CE20:4/Cer(d18:1/24:1) 0.000004 −28.636879 CE 20:3/Cer(d18:1/24:1)0.000007 −30.787067 CE 14:0/Cer(d18:1/24:1) 0.000008 −32.409429Cer(d18:0/22:0)/Cer(d18:1/24:1) 0.000011 −34.086320 CE20:4/Cer(d18:1/18:0) 0.000017 −31.313949 CE 18:3/LacCer(d18:1/20:0)0.000017 −45.652383 CE 18:3/Cer(d18:1/20:0) 0.000019 −34.938575 CE17:1/Cer(d18:1/24:1) 0.000020 −27.626744 CE 18:3/Cer(d18:1/18:0)0.000022 −39.797182 CE 18:3/PS O-16:0/18:2-alkenyl 0.000023 −40.724368CE 18:3/PS O-16:1/18:2-alkyl 0.000023 −40.724368 CE 18:3/PC O-34:10.000025 −36.379680 CE 18:3/Total DAG 0.000025 −40.454303 CE 18:3/PC16:0/16:0 0.000026 −31.169278 CE 18:2/Cer(d18:1/24:1) 0.000027−23.500781 Cer(d18:0/22:0)/Cer(d18:1/18:0) 0.000031 −38.447200 CE18:3/Total Cer 0.000034 −30.424215 Cer(d18:0/22:0)/PSO-16:0/18:2-alkenyl 0.000045 −37.930990 Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl 0.000045 −37.930990 LPC 18:2/LacCer(d18:1/20:0)0.000045 −40.925010 PC 18:0/20:4/PS O-16:0/18:2-alkenyl 0.000046−31.467609 PC 18:0/20:4/PS O-16:1/18:2-alkyl 0.000046 −31.467609 PC16:0/20:4/Total DAG 0.000046 −36.637600 CE 16:0/Cer(d18:1/18:0) 0.000047−26.423623 Cer(d18:0/22:0)/Cer(d18:1/20:0) 0.000051 −32.923442 PC16:0/20:3/PS O-16:0/18:2-alkenyl 0.000051 −30.612669 PC 16:0/20:3/PSO-16:1/18:2-alkyl 0.000051 −30.612669 Cer(d18:0/24:0)/Cer(d18:1/18:0)0.000052 −41.966868 CE 17:1/Cer(d18:1/18:0) 0.000062 −30.441023 CE20:4/LacCer(d18:1/20:0) 0.000062 −34.937892Cer(d18:0/24:0)/Cer(d18:1/20:0) 0.000077 −36.424116 CE18:3/GlcCer(d18:1/20:0) 0.000078 −38.775015 PC 16:0/20:4/PSO-16:0/18:2-alkenyl 0.000079 −31.649115 PC 16:0/20:4/PSO-16:1/18:2-alkyl 0.000079 −31.649115 Cer(d18:0/24:0)/PSO-16:0/18:2-alkenyl 0.000082 −40.069396 Cer(d18:0/24:0)/PSO-16:1/18:2-alkyl 0.000082 −40.069396 Cer(d18:0/24:0)/Total Cer 0.000091−30.775984 Cer(d18:0/22:0)/Total DAG 0.000096 −39.183597 CE18:3/Cer(d18:1/16:0) 0.000101 −32.942871 PC 18:1/18:2/PSO-16:0/18:2-alkenyl 0.000106 −24.667433 PC 18:1/18:2/PSO-16:1/18:2-alkyl 0.000106 −24.667433 CE 18:3/Cer(d18:1/22:0) 0.000109−30.876034 CE 14:0/Cer(d18:1/18:0) 0.000117 −35.001327 PC 18:0/20:3/PSO-16:0/18:2-alkenyl 0.000119 −29.825217

TABLE 6 Table of significant lipid to clinical ratios in LURIC studysorted by p-value. Lipid names and clinical measurement, p-values andpercentage change both for positive and negative correlation arepresented. Table 6a shows significant lipids from all study subjects.The significant lipids from subjects not undergoing statin treatment arelisted in table 6b 6a) Significant lipid to clinical ratios in LURICstudy sorted by p-value from all study subjects. Lipid name/clinicalmeasurement p-value Percentage change Positive correlationLacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00000 43.04967LacCer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL) 0.00000 41.46919LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL) 0.00000 32.24669LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL) 0.00001 54.05564LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 0.00001 32.96039Cer(d18:1/18:0)/triglycerides (EDTA) (mg/dL) 0.00001 40.06643Cer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL) 0.00002 31.56099LacCer(d18:1/20:0)/apolipoprotein B (mg/dL) 0.00002 37.03057Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL) 0.00003 34.46408Cer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL) 0.00003 25.23403LacCer(d18:1/18:0)/triglycerides (EDTA) (mg/dL) 0.00004 52.60972LacCer(d18:1/24:1)/triglycerides (EDTA) (mg/dL) 0.00004 60.79934LacCer(d18:1/22:0)/apolipoprotein B (mg/dL) 0.00004 29.83861Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00004 31.35691LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL) 0.00005 38.87517Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL) 0.00005 32.27486LacCer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL) 0.00006 39.32664LacCer(d18:1/22:0)/triglycerides (EDTA) (mg/dL) 0.00006 49.54525LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00007 41.61371LacCer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL) 0.00007 36.35465Total LacCer/total cholesterol (EDTA) (mg/dL) 0.00008 23.69633Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00008 37.38237Cer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL) 0.00011 21.94547Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 0.00011 27.12684Cer(d18:1/18:0)/apolipoprotein B (mg/dL) 0.00017 27.27914LacCer(d18:1/20:0)/total-c/HDL-c 0.00018 33.48550LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 0.00018 36.33201 TotalLacCer/triglycerides (EDTA) (mg/dL) 0.00022 38.52220LacCer(d18:1/24:1)/apolipoprotein B (mg/dL) 0.00022 33.98045LacCer(d18:1/18:0)/apolipoprotein B (mg/dL) 0.00022 33.69302LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL) 0.00024 29.19905 TotalLacCer/apolipoprotein A-I (mg/dL) 0.00025 25.87122 PC O-32:0(KDdiA-PC)/triglycerides (EDTA) (mg/dL) 0.00029 48.31010LacCer(d18:1/20:0)/LDL cholesterol (EDTA) (mg/dL) 0.00031 31.95659Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL) 0.00037 28.23304 TotalCer/triglycerides (EDTA) (mg/dL) 0.00043 26.80115 LacCer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL) 0.00050 24.24011Cer(d18:1/20:0)/apolipoprotein B (mg/dL) 0.00052 20.79615LacCer(d18:1/22:0)/total-c/HDL-c 0.00061 27.84411 TotalLacCer/apolipoprotein B (mg/dL) 0.00065 20.63257 PC O-34:1/triglycerides(EDTA) (mg/dL) 0.00066 38.80785 PC O-32:0 (KDdiA-PC)/apolipoprotein A-I(mg/dL) 0.00066 36.57664 Cer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL)0.00067 30.67863 LacCer(d18:1/18:0)/total-c/HDL-c 0.00073 30.67436 PSO-18:2/16:0-alkenyl/HDL cholesterol (EDTA) (mg/dL) 0.00073 57.54661LacCer(d18:1/18:0)/HDL cholesterol (EDTA) (mg/dL) 0.00079 38.04132Cer(d18:1/16:0)/triglycerides (EDTA) (mg/dL) 0.00083 28.51323Cer(d18:1/18:0)/HDL cholesterol (EDTA) (mg/dL) 0.00085 36.16483Cer(d18:1/18:0)/total-c/HDL-c 0.00087 21.75165LacCer(d18:1/20:0)/apoA1/apoB 0.00090 32.36387 Negative correlation CE18:3/apolipoprotein B (mg/dL) 0.00016 −25.31907 CE 18:3/totalcholesterol (EDTA) (mg/dL) 0.00026 −23.67665 CE 18:3/LDL cholesterol(EDTA) (mg/dL) 0.00052 −27.21759 CE 18:3/apolipoprotein A-I (mg/dL)0.00054 −23.09816 CE 18:3/LDL-c/HDL-c 0.00060 −31.33346 CE18:3/apoA1/apoB 0.00068 −27.55825 CE 18:3/total-c/HDL-c 0.00070−27.28733 CE 18:3/HDL cholesterol (EDTA) (mg/dL) 0.00072 −24.04060Cer(d18:0/24:0)/apolipoprotein B (mg/dL) 0.00181 −26.25271 CE14:0/LDL-c/HDL-c 0.00241 −27.07756 Cer(d18:0/24:0)/total cholesterol(EDTA) (mg/dL) 0.00281 −24.73116 Cer(d18:0/24:0)/total-c/HDL-c 0.00347−27.84469 CE 14:0/total-c/HDL-c 0.00356 −23.22809 PC16:0/20:3/total-c/HDL-c 0.00364 −19.07121 CE 14:0/apolipoprotein B(mg/dL) 0.00375 −19.76414 Total PC/LDL-c/HDL-c 0.00402 −21.24583Cer(d18:0/24:0)/LDL-c/HDL-c 0.00502 −33.76759 Total PC/apolipoprotein B(mg/dL) 0.00513 −12.91145 Total PC/total-c/HDL-c 0.00535 −16.13350 CE20:3/LDL-c/HDL-c 0.00547 −21.16631 PC 16:0/20:4/apolipoprotein B (mg/dL)0.00576 −15.39247 PC 16:0/20:4/total-c/HDL-c 0.00682 −18.06323Cer(d18:0/22:0)/LDL-c/HDL-c 0.00748 −29.05891 Total PC/total cholesterol(EDTA) (mg/dL) 0.00760 −10.60231 Cer(d18:0/22:0)/total-c/HDL-c 0.00765−23.72182 PC 16:0/20:3/LDL-c/HDL-c 0.00784 −22.56336 PC18:0/20:3/total-c/HDL-c 0.00794 −17.83335 CE 14:0/total cholesterol(EDTA) (mg/dL) 0.00816 −17.44260 CE 20:3/total-c/HDL-c 0.00819 −17.34055PC 16:0/20:4/LDL-c/HDL-c 0.00828 −21.49898 CE 17:1/LDL-c/HDL-c 0.00832−21.33179 CE 14:0/LDL cholesterol (EDTA) (mg/dL) 0.00832 −20.55966Cer(d18:0/24:0)/LDL cholesterol (EDTA) (mg/dL) 0.00848 −30.08563 LPC18:2/LDL-c/HDL-c 0.00873 −21.70580 Total LPC/LDL-c/HDL-c 0.00881−20.39287 PC 18:0/20:3/LDL-c/HDL-c 0.00947 −22.19538Cer(d18:0/24:0)/apolipoprotein A-I (mg/dL) 0.01052 −22.39254Cer(d18:0/22:0)/apolipoprotein B (mg/dL) 0.01094 −21.02661 CE20:3/apolipoprotein B (mg/dL) 0.01105 −15.18746 PC 16:0/20:4/totalcholesterol (EDTA) (mg/dL) 0.01131 −13.37554 Total LPC/total-c/HDL-c0.01183 −16.82334 LPC 18:2/apoA1/apoB 0.01189 −19.23316 PC16:0/20:3/apolipoprotein B (mg/dL) 0.01273 −15.11848 CE16:1/apolipoprotein B (mg/dL) 0.01456 −26.99397 Cer(d18:0/24:0)/HDLcholesterol (EDTA) (mg/dL) 0.01507 −23.10073 CE 16:1/LDL cholesterol(EDTA) (mg/dL) 0.01581 −29.68280 PC 18:0/18:1/LDL-c/HDL-c 0.01581−25.72002 CE 20:5/HDL cholesterol (EDTA) (mg/dL) 0.01584 −23.45029 CE20:5/apolipoprotein B (mg/dL) 0.01619 −27.03163 LPC 18:2/LDL cholesterol(EDTA) (mg/dL) 0.01648 −17.26480 6b) Significant lipid to clinicalratios in LURIC study sorted by p-value from subjects not undergoingstatin treatment. Lipid name/Clinical measurement p-value Percentagechange Positive correlation Cer(d18:1/20:0)/total cholesterol (EDTA)(mg/dL) 0.00000 38.78716 Cer(d18:1/20:0)/apolipoprotein B (mg/dL)0.00000 35.29473 Cer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL)0.00000 44.87416 Cer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL)0.00000 31.81230 Cer(d18:1/18:0)/apolipoprotein B (mg/dL) 0.0000041.46939 Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00000 43.22923Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 0.00000 36.15491LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00001 47.52465Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00001 49.43693LacCer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL) 0.00001 47.43498Cer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL) 0.00001 26.21569LacCer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL) 0.00001 36.57029Cer(d18:1/24:1)/apolipoprotein B (mg/dL) 0.00001 29.03655LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 0.00001 35.92744Cer(d18:1/18:0)/triglycerides (EDTA) (mg/dL) 0.00002 45.88769Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL) 0.00002 41.38147LacCer(d18:1/20:0)/apolipoprotein B (mg/dL) 0.00002 43.58427 TotalCer/total cholesterol (EDTA) (mg/dL) 0.00002 22.69184 TotalDAG/triglycerides (EDTA) (mg/dL) 0.00003 42.61436 LacCer(d18:1/20:0)/LDLcholesterol (EDTA) (mg/dL) 0.00003 42.53680Cer(d18:1/18:0)/total-c/HDL-c 0.00003 32.87649Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL) 0.00004 37.38060Cer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL) 0.00004 44.64484LacCer(d18:1/22:0)/apolipoprotein B (mg/dL) 0.00004 35.19942Cer(d18:1/22:0)/apolipoprotein B (mg/dL) 0.00005 24.23877LacCer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL) 0.00006 43.51653LacCer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL) 0.00006 45.00931 TotalLacCer/total cholesterol (EDTA) (mg/dL) 0.00007 27.38505Cer(d18:1/18:0)/HDL cholesterol (EDTA) (mg/dL) 0.00008 50.71310Cer(d18:1/24:1)/HDL cholesterol (EDTA) (mg/dL) 0.00008 36.69128LacCer(d18:1/20:0)/triglycerides (EDTA) (mg/dL) 0.00009 53.20068LacCer(d18:1/24:1)/apolipoprotein B (mg/dL) 0.00009 42.74199Cer(d18:1/20:0)/total-c/HDL-c 0.00010 26.38965 LacCer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL) 0.00010 31.99739Cer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 0.00011 28.85911LacCer(d18:1/24:1)/triglycerides (EDTA) (mg/dL) 0.00013 64.74061 TotalCer/apolipoprotein B (mg/dL) 0.00015 21.06506 Total Cer/apolipoproteinA-I (mg/dL) 0.00016 25.36811 Cer(d18:1/16:0)/total cholesterol (EDTA)(mg/dL) 0.00016 27.48182 LacCer(d18:1/24:1)/apolipoprotein A-I (mg/dL)0.00017 41.35186 Cer(d18:1/20:0)/LDL cholesterol (EDTA) (mg/dL) 0.0001835.64759 LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL) 0.0001942.30922 LacCer(d18:1/22:0)/HDL cholesterol (EDTA) (mg/dL) 0.0002033.63345 LacCer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00022 44.38352Cer(d18:1/18:0)/LDL cholesterol (EDTA) (mg/dL) 0.00023 42.34532 TotalLacCer/apolipoprotein A-I (mg/dL) 0.00031 28.05057 TotalLacCer/apolipoprotein B (mg/dL) 0.00035 24.82894Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL) 0.00039 32.11726LacCer(d18:1/20:0)/total-c/HDL-c 0.00040 37.19117Cer(d18:1/16:0)/apolipoprotein A-I (mg/dL) 0.00042 30.73655 Negativecorrelation CE 18:3/apoA1/apoB 0.00213 −27.06449 CE 18:3/apolipoproteinA-I (mg/dL) 0.00385 −21.63982 CE 18:3/apolipoprotein B (mg/dL) 0.00576−21.66212 CE 18:3/total cholesterol (EDTA) (mg/dL) 0.00593 −20.58905 CE18:3/HDL cholesterol (EDTA) (mg/dL) 0.00621 −21.44255 CE18:3/total-c/HDL-c 0.01166 −23.94433 CE 18:3/LDL-c/HDL-c 0.01395−25.96634 CE 18:3/LDL cholesterol (EDTA) (mg/dL) 0.01410 −22.13225 CE14:0/total-c/HDL-c 0.02379 −20.97683 CE 14:0/LDL-c/HDL-c 0.03038−22.86773 Cer(d18:0/24:0)/apolipoprotein B (mg/dL) 0.03428 −21.10483 CE14:0/apolipoprotein B (mg/dL) 0.03640 −16.53355Cer(d18:0/24:0)/total-c/HDL-c 0.04122 −23.22174 Cer(d18:0/24:0)/totalcholesterol (EDTA) (mg/dL) 0.04309 −19.71324 CE 14:0/apoA1/apoB 0.04354−18.62921 CE 16:1/apoA1/apoB 0.04511 −23.73367

The biomarker ability of measured lipids was assessed also bycalculating the sensitivity and specificity values for each lipid andtheir ratios to other lipids or classical biomarkers such as LDL-C andapolipoproteins. This ROC curve analysis revealed a number of biomarkercandidates that have equal of higher than 60% sensitivity andspecificity for predicting CVD complications (Tables 7-9).

TABLE 7 Significant lipids in LURIC study sorted by top sensitivity andspecificity. Table 7a shows significant lipids from all study subjects.The significant lipids from subjects not undergoing statin treatment arelisted in table 7b. Percentage Lipid name Sensitivity Specificity change7a) Significant lipids in LURIC study sorted by top sensitivity andspecificity from all study subjects. Positive correlationLacCer(d18:1/20:0) 66.03774 63.70370 29.52421 Total LacCer 63.1578960.12270 13.83938 Cer(d18:1/24:1) 61.40351 60.12270 14.88898 Negativecorrelation Total PC 71.92982 63.29114 −16.07367 PC 16:0/20:3 71.4285760.75949 −18.78110 Total LPC 70.17544 60.75949 −17.02070 PC 18:0/20:366.03774 63.05732 −17.20664 LPC 18:1 64.91228 60.12658 −14.45827 SM(d18:1/14:0) (d18:1/13:1-OH) 63.79310 60.50955 −10.49341 Cer(d18:0/22:0)61.40351 61.34969 −22.37263 PC 16:0/18:2 61.40351 60.12658 −8.30551 PC16:0/22:6 60.37736 61.14650 −16.65050 7b) Significant lipids in LURICstudy sorted by top sensitivity and specificity from subjects notundergoing statin treatment. Positive correlation LacCer(d18:1/20:0)70.45455 60.00000 29.52421 Cer(d18:1/24:1) 69.56522 60.34483 14.88898Cer(d18:1/20:0) 65.21739 64.65517 17.32385 Cer(d18:1/22:0) 60.8695762.93103 10.65433 GlcCer(d18:1/24:1) 60.86957 62.06897 12.75066LacCer(d18:1/22:0) 60.00000 61.76471 22.75541 Negative correlation TotalPC 69.56522 61.60714 −16.07367 PC 16:0/20:3 64.44444 60.71429 −18.78110SM (d18:1/14:0) 63.82979 60.71429 −10.49341 (d18:1/13:1-OH) LPC 18:163.04348 60.71429 −14.45827 Total LPC 63.04348 60.71429 −17.02070 PCO-40:3 60.97561 60.43956 −1.88354 PC 16:0/20:4 60.86957 60.71429−18.06547

TABLE 8 Table of significant lipid to lipid ratios in LURIC study sortedby top sensitivity and specificity. Table 8a shows significant lipidsfrom all study subjects. The significant lipids from subjects notundergoing statin treatment are listed in table 8b. Lipid name/Lipidname Sensitivity Specificity Percentage change 8a) Table of significantlipid to lipid ratios in LURIC study sorted by top sensitivity andspecificity from all study subjects. Positive correlation PSO-16:0/18:2-alkenyl/Total PS O 98.24561 63.92405 26.07240 PSO-16:1/18:2-alkyl/Total PS O 98.24561 63.92405 26.07240 PSO-18:2/16:0-alkenyl/Total PS O 85.45455 70.66667 28.78267LacCer(d18:1/20:0)/PC 16:0/20:3 80.39216 65.11628 57.24752 CE 18:2/CE18:3 79.31034 60.37736 26.34366 LacCer(d18:1/20:0)/Total LPC 78.8461561.24031 53.68111 LacCer(d18:1/20:0)/Total PC 78.84615 64.34109 55.30769LacCer(d18:1/20:0)/PC 18:0/20:3 77.08333 60.15625 56.31253Cer(d18:1/24:1)/LPC 18:2 75.92593 63.69427 48.79017 CE 16:0/CE 18:375.86207 60.37736 25.64615 LacCer(d18:1/20:0)/Total SM 75.47170 60.6060629.12486 Cer(d18:1/16:0)/Total PC 75.00000 61.14650 32.91697Cer(d18:1/18:0)/PC 16:0/20:4 75.00000 63.05732 65.70609Cer(d18:1/18:0)/Total LPC 75.00000 61.14650 45.10211 Cer(d18:1/24:1)/SM(d18:1/24:0) (d18:1/23:1- 75.00000 62.42038 36.77357 OH)Cer(d18:1/24:1)/Total LPC 75.00000 63.05732 37.58734Cer(d18:1/24:1)/Total PC 75.00000 60.50955 38.66127LacCer(d18:1/18:0)/Total LPC 75.00000 60.13072 55.13308LacCer(d18:1/20:0)/SM (d18:1/17:1-OH) 75.00000 62.60163 36.30844LacCer(d18:1/20:0)/SM (d18:1/18:0) 75.00000 62.60163 36.30844 TotalCer/Total PC 75.00000 63.92405 28.86380 LacCer(d18:1/24:0)/Total LPC74.54545 61.94030 36.27249 LacCer(d18:1/20:0)/PC 18:2/18:2 74.4680960.31746 47.81762 PC 16:0/16:0/Total PC 73.68421 65.18987 26.13285Cer(d18:1/22:0)/Total PC 73.21429 61.78344 31.36049GlcCer(d18:1/20:0)/Total PC 73.21429 60.50955 36.81380LacCer(d18:1/16:0)/Total LPC 73.21429 60.50955 26.35547LacCer(d18:1/18:0)/Total PC 73.21429 61.43791 53.58552LacCer(d18:1/22:0)/SM (d18:1/14:0) 73.21429 60.00000 30.07361(d18:1/13:1-OH) Total LacCer/Total PC 73.21429 60.50955 40.03890LacCer(d18:1/20:0)/PC 16:0/18:1 73.07692 62.01550 46.35288LacCer(d18:1/20:0)/PC 18:1/18:2 73.07692 60.46512 47.48070Cer(d18:1/26:0)/PC O-40:0 72.72727 62.22222 9.97951LacCer(d18:1/22:0)/Total LPC 72.72727 64.92537 41.61463LacCer(d18:1/24:1)/Total LPC 72.72727 60.44776 45.29327 PCO-18:0/18:2-alkyl/PC O-36:5 72.72727 61.18421 25.99402 PC O-32:0(KDdiA-PC)/PC O-38:5 72.54902 61.36364 34.00112 Cer(d18:1/22:0)/LPC 18:272.22222 61.78344 41.72749 LacCer(d18:1/22:0)/PC 16:0/20:3 72.2222266.41791 51.38070 LacCer(d18:1/24:0)/PC 16:0/20:3 72.22222 61.1940339.48118 Cer(d18:1/24:1)/Total CE 71.92982 61.39241 31.32927 PC16:0/16:0/PC 16:0/20:4 71.92982 61.39241 38.61464 PC 16:0/18:2/Total PC71.92982 60.75949 8.88941 Total LacCer/Total PC O 71.92982 60.2484517.49430 Cer(d18:1/16:0)/LPC 18:1 71.42857 63.69427 30.55279Cer(d18:1/18:0)/LPC 16:0 71.42857 61.14650 40.41256 Cer(d18:1/18:0)/LPC18:1 71.42857 61.78344 45.33865 GlcCer(d18:1/20:0)/PC 16:0/20:4 71.4285760.50955 46.04915 LacCer(d18:1/24:1)/Total PC O 71.42857 60.1449321.09716 CE 19:1/Cer(d18:0/22:0) 71.15385 60.14493 39.21301 Negativecorrelation CE 18:3/LacCer(d18:1/20:0) 84.90566 62.87879 −44.30634 CE18:3/Cer(d18:1/24:1) 80.70175 60.12658 −35.95912 Cer(d18:0/24:0)/TotalCer 80.70175 60.12270 −31.45318 LPC 18:2/LacCer(d18:1/20:0) 80.0000064.34109 −41.66044 CE 18:3/Total CE 79.31034 61.00629 −20.28821GlcCer(d18:1/26:0)/LacCer(d18:1/20:0) 79.16667 61.40351 −23.71130 CE16:1/Cer(d18:1/20:0) 78.94737 61.39241 −33.84979 CE 16:1/Cer(d18:1/24:1)77.19298 61.39241 −36.17234 CE 16:1/LacCer(d18:1/18:0) 77.19298 60.38961−37.93756 CE 18:3/Cer(d18:1/20:0) 77.19298 60.75949 −33.62034 LPC18:1/LacCer(d18:1/20:0) 76.92308 63.56589 −34.40451 CE18:3/LacCer(d18:1/22:0) 76.78571 61.02941 −37.15258 CE 16:1/CE 19:175.47170 60.86957 −66.77151 CE 16:1/Cer(d18:1/18:0) 75.43860 61.39241−39.42716 CE 16:1/LacCer(d18:1/16:0) 75.43860 60.12658 −30.53235 CE16:1/Total LacCer 75.43860 60.75949 −34.87060 CE 18:3/PC 16:0/16:075.43860 60.00000 −30.47160 CE 18:3/PS O-16:0/18:2-alkenyl 75.4386060.64516 −38.50943 CE 18:3/PS O-16:1/18:2-alkyl 75.43860 60.64516−38.50943 CE 18:3/Total LacCer 75.43860 63.29114 −34.13080Cer(d18:0/24:0)/Cer(d18:1/22:0) 75.43860 66.25767 −32.40867 CE16:1/LacCer(d18:1/22:0) 75.00000 61.02941 −37.29505 CE16:1/LacCer(d18:1/24:0) 75.00000 60.29412 −36.84318GlcCer(d18:1/26:0)/LacCer(d18:1/22:0) 75.00000 60.86957 −20.64622 LPC16:0/LacCer(d18:1/20:0) 75.00000 61.24031 −35.61882 Total LPC/TotalLacCer 75.00000 61.78344 −26.08820 LPC 16:0/LacCer(d18:1/24:1) 74.5454560.44776 −24.61533 CE 17:1/GlcCer(d18:1/24:1) 74.07407 60.25641−24.94421 CE 16:1/GlcCer(d18:1/18:0) 73.68421 60.12658 −36.48698 CE16:1/GlcCer(d18:1/20:0) 73.68421 60.75949 −38.30453 CE 16:1/PC 16:0/16:073.68421 60.64516 −29.10430 CE 18:1/Total LacCer 73.68421 60.12658−20.87773 CE 18:3/Cer(d18:1/16:0) 73.68421 67.08861 −32.55987 CE18:3/Cer(d18:1/22:0) 73.68421 61.39241 −30.65953 CE 20:3/Cer(d18:1/24:1)73.68421 61.39241 −28.12167 Cer(d18:0/22:0)/Cer(d18:1/24:1) 73.6842161.96319 −32.18870 Cer(d18:0/24:0)/Cer(d18:1/18:0) 73.68421 63.80368−40.29603 Cer(d18:0/24:0)/Cer(d18:1/24:1) 73.68421 65.64417 −36.12881Cer(d18:0/24:0)/GlcCer(d18:1/20:0) 73.68421 60.73620 −40.34621 CE16:1/LacCer(d18:1/20:0) 73.58491 62.12121 −39.47654 CE20:3/LacCer(d18:1/20:0) 73.58491 62.12121 −35.94789 CE18:3/LacCer(d18:1/24:0) 73.21429 62.50000 −35.91095 CE 18:3/PSO-16:0/18:1-alkenyl (PS O- 73.21429 60.64516 −34.16720 16:1/18:1-alkyl)Cer(d18:0/22:0)/LacCer(d18:1/24:0) 73.21429 60.00000 −31.24173Cer(d18:0/24:0)/LacCer(d18:1/24:0) 73.21429 62.85714 −37.02872 LPC16:0/Total LacCer 73.21429 61.78344 −24.37341 SM (d18:1/24:0)(d18:1/23:1-OH)/Total Cer 73.21429 61.14650 −13.97590 Cer(d18:0/24:0)/SM(d18:1/17:0) (d18:1/16:1- 72.91667 60.00000 −44.87505 OH) LPC16:0/LacCer(d18:1/22:0) 72.72727 67.16418 −27.47521 CE17:1/LacCer(d18:1/18:0) 72.22222 60.52632 −27.90709 8b) Table ofsignificant lipid to lipid ratios in LURIC study sorted by topsensitivity and specificity from subjects not undergoing statintreatment. Positive correlation PS O-16:0/18:2-alkenyl/Total PS O97.82609 62.50000 26.42621 PS O-16:1/18:2-alkyl/Total PS O 97.8260962.50000 26.42621 PS O-18:2/16:0-alkenyl/Total PS O 88.63636 72.6415129.59068 Cer(d18:1/24:1)/LPC 18:2 81.39535 62.16216 51.68188 CE 18:2/CE18:3 80.85106 60.52632 24.84398 Cer(d18:1/18:0)/PC 16:0/20:4 80.0000062.16216 73.07370 Cer(d18:1/24:1)/PC 16:0/18:2 80.00000 60.3603627.45405 Cer(d18:1/24:1)/Total LPC 80.00000 62.16216 38.68474Cer(d18:1/24:1)/Total PC 80.00000 62.16216 43.04080LacCer(d18:1/20:0)/PC 16:0/20:4 79.06977 68.42105 82.44735LacCer(d18:1/20:0)/PC 16:0/20:3 78.57143 64.21053 56.97265Cer(d18:1/16:0)/Total PC 77.77778 60.36036 34.07762 Cer(d18:1/18:0)/LPC18:1 77.77778 60.36036 45.52166 Cer(d18:1/24:1)/SM (d18:1/24:0)(d18:1/23:1-OH) 77.77778 60.17699 32.27927 Cer(d18:1/24:1)/PC O-40:377.50000 60.43956 20.46959 LacCer(d18:1/20:0)/Total LPC 76.7441960.00000 49.56627 LacCer(d18:1/20:0)/Total PC 76.74419 63.15789 55.68613Cer(d18:1/18:0)/Total CE 76.08696 60.17699 49.43112 Cer(d18:1/20:0)/SM(d18:1/14:0) (d18:1/13:1-OH) 76.08696 60.71429 28.98221Cer(d18:1/20:0)/Total PC O 76.08696 60.86957 29.01076Cer(d18:1/24:1)/Total CE 76.08696 60.17699 39.34990 PSO-16:0/18:2-alkenyl/Total PC O 76.08696 61.60714 20.69456 PSO-16:1/18:2-alkyl/Total PC O 76.08696 61.60714 20.69456Cer(d18:1/16:0)/LPC 18:1 75.55556 60.36036 26.36925Cer(d18:1/18:0)/Total LPC 75.55556 63.06306 44.40414Cer(d18:1/22:0)/Total PC 75.55556 63.06306 34.70483 Total Cer/Total PC75.55556 61.60714 29.94912 LacCer(d18:1/20:0)/Total SM 75.00000 61.6161627.48798 LacCer(d18:1/24:0)/Total LPC 75.00000 67.01031 34.46432 PSO-18:2/16:0-alkenyl/Total PC O 75.00000 60.37736 21.65448 CE 16:0/CE18:3 74.46809 61.40351 25.51627 CE 18:0/CE 18:3 74.46809 65.1376129.77017 Cer(d18:1/22:0)/LPC 18:2 74.41860 60.36036 44.40272LacCer(d18:1/20:0)/PC 18:1/18:2 74.41860 64.21053 48.43279LacCer(d18:1/20:0)/SM (d18:1/17:1-OH) 74.41860 60.86957 34.96305LacCer(d18:1/20:0)/SM (d18:1/18:0) 74.41860 60.86957 34.96305LacCer(d18:1/20:0)/PC 18:0/20:3 74.35897 62.76596 55.40327Cer(d18:1/18:0)/SM (d18:1/14:0) (d18:1/13:1-OH) 73.91304 74.1071434.95249 Cer(d18:1/18:0)/SM (d18:1/17:2-OH) 73.91304 60.00000 25.13954Cer(d18:1/18:0)/SM (d18:1/18:1) 73.91304 60.00000 25.13954Cer(d18:1/24:1)/SM (d18:1/23:0) (d18:1/22:1-OH) 73.91304 60.7142929.95139 PC 16:0/16:0/PC 16:0/20:4 73.91304 60.71429 42.51274Cer(d18:1/20:0)/Total LPC 73.33333 61.26126 36.63159 Cer(d18:1/24:1)/PC16:0/20:4 73.33333 62.16216 59.87613 Cer(d18:1/24:1)/PC 18:0/18:273.33333 62.16216 29.37710 Cer(d18:1/24:1)/PC 18:1/18:2 73.3333361.26126 36.88389 Cer(d18:1/24:1)/SM (d18:1/17:1-OH) 73.33333 64.4230823.41916 Cer(d18:1/24:1)/SM (d18:1/18:0) 73.33333 64.42308 23.41916LacCer(d18:1/20:0)/PC 18:0/18:1 73.17073 62.10526 50.18761LacCer(d18:1/20:0)/Total CE 72.72727 62.62626 53.71776 Negativecorrelation DAG 16:0/18:1/Total DAG 88.88889 61.16505 −17.30528 CE18:3/LacCer(d18:1/20:0) 86.36364 66.66667 −45.65238 LPC18:2/LacCer(d18:1/20:0) 82.92683 62.10526 −40.92501 CE18:3/Cer(d18:1/24:1) 82.60870 61.06195 −37.97573GlcCer(d18:1/26:0)/LacCer(d18:1/20:0) 80.48780 64.77273 −26.83109 CE14:0/Total DAG 80.00000 61.16505 −39.38279 CE 18:3/Total CE 78.7234062.28070 −19.58872 PC 18:0/20:3/PS O-16:0/18:2-alkenyl 78.57143 60.36036−29.82522 PC 18:0/20:3/PS O-16:1/18:2-alkyl 78.57143 60.36036 −29.82522CE 16:1/Cer(d18:1/24:1) 78.26087 61.06195 −37.53854 CE 18:3/PSO-16:0/18:2-alkenyl 78.26087 60.90909 −40.72437 CE 18:3/PSO-16:1/18:2-alkyl 78.26087 60.90909 −40.72437 CE 18:3/Total LacCer78.26087 60.17699 −32.64187 Cer(d18:0/24:0)/Total Cer 78.26087 62.06897−30.77598 GlcCer(d18:1/26:0)/LacCer(d18:1/22:0) 78.04878 61.79775−21.27116 CE 18:3/LacCer(d18:1/22:0) 77.77778 63.63636 −34.76187 CE20:3/LacCer(d18:1/20:0) 77.27273 60.60606 −36.58675 PC O-40:3/PSO-18:2/16:0-alkenyl 76.92308 62.79070 −28.59638 LPC18:1/LacCer(d18:1/20:0) 76.74419 60.00000 −33.84809 CE16:0/Cer(d18:1/24:1) 76.08696 61.06195 −23.25713 CE 16:1/Cer(d18:1/18:0)76.08696 63.71681 −41.11023 CE 16:1/Cer(d18:1/20:0) 76.08696 66.37168−34.98271 CE 16:1/GlcCer(d18:1/24:1) 76.08696 60.17699 −39.81218 CE16:1/LacCer(d18:1/18:0) 76.08696 60.36036 −37.28535 CE18:3/Cer(d18:1/20:0) 76.08696 63.71681 −34.93858 CE 18:3/Cer(d18:1/22:0)76.08696 61.94690 −30.87603 Cer(d18:0/22:0)/Cer(d18:1/24:1) 76.0869661.20690 −34.08632 Cer(d18:0/22:0)/Total GlcCer 76.08696 60.34483−28.95910 Cer(d18:0/24:0)/Cer(d18:1/20:0) 76.08696 60.34483 −36.42412 PC18:0/20:3/PS O-18:2/16:0-alkenyl 75.60976 60.95238 −29.83126 CE16:1/LacCer(d18:1/24:0) 75.55556 60.60606 −36.83943 CE18:3/LacCer(d18:1/24:0) 75.55556 60.60606 −37.84417 PC 18:1/18:2/TotalCer 75.55556 60.71429 −19.58862 SM (d18:1/23:0) (d18:1/22:1-OH)/TotalDAG 75.55556 63.10680 −37.45206 SM (d18:1/24:0) (d18:1/23:1-OH)/TotalCer 75.55556 61.94690 −11.07113 Total CE/Total DAG 75.55556 66.01942−31.35698 Total LPC/Total LacCer 75.55556 69.36937 −23.44706 CE 16:1/CE19:1 75.00000 60.82474 −56.18741 CE 20:5/LacCer(d18:1/20:0) 75.0000061.61616 −37.54401 LPC 16:0/LacCer(d18:1/24:0) 75.00000 60.82474−25.29458 CE 15:0/Cer(d18:1/20:0) 74.41860 60.57692 −21.94830 CE16:0/Cer(d18:1/18:0) 73.91304 61.06195 −26.42362 CE 16:1/Total LacCer73.91304 63.71681 −33.50629 CE 18:2/Cer(d18:1/20:0) 73.91304 61.94690−19.85408 CE 18:3/Cer(d18:1/24:0) 73.91304 61.40351 −28.00256 CE18:3/GlcCer(d18:1/20:0) 73.91304 65.48673 −38.77502 CE 18:3/PC 16:0/16:073.91304 63.63636 −31.16928 CE 20:3/Cer(d18:1/24:1) 73.91304 61.06195−30.78707 CE 20:4/GlcCer(d18:1/20:0) 73.91304 62.83186 −30.95570 CE20:4/GlcCer(d18:1/24:1) 73.91304 61.06195 −28.82844

TABLE 9 Table of significant lipid to clinical ratios in LURIC studysorted by top sensitivity and specificity. Table 9a shows significantlipids from all study subjects. The significant lipids from subjects notundergoing statin treatment are listed in table 9b. Percentage Lipidname/Clinical measurement Sensitivity Specificity change 9a) Table ofsignificant lipid to clinical ratios in LURIC study sorted by topsensitivity and specificity from all study subjects. Positivecorrelation LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 75.4717061.48148 43.04967 Cer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL)70.17544 60.73620 21.94547 Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL)70.17544 60.12270 32.27486 LacCer(d18:1/20:0)/HDL cholesterol (EDTA)(mg/dL) 69.81132 62.22222 39.32664 LacCer(d18:1/20:0)/apoA1/apoB67.92453 61.48148 32.36387 LacCer(d18:1/22:0)/HDL cholesterol (EDTA)(mg/dL) 67.85714 60.00000 29.19905 Cer(d18:1/16:0)/triglycerides (EDTA)(mg/dL) 66.66667 61.34969 28.51323 Cer(d18:1/22:0)/apolipoprotein B(mg/dL) 66.66667 60.12270 14.20773 Cer(d18:1/24:1)/apolipoprotein B(mg/dL) 66.66667 62.57669 18.05222 Total Cer/total cholesterol (EDTA)(mg/dL) 66.66667 65.85366 15.12131 LacCer(d18:1/20:0)/LDL-c/HDL-c66.03774 60.74074 23.54484 LacCer(d18:1/20:0)/total cholesterol (EDTA)(mg/dL) 66.03774 62.96296 41.46919 LacCer(d18:1/20:0)/total-c/HDL-c66.03774 60.00000 33.48550 Cer(d18:1/18:0)/triglycerides (EDTA) (mg/dL)64.91228 60.73620 40.06643 Cer(d18:1/22:0)/total cholesterol (EDTA)(mg/dL) 64.91228 61.34969 17.20335 Cer(d18:1/24:1)/total-c/HDL-c64.91228 61.34969 13.34657 GlcCer(d18:1/24:0)/total cholesterol (EDTA)(mg/dL) 64.91228 61.96319 17.04608 LacCer(d18:1/18:0)/apolipoprotein A-I(mg/dL) 64.91228 60.37736 41.61371 LacCer(d18:1/18:0)/total cholesterol(EDTA) (mg/dL) 64.91228 61.00629 38.87517 Total LacCer/total cholesterol(EDTA) (mg/dL) 64.91228 65.03067 23.69633 LacCer(d18:1/22:0)/apoA1/apoB64.28571 62.85714 24.17423 LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL)64.28571 62.85714 32.96039 LacCer(d18:1/22:0)/total cholesterol (EDTA)(mg/dL) 64.28571 60.00000 32.24669 LacCer(d18:1/24:0)/apoA1/apoB64.28571 62.14286 15.23336 LacCer(d18:1/20:0)/LDL cholesterol (EDTA)(mg/dL) 64.15094 61.48148 31.95659 LacCer(d18:1/20:0)/apolipoprotein B(mg/dL) 64.15094 60.00000 37.03057 PS O-18:2/16:0-alkenyl/triglycerides(EDTA) (mg/dL) 63.63636 63.33333 99.88127 Cer(d18:1/20:0)/apolipoproteinB (mg/dL) 63.15789 60.12270 20.79615 Cer(d18:1/20:0)/total cholesterol(EDTA) (mg/dL) 63.15789 61.96319 25.23403 Cer(d18:1/22:0)/LDLcholesterol (EDTA) (mg/dL) 63.15789 60.12270 11.30545Cer(d18:1/24:1)/LDL cholesterol (EDTA) (mg/dL) 63.15789 60.1227014.20759 PS O-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL) 63.1578963.29114 97.78843 PS O-16:1/18:2-alkyl/triglycerides (EDTA) (mg/dL)63.15789 63.29114 97.78843 Total GlcCer/total cholesterol (EDTA) (mg/dL)63.15789 60.73620 17.56924 Total LacCer/apolipoprotein A-I (mg/dL)63.15789 61.34969 25.87122 Total LacCer/apolipoprotein B (mg/dL)63.15789 61.96319 20.63257 LacCer(d18:1/24:1)/triglycerides (EDTA)(mg/dL) 62.50000 62.14286 60.79934 PS O-16:0/18:1-alkenyl (PSO-16:1/18:1- 62.50000 61.39241 65.88734 alkyl)/triglycerides (EDTA)(mg/dL) Cer(d18:1/20:0)/triglycerides (EDTA) (mg/dL) 61.40351 60.7362034.46408 Cer(d18:1/22:0)/triglycerides (EDTA) (mg/dL) 61.40351 63.1901828.23304 Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 61.40351 65.0306727.12684 LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL) 61.4035164.41718 25.01312 LacCer(d18:1/18:0)/HDL cholesterol (EDTA) (mg/dL)61.40351 60.37736 38.04132 LacCer(d18:1/18:0)/LDL cholesterol (EDTA)(mg/dL) 61.40351 64.15094 28.50180 LacCer(d18:1/18:0)/apolipoprotein B(mg/dL) 61.40351 61.00629 33.69302 LacCer(d18:1/18:0)/triglycerides(EDTA) (mg/dL) 61.40351 62.26415 52.60972 Total Cer/apolipoprotein A-I(mg/dL) 61.40351 63.41463 19.09944 Total GlcCer/apolipoprotein B (mg/dL)61.40351 60.12270 14.92180 Total LacCer/triglycerides (EDTA) (mg/dL)61.40351 62.57669 38.52220 LacCer(d18:1/22:0)/apolipoprotein B (mg/dL)60.71429 65.00000 29.83861 Negative correlation CE 18:3/total-c/HDL-c67.24138 62.89308 −27.28733 LPC 18:2/apolipoprotein B (mg/dL) 65.4545560.12658 −16.19596 Total PC/apolipoprotein B (mg/dL) 64.91228 61.39241−12.91145 Total PC/total cholesterol (EDTA) (mg/dL) 64.91228 60.75949−10.60231 CE 16:1/HDL cholesterol (EDTA) (mg/dL) 63.79310 61.63522−22.01197 CE 18:3/HDL cholesterol (EDTA) (mg/dL) 63.79310 62.26415−24.04060 CE 18:3/LDL cholesterol (EDTA) (mg/dL) 63.79310 62.26415−27.21759 LPC 18:2/LDL-c/HDL-c 63.63636 61.39241 −21.70580 TotalPC/total-c/HDL-c 63.15789 60.12658 −16.13350 PC 16:0/20:3/HDLcholesterol (EDTA) (mg/dL) 62.50000 62.65823 −11.45558 PC16:0/20:3/apolipoprotein B (mg/dL) 62.50000 60.12658 −15.11848 CE16:1/apolipoprotein B (mg/dL) 62.06897 62.26415 −26.99397 CE 16:1/totalcholesterol (EDTA) (mg/dL) 62.06897 60.37736 −24.28770 CE18:3/LDL-c/HDL-c 62.06897 62.89308 −31.33346 CE 18:3/apolipoprotein A-I(mg/dL) 62.06897 60.37736 −23.09816 LPC 18:2/HDL cholesterol (EDTA)(mg/dL) 61.81818 60.75949 −16.07209 LPC 18:2/apoA1/apoB 61.8181863.92405 −19.23316 PC 16:0/20:4/LDL cholesterol (EDTA) (mg/dL) 61.4035160.12658 −15.98292 PC 16:0/20:4/apolipoprotein A-I (mg/dL) 61.4035160.75949 −12.23661 PC 16:0/20:4/total cholesterol (EDTA) (mg/dL)61.40351 61.39241 −13.37554 Total PC/LDL-c/HDL-c 61.40351 62.65823−21.24583 PC 16:0/20:3/total-c/HDL-c 60.71429 61.39241 −19.07121 PC18:0/20:4/apoA1/apoB 60.71429 62.02532 −13.36540 CE 18:3/apoA1/apoB60.34483 60.37736 −27.55825 CE 18:3/apolipoprotein B (mg/dL) 60.3448361.00629 −25.31907 CE 20:5/HDL cholesterol (EDTA) (mg/dL) 60.3448360.37736 −23.45029 CE 20:5/LDL cholesterol (EDTA) (mg/dL) 60.3448360.37736 −25.93288 LPC 18:2/LDL cholesterol (EDTA) (mg/dL) 60.0000062.02532 −17.26480 LPC 18:2/total cholesterol (EDTA) (mg/dL) 60.0000062.65823 −14.92954 9b) Table of significant lipid to clinical ratios inLURIC study sorted by top sensitivity and specificity from subjects notundergoing statin treatment. Positive correlationCer(d18:1/24:1)/apolipoprotein B (mg/dL) 82.60870 62.06897 18.05222Cer(d18:1/24:1)/total cholesterol (EDTA) (mg/dL) 80.43478 61.2069021.94547 LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 77.27273 67.0000043.04967 Cer(d18:1/22:0)/LDL cholesterol (EDTA) (mg/dL) 73.9130460.34483 11.30545 Total Cer/LDL cholesterol (EDTA) (mg/dL) 73.9130462.39316 8.25598 Total Cer/total cholesterol (EDTA) (mg/dL) 73.9130470.08547 15.12131 LacCer(d18:1/20:0)/HDL cholesterol (EDTA) (mg/dL)72.72727 61.00000 39.32664 LacCer(d18:1/20:0)/apoA1/apoB 72.7272760.00000 32.36387 Cer(d18:1/22:0)/total cholesterol (EDTA) (mg/dL)71.73913 61.20690 17.20335 Cer(d18:1/24:1)/LDL cholesterol (EDTA)(mg/dL) 71.73913 61.20690 14.20759 Cer(d18:1/24:1)/total-c/HDL-c71.73913 60.34483 13.34657 Total Cer/apolipoprotein A-I (mg/dL) 71.7391361.53846 19.09944 Total Cer/apolipoprotein B (mg/dL) 71.73913 61.5384612.34421 LacCer(d18:1/20:0)/LDL cholesterol (EDTA) (mg/dL) 70.4545561.00000 31.95659 LacCer(d18:1/20:0)/LDL-c/HDL-c 70.45455 61.0000023.54484 Cer(d18:1/20:0)/LDL cholesterol (EDTA) (mg/dL) 69.5652260.34483 18.51094 Cer(d18:1/20:0)/apolipoprotein B (mg/dL) 69.5652268.10345 20.79615 Cer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL)69.56522 71.55172 25.23403 Cer(d18:1/20:0)/total-c/HDL-c 69.5652260.34483 14.96816 Cer(d18:1/22:0)/apolipoprotein B (mg/dL) 69.5652265.51724 14.20773 Cer(d18:1/24:0)/total cholesterol (EDTA) (mg/dL)69.56522 60.68376 11.30123 Cer(d18:1/24:1)/LDL-c/HDL-c 69.56522 62.931035.34922 Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 69.56522 60.3448327.12684 Cer(d18:1/24:1)/triglycerides (EDTA) (mg/dL) 69.56522 63.7931032.27486 GlcCer(d18:1/24:1)/apolipoprotein B (mg/dL) 69.56522 61.2069017.03707 Total DAG/apolipoprotein A-I (mg/dL) 68.88889 60.19417 15.46034LacCer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL) 68.18182 61.0000041.46919 PC O-34:1/apolipoprotein B (mg/dL) 68.18182 60.00000 22.73127Cer(d18:1/16:0)/LDL cholesterol (EDTA) (mg/dL) 67.39130 62.0689710.42412 Cer(d18:1/18:0)/total-c/HDL-c 67.39130 61.20690 21.75165Cer(d18:1/18:0)/triglycerides (EDTA) (mg/dL) 67.39130 64.65517 40.06643Cer(d18:1/24:0)/LDL cholesterol (EDTA) (mg/dL) 67.39130 62.39316 4.69599Cer(d18:1/24:0)/apolipoprotein A-I (mg/dL) 67.39130 61.53846 14.67208GlcCer(d18:1/20:0)/total cholesterol (EDTA) (mg/dL) 67.39130 60.3448320.60005 Total GlcCer/apolipoprotein B (mg/dL) 67.39130 60.3448314.92180 Total LacCer/total cholesterol (EDTA) (mg/dL) 67.39130 62.9310323.69633 LacCer(d18:1/22:0)/apoA1/apoB 66.66667 61.76471 24.17423LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 66.66667 60.78431 32.96039LacCer(d18:1/20:0)/apolipoprotein B (mg/dL) 65.90909 61.00000 37.03057LacCer(d18:1/20:0)/total-c/HDL-c 65.90909 62.00000 33.48550Cer(d18:1/16:0)/triglycerides (EDTA) (mg/dL) 65.21739 62.06897 28.51323Cer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 65.21739 66.37931 21.04730Cer(d18:1/24:0)/apolipoprotein B (mg/dL) 65.21739 62.39316 9.26738GlcCer(d18:1/20:0)/apolipoprotein B (mg/dL) 65.21739 60.34483 17.00627GlcCer(d18:1/26:1)/apolipoprotein A-I (mg/dL) 65.21739 61.60714 21.90520LacCer(d18:1/16:0)/triglycerides (EDTA) (mg/dL) 65.21739 60.3448325.01312 LacCer(d18:1/18:0)/apolipoprotein B (mg/dL) 65.21739 61.4035133.69302 LacCer(d18:1/18:0)/total cholesterol (EDTA) (mg/dL) 65.2173962.28070 38.87517 PS O-16:0/18:2-alkenyl/triglycerides (EDTA) (mg/dL)65.21739 61.60714 97.78843 PS O-16:1/18:2-alkyl/triglycerides (EDTA)(mg/dL) 65.21739 61.60714 97.78843 Negative correlation CE18:3/total-c/HDL-c 68.08511 62.28070 −27.28733 CE 18:3/LDL-c/HDL-c63.82979 60.52632 −31.33346 CE 18:3/apoA1/apoB 61.70213 64.03509−27.55825 CE 20:5/triglycerides (EDTA) (mg/dL) 61.70213 60.52632−15.26342 PC O-38:6/apolipoprotein A-I (mg/dL) 60.86957 62.03704−3.87776 Total LPC/apoA1/apoB 60.86957 60.71429 −14.81039 TotalPC/apolipoprotein A-I (mg/dL) 60.86957 62.50000 −8.50761 PC18:0/20:4/apoA1/apoB 60.00000 64.28571 −13.36540

The preferred lipid molecules of the invention were selected as follows:a) it was likely to be biologically meaningful, b) it preferably belongsto a family of lipids that are behaving similarly, c) it is expressed inmeaningful & measurable concentrations, d) it has very significantp-value or good AUC-value (>0.65) and for most also the %-change issubstantial (>20%), and e) it appeared significant in different tests.About 15 lipids or lipid ratios, each with either a positive or negativeCVD correlation, were selected based on the highest p-values and bestsensitivity and specificity subjectively ensuring the balancedrepresentation of all lipid classes. Sensitivity and specificitythresholds were annotated in cases where the threshold of 60 and 70 werereached, respectively. The preferred embodiment lipids, lipid-lipidratios and lipid-clinical ratios are presented in tables 10-13.

TABLE 10 The preferred embodiment lipids selected from significantlipids detected from LURIC sample set. Percentage Lipid name p-valuechange Sensitivity Specificity Positive correlation Cer(d18:1/20:0)0.00004 28.00357 LacCer(d18:1/20:0) 0.00010 32.91154 70.45455 60.00000Cer(d18:1/24:1) 0.00039 23.37606 69.56522 60.34483 LacCer(d18:1/24:1)0.00199 29.83279 PS O-18:2/16:0-alkenyl 0.00432 33.81177 PSO-16:1/18:2-alkyl 0.00590 32.17190 Total Cer 0.00932 15.44601 TotalLacCer 0.01105 16.00541 GlcCer(d18:1/24:1) 12.75066 60.86957 62.06897LacCer(d18:1/22:0) 0.00046 22.75541 Cer(d18:1/18:0) 0.00009 34.32550Negative correlation Total PC 0.00921 −12.44220 PC 16:0/20:4 0.02256−14.96966 Cer(d18:0/24:0) 0.03376 −21.87004 Total LPC 0.03443 −12.91576CE 14:0 0.01090 −21.01258 CE 20:3 0.02157 −16.03606 CE 17:1 0.02204−15.93952 PC 16:0/20:3 −18.78110 64.44444 60.71429 LPC 18:1 −14.4582763.04348 60.71429 PC 18:0/20:3 0.00726 −17.20664 PC 18:0/18:1 0.00765−18.18002 Cer(d18:0/22:0) 0.01158 −22.37263

TABLE 11 Preferred embodiments from significant lipid to lipid ratiosdetected from LURIC sample set. Lipid name/Lipid name p-value Percentagechange Sensitivity Specificity Positive correlationGlcCer(d18:1/26:1)/Total CE 0.000000 35.356592 Cer(d18:1/24:1)/Total PC0.000000 43.040800 Cer(d18:1/24:1)/PC 16:0/20:4 0.000000 59.876132Cer(d18:1/20:0)/PC 16:0/20:4 0.000000 64.045788 LacCer(d18:1/20:0)/PC16:0/20:3 0.000008 56.972652 80.39216 65.11628 Total Cer/Total PC0.000011 29.949121 Total LacCer/Total PC 0.000012 37.815865LacCer(d18:1/20:0)/PC 18:1/18:2 0.000013 48.432788 PSO-16:0/18:2-alkenyl/Total PS O 26.42621 97.82609 62.50000Cer(d18:1/18:0)/PC 16:0/20:4 73.07370 80.00000 62.16216LacCer(d18:1/20:0)/Total LPC 53.68111 78.84615 61.24031LacCer(d18:1/20:0)/PC 16:0/20:4 82.44735 79.06977 68.42105 Negativecorrelation Cer(d18:0/24:0)/Cer(d18:1/24:1) 0.000003 −36.760563Cer(d18:0/22:0)/Cer(d18:1/24:1) 0.000011 −34.086320 DAG 16:0/18:1/TotalDAG −17.30528 88.88889 61.16505 Cer(d18:0/24:0)/Cer(d18:1/22:0)−32.40867 75.43860 66.25767 Cer(d18:0/24:0)/Total CE 0.0000000−18.9531828 Cer(d18:0/24:0)/Cer(d18:1/24:1) 0.000003 −36.760563Cer(d18:0/24:0)/Total Cer 0.0000049 −31.4531758Cer(d18:0/24:0)/Cer(d18:1/18:0) 0.0000052 −40.2960344 Cer(d18:0/24:0)/PSO-16:0/18:2- 0.0000059 −40.8329837 alkenylCer(d18:0/24:0)/LacCer(d18:1/24:0) 0.0000067 −37.0287234Cer(d18:0/22:0)/Cer(d18:1/18:0) 0.0000071 −36.5400374Cer(d18:0/24:0)/Cer(d18:1/22:0) 0.0000105 −32.4086711Cer(d18:0/22:0)/Cer(d18:1/20:0) 0.0000165 −31.5266149 Cer(d18:0/22:0)/PSO-16:0/18:2- 0.000045 −37.930990 alkenyl Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl 0.000045 −37.930990GlcCer(d18:1/26:0)/LacCer(d18:1/20:0) −26.83109 80.48780 64.77273 TotalLPC/Total LacCer 0.0000469 −26.08820GlcCer(d18:1/26:0)/LacCer(d18:1/22:0) −21.27116 78.04878 61.79775

TABLE 12 Preferred embodiments from significant lipid to clinical ratiosfrom LURIC sample sct. Lipid name/Clinical measurement p-valuePercentage change Sensitivity Specificity Positive correlationCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00000 43.22923Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 0.00000 36.15491 69.5652260.34483 LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00001 47.5246577.27273 67.00000 Total Cer/apolipoprotein A-I (mg/dL) 0.00016 25.36811Total LacCer/apolipoprotein A-I (mg/dL) 0.00031 28.05057 71.7391361.53846 Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00001 49.43693LacCer(d18:1/22:0)/apolipoprotein A-I (mg/dL) 0.00001 35.92744LacCer(d18:1/20:0)/HDL cholesterol (EDTA) 39.32664 72.72727 61.00000(mg/dL) Cer(d18:1/24:1)/apolipoprotein B (mg/dL) 18.05222 82.6087062.06897 Negative correlation Cer(d18:0/24:0)/apolipoprotein B (mg/dL)0.03428 −21.10483 Cer(d18:0/24:0)/total cholesterol (EDTA) 0.04309−19.71324 (mg/dL) Cer(d18:0/24:0)/apolipoprotein B (mg/dL) 0.00181−26.25271 PC 16:0/20:4/apolipoprotein B (mg/dL) 0.00576 −15.39247Cer(d18:0/24:0)/apolipoprotein A-I (mg/dL) 0.01052 −22.39254

TABLE 13 Top candidates from each category, if available, are listed.The best candidates were selected based on following criteria: t-testp-value ≦0.05 and sensitivity ≧60% and specificity ≧60%. PercentageMeasurement name p-value change Positive correlation Cer(d18:1/20:0)0.00004 28.00357 LacCer(d18:1/20:0) 0.00010 32.91154 Cer(d18:1/24:1)0.00039 23.37606 LacCer(d18:1/24:1) 0.00199 29.83279 LacCer(d18:1/22:0)0.00046 22.75541 Cer(d18:1/18:0) 0.00009 34.32550 Cer(d18:1/24:1)/PC16:0/20:4 0.000000 59.876132 LacCer(d18:1/20:0)/PC 16:0/20:3 0.00000856.972652 PS O-16:0/18:2-alkenyl/Total PS O 26.42621 Cer(d18:1/18:0)/PC16:0/20:4 0.000000 73.073704 Cer(d18:1/20:0)/apolipoprotein A-I (mg/dL)0.00000 43.22923 Cer(d18:1/24:1)/apolipoprotein A-I (mg/dL) 0.0000036.15491 LacCer(d18:1/20:0)/apolipoprotein A-I (mg/dL) 0.00001 47.52465Total LacCer/apolipoprotein A-I (mg/dL) 0.00031 28.05057LacCer(d18:1/20:0)/HDL cholesterol (EDTA) 39.32664 (mg/dL)Cer(d18:1/18:0)/apolipoprotein A-I (mg/dL) 0.00001 49.43693 Negativecorrelation PC 16:0/20:4 0.02256 −14.96966 Cer(d18:0/24:0) 0.03376−21.87004 GlcCer(d18:1/26:0)/LacCer(d18:1/20:0) −26.83109 DAG16:0/18:1/Total DAG −17.30528 Cer(d18:0/24:0)/Total Cer −31.45318 TotalLPC/Total LacCer −26.08820 GlcCer(d18:1/26:0)/LacCer(d18:1/22:0)−21.27116 Cer(d18:0/24:0)/Cer(d18:1/24:1) 0.0000004 −36.1288066Cer(d18:0/24:0)/Cer(d18:1/18:0) 0.0000052 −40.2960344 Cer(d18:0/24:0)/PSO-16:0/18:2-alkenyl 0.0000059 −40.8329837Cer(d18:0/24:0)/Cer(d18:1/22:0) 0.0000105 −32.4086711 Cer(d18:0/22:0)/PSO-16:0/18:2-alkenyl 0.000045 −37.930990 Cer(d18:0/22:0)/PSO-16:1/18:2-alkyl 0.000045 −37.930990 Cer(d18:0/24:0)/LacCer(d18:1/24:0)0.0000067 −37.0287234

Lipidomic analysis proved to be efficient in identifying novel plasmabiomarkers for CVD complications.

Molecular lipid to molecular lipid ratio could be an important indicatorof cellular lipid metabolism including e.g., enzyme activities in thelipid metabolism pathways. Thus, these ratios may provide moreinformation as the absolute plasma concentrations of the molecularlipids alone. As the absolute molecular lipid plasma concentrationdifferences in general between healthy individuals and atheroscleroticpatients seem to be between 30-70%, it might be reasonable to calculateand use different ratios instead of absolute concentrations only. Aslipoprotein particles (e.g. LDL, HDL, and VLDL) are serving as carriersfor most of the lipids in the blood stream it is appropriate to relatemolecular lipid concentrations to lipoprotein data. Thus, the molecularlipid to HDL-cholesterol, LDL-cholesterol, apolipoprotein A-I andapolipoprotein B ratios were calculated. In fact, a number of ratiosbetween the concentrations of different molecular lipids outperformedabsolute plasma concentrations as disease biomarkers in CVD patients.

As the detected lipids are carried in the lipoprotein particles (LDL,VLDL and HDL) it is obvious that the corresponding lipoprotein fractionconcentrations will even improve the prediction potential of molecularlipids from the results of the present study in total serum/plasmasamples.

The lipid lowering drug efficiency measurements have so far been basedon LDL-C and HDL-C assays. As the inventors have herein observed morepotential biomarkers that predict the development of high-risk CVDcomplications better than these classical analyses, future drugefficiency profiling should be based on new sensitive and specificbiomarkers that are more directly related to the risk of severeCVD-related complications rather than to LDL-C.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, numerous equivalents to thespecific embodiments described herein both in the Examples in the bodyof the entire patent description. Such equivalents are considered to bewithin the scope of this invention and are covered by the followingclaims.

1-26. (canceled)
 27. A method for determining whether a subject is atrisk to develop one or more Cardiovascular Disease (CVD) complications,comprising: a) determining in a sample from said subject theconcentration(s) of one or more lipid(s), wherein (an) increased ordecreased concentration(s) in said sample, when compared to a controlsample, is (are) indicative of said subject having an increased risk ofdeveloping one or more CVD complications, wherein the one or morelipid(s) whose increase(s) in concentration is (are) compared to thecontrol is (are) selected from: Cer(d18:1/16:0), Cer(d18:1/18:0),Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:1/24:1), Cer(d18:1/26:1), andTotal Cer, and wherein the one or more lipid(s) whose decrease(s) inconcentration is (are) compared to the control is (are) selected from:Cer(d18:0/22:0), and Cer(d18:0/24:0), b) determining in a sample fromsaid subject one or more lipid-lipid ratio(s), wherein (an) increased ordecreased lipid-lipid ratio(s) in said sample, when compared to acontrol sample, is (are) indicative of said subject having an increasedrisk of developing one or more CVD complications, wherein the one ormore lipid-lipid ratio(s) whose increase(s) is (are) compared to thecontrol is (are) selected from: Cer(d18:1/16:0)/LPC 18:1,Cer(d18:1/18:0)/LPC 16:0, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/Total LPC, Cer(d18:1/20:0)/Total LPC,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/Total LPC, Cer(d18:1/22:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/24:1)/Total CE, Cer(d18:1/18:0)/Total CE, and CE19:1/Cer(d18:0/22:0), and wherein the one or more lipid-lipid ratio(s)whose decrease(s) is (are) compared to the control is (are) selectedfrom: Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Total CE,Cer(d18:0/24:1)/Total CE, CE 18:3/Cer(d18:1/24:1), CE20:3/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/20:0), CE 14:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/16:0), CE 18:3/Cer(d18:1/18:0), CE18:3/Cer(d18:1/22:0), CE 17:1/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/24:0), CE 20:4/Cer(d18:1/24:1), CE20:4/Cer(d18:1/18:0), CE 18:2/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/18:0),CE 17:1/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/18:0), CE16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1), CE 16:1/Cer(d18:1/18:0),CE 15:0/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/20:0), and CE 18:3/Total Cer,or c) determining in a sample from said subject one or morelipid-clinical concentration ratio(s), wherein (an) increased ordecreased lipid-clinical concentration ratio(s) in said sample, whencompared to a control sample, is (are) indicative of said subject havingan increased risk of developing one or more CVD complications, whereinthe one or more lipid-clinical concentration ratio(s) whose increase(s)is (are) compared to the control is (are) selected from:Cer(d18:1/16:0)/apolipoprotein A-I, Cer(d18:1/16:0)/LDL cholesterol,Cer(d18:1/16:0)/triglycerides, Cer(d18:1/18:0)/apolipoprotein B,Cer(d18:1/18:0)/HDL cholesterol, Cer(d18:1/18:0)/total-c/HDL-c,Cer(d18:1/18:0)/total cholesterol, Cer(d18:1/18:0)/triglycerides,Cer(d18:1/20:0)/apolipoprotein B, Cer(d18:1/20:0)/HDL cholesterol,Cer(d18:1/20:0)/total cholesterol, Cer(d18:1/20:0)/triglycerides,Cer(d18:1/20:0)/total-c/HDL-c, Cer(d18:1/20:0)/LDL cholesterol,Cer(d18:1/22:0)/apolipoprotein A-I, Cer(d18:1/22:0)/apolipoprotein B,Cer(d18:1/22:0)/LDL cholesterol, Cer(d18:1/22:0)/triglycerides,Cer(d18:1/22:0)/total cholesterol, Cer(d18:1/24:0)/apolipoprotein A-I,Cer(d18:1/24:0)/apolipoprotein B, Cer(d18:1/24:0)/LDL cholesterol,Cer(d18:1/24:0)/total cholesterol, Cer(d18:1/24:1)/HDL cholesterol,Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/LDL cholesterol, Cer(d18:1/24:1)/total cholesterol,Cer(d18:1/24:1)/triglycerides, Total Cer/apolipoprotein B, Total Cer/LDLcholesterol, Total Cer/total cholesterol, and Total Cer/triglycerides,and wherein the one or more lipid-clinical concentration ratio(s) whosedecrease(s) is (are) compared to the control is (are) selected from:Cer(d18:0/22:0)/apolipoprotein B, Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/HDL cholesterol,Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total-c/HDL-c, andCer(d18:0/24:0)/LDL cholesterol.
 28. A method for evaluating theeffectiveness of a treatment of CVD and/or one or more of itscomplications, in a subject, comprising: a) determining in a sample fromsaid subject the concentration(s) of one or more lipid (s), wherein (an)increased or decreased concentration(s) in said sample, when compared toa control sample, is (are) indicative of effectiveness of saidtreatment, wherein the one or more lipid(s) whose decrease(s) inconcentration is (are) compared to the control is (are) selected from:Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0),Cer(d18:1/24:1), Cer(d18:1/26:1), and Total Cer, and wherein the one ormore lipid(s) whose increase(s) in concentration is (are) compared tothe control is (are) selected from: Cer(d18:0/22:0), andCer(d18:0/24:0), b) determining in a sample from said subject one ormore lipid-lipid ratio(s), wherein (an) increased or decreasedlipid-lipid ratio(s) in said sample, when compared to a control sample,is (are) indicative of effectiveness of said treatment, wherein the oneor more lipid-lipid ratio(s) whose decrease(s) is (are) compared to thecontrol is (are) selected from: Cer(d18:1/16:0)/LPC 18:1,Cer(d18:1/18:0)/LPC 16:0, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/Total LPC, Cer(d18:1/20:0)/Total LPC,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/Total LPC, Cer(d18:1/22:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/24:1)/Total CE, Cer(d18:1/18:0)/Total CE, and CE19:1/Cer(d18:0/22:0), and wherein the one or more lipid-lipid ratio(s)whose increase(s) is (are) compared to the control is (are) selectedfrom: Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Total CE,Cer(d18:0/24:1)/Total CE, CE 18:3/Cer(d18:1/24:1), CE20:3/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/20:0), CE 14:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/16:0), CE 18:3/Cer(d18:1/18:0), CE18:3/Cer(d18:1/22:0), CE 17:1/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/24:0), CE 20:4/Cer(d18:1/24:1), CE20:4/Cer(d18:1/18:0), CE 18:2/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/18:0),CE 17:1/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/18:0), CE16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1), CE 16:1/Cer(d18:1/18:0),CE 15:0/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/20:0), and CE 18:3/Total Cer,or c) determining in a sample from said subject one or morelipid-clinical concentration ratio(s), wherein (an) increased ordecreased lipid-clinical concentration ratio(s) in said sample, whencompared to a control sample, is (are) indicative of effectiveness ofsaid treatment, wherein the one or more lipid-clinical concentrationratio(s) whose decrease(s) is (are) compared to the control is (are)selected from: Cer(d18:1/16:0)/apolipoprotein A-I, Cer(d18:1/16:0)/LDLcholesterol, Cer(d18:1/16:0)/triglycerides,Cer(d18:1/18:0)/apolipoprotein B, Cer(d18:1/18:0)/HDL cholesterol,Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/total cholesterol,Cer(d18:1/18:0)/triglycerides, Cer(d18:1/20:0)/apolipoprotein B,Cer(d18:1/20:0)/HDL cholesterol, Cer(d18:1/20:0)/total cholesterol,Cer(d18:1/20:0)/triglycerides, Cer(d18:1/20:0)/total-c/HDL-c,Cer(d18:1/20:0)/LDL cholesterol, Cer(d18:1/22:0)/apolipoprotein A-I,Cer(d18:1/22:0)/apolipoprotein B, Cer(d18:1/22:0)/LDL cholesterol,Cer(d18:1/22:0)/triglycerides, Cer(d18:1/22:0)/total cholesterol,Cer(d18:1/24:0)/apolipoprotein A-I, Cer(d18:1/24:0)/apolipoprotein B,Cer(d18:1/24:0)/LDL cholesterol, Cer(d18:1/24:0)/total cholesterol,Cer(d18:1/24:1)/HDL cholesterol, Cer(d18:1/24:1)/LDL-c/HDL-c,Cer(d18:1/24:1)/total-c/HDL-c, Cer(d18:1/24:1)/LDL cholesterol,Cer(d18:1/24:1)/total cholesterol, Cer(d18:1/24:1)/triglycerides, TotalCer/apolipoprotein B, Total Cer/LDL cholesterol, Total Cer/totalcholesterol, and Total Cer/triglycerides, and wherein the one or morelipid-clinical concentration ratio(s) whose increase(s) is (are)compared to the control is (are) selected from:Cer(d18:0/22:0)/apolipoprotein B, Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/HDL cholesterol,Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total-c/HDL-c, andCer(d18:0/24:0)/LDL cholesterol.
 29. A method of choosing an appropriatetreatment of CVD and/or one or more of its complications, in a subject,comprising: a) determining in a sample from said subject theconcentration(s) of one or more lipid(s), wherein (an) increased ordecreased concentration(s) in said sample, when compared to a controlsample, is (are) indicative of said subject being in need of treatmentor a change in, or supplementation of, an already administeredtreatment, wherein the one or more lipid(s) whose increase(s) inconcentration is (are) compared to the control is (are) selected from:Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0),Cer(d18:1/24:1), Cer(d18:1/26:1), and Total Cer, and wherein the one ormore lipid(s) whose decrease(s) in concentration is (are) compared tothe control is (are) selected from: Cer(d18:0/22:0), andCer(d18:0/24:0), b) determining in a sample from said subject one ormore lipid-lipid ratio(s), wherein (an) increased or decreasedlipid-lipid ratio(s) in said sample, when compared to a control sample,is (are) indicative of said subject being in need of treatment or achange in, or supplementation of, an already administered treatment,wherein the one or more lipid-lipid ratio(s) whose increase(s) is (are)compared to the control is (are) selected from: Cer(d18:1/16:0)/LPC18:1, Cer(d18:1/18:0)/LPC 16:0, Cer(d18:1/18:0)/LPC 18:1,Cer(d18:1/18:0)/Total LPC, Cer(d18:1/20:0)/Total LPC,Cer(d18:1/22:0)/LPC 18:2, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/24:1)/Total LPC, Cer(d18:1/22:0)/PC 16:0/20:4,Cer(d18:1/18:0)/PC 18:0/20:4, Cer(d18:1/24:1)/PC 18:0/20:4,Cer(d18:1/20:0)/PC 18:0/20:4, Cer(d18:1/22:0)/PC 18:0/20:4,Cer(d18:1/24:1)/Total CE, Cer(d18:1/18:0)/Total CE, and CE19:1/Cer(d18:0/22:0), and wherein the one or more lipid-lipid ratio(s)whose decrease(s) is (are) compared to the control is (are) selectedfrom: Cer(d18:0/22:0)/Cer(d18:1/22:0), Cer(d18:0/24:0)/Cer(d18:1/16:0),Cer(d18:0/24:0)/Cer(d18:1/20:0), Cer(d18:0/22:0)/Total CE,Cer(d18:0/24:1)/Total CE, CE 18:3/Cer(d18:1/24:1), CE20:3/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/20:0), CE 14:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/16:0), CE 18:3/Cer(d18:1/18:0), CE18:3/Cer(d18:1/22:0), CE 17:1/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/24:0), CE 20:4/Cer(d18:1/24:1), CE20:4/Cer(d18:1/18:0), CE 18:2/Cer(d18:1/24:1), CE 16:0/Cer(d18:1/18:0),CE 17:1/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/18:0), CE16:1/Cer(d18:1/20:0), CE 16:1/Cer(d18:1/24:1), CE 16:1/Cer(d18:1/18:0),CE 15:0/Cer(d18:1/20:0), CE 18:2/Cer(d18:1/20:0), and CE 18:3/Total Cer,or c) determining in a sample from said subject one or morelipid-clinical concentration ratio(s), wherein (an) increased ordecreased lipid-clinical concentration ratio(s) in said sample, whencompared to a control sample, is (are) indicative of said subject beingin need of treatment or a change in, or supplementation of, an alreadyadministered treatment, wherein the one or more lipid-clinicalconcentration ratio(s) whose increase(s) is (are) compared to thecontrol is (are) selected from: Cer(d18:1/16:0)/apolipoprotein A-I,Cer(d18:1/16:0)/LDL cholesterol, Cer(d18:1/16:0)/triglycerides,Cer(d18:1/18:0)/apolipoprotein B, Cer(d18:1/18:0)/HDL cholesterol,Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/total cholesterol,Cer(d18:1/18:0)/triglycerides, Cer(d18:1/20:0)/apolipoprotein B,Cer(d18:1/20:0)/HDL cholesterol, Cer(d18:1/20:0)/total cholesterol,Cer(d18:1/20:0)/triglycerides, Cer(d18:1/20:0)/total-c/HDL-c,Cer(d18:1/20:0)/LDL cholesterol, Cer(d18:1/22:0)/apolipoprotein A-I,Cer(d18:1/22:0)/apolipoprotein B, Cer(d18:1/22:0)/LDL cholesterol,Cer(d18:1/22:0)/triglycerides, Cer(d18:1/22:0)/total cholesterol,Cer(d18:1/24:0)/apolipoprotein A-I, Cer(d18:1/24:0)/apolipoprotein B,Cer(d18:1/24:0)/LDL cholesterol, Cer(d18:1/24:0)/total cholesterol,Cer(d18:1/24:1)/HDL cholesterol, Cer(d18:1/24:1)/LDL-c/HDL-c,Cer(d18:1/24:1)/total-c/HDL-c, Cer(d18:1/24:1)/LDL cholesterol,Cer(d18:1/24:1)/total cholesterol, Cer(d18:1/24:1)/triglycerides, TotalCer/apolipoprotein B, Total Cer/LDL cholesterol, Total Cer/totalcholesterol, and Total Cer/triglycerides, and wherein the one or morelipid-clinical concentration ratio(s) whose decrease(s) is (are)compared to the control is (are) selected from:Cer(d18:0/22:0)/apolipoprotein B, Cer(d18:0/22:0)/LDL-c/HDL-c,Cer(d18:0/22:0)/total-c/HDL-c, Cer(d18:0/24:0)/HDL cholesterol,Cer(d18:0/24:0)/LDL-c/HDL-c, Cer(d18:0/24:0)/total-c/HDL-c, andCer(d18:0/24:0)/LDL cholesterol.
 30. The method of any one of claims27-29, wherein determining the lipid-lipid ratio(s) or thelipid-clinical concentration ratio(s) is done using an assay.
 31. Themethod of claim 28 or 29, wherein said treatment is a lipid modifyingtreatment.
 32. The method of claim 27 or 29, wherein a) the one or morelipid(s) whose increase in concentration is compared to the control isselected from: Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1) andCer(d18:1/26:1), b) the one or more lipid(s) whose decrease inconcentration is compared to the control is selected from:Cer(d18:0/22:0) and Cer(d18:0/24:0), c) the one or more lipid-lipidratio(s) whose increase is compared to the control is selected from:Cer(d18:1/16:0)/LPC 18:1, Cer(d18:1/18:0)/LPC 16:0, Cer(d18:1/18:0)/LPC18:1, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC 18:2,Cer(d18:1/18:0)/PC 18:0/20:4 and Cer(d18:1/24:1)/PC 18:0/20:4, d) theone or more lipid-lipid ratio(s) whose decrease is compared to thecontrol is selected from: Cer(d18:0/22:0)/Cer(d18:1/22:0),Cer(d18:0/24:0)/Cer(d18:1/16:0), Cer(d18:0/24:0)/Cer(d18:1/20:0), CE18:3/Cer(d18:1/24:1), CE 20:3/Cer(d18:1/24:1), CE 14:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/16:0), CE 18:3/Cer(d18:1/18:0), CE16:0/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/24:0), CE 20:4/Cer(d18:1/24:1),CE 20:4/Cer(d18:1/18:0), CE 18:2/Cer(d18:1/24:1), CE16:0/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/24:1)and CE 16:1/Cer(d18:1/18:0), e) the one or more lipid-clinicalconcentration ratio(s) whose increase is compared to the control isselected from: Cer(d18:1/16:0)/apolipoprotein A-I, Cer(d18:1/16:0)/LDLcholesterol, Cer(d18:1/16:0)/triglycerides,Cer(d18:1/18:0)/apolipoprotein B, Cer(d18:1/18:0)/HDL cholesterol,Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/total cholesterol,Cer(d18:1/18:0)/triglycerides, Cer(d18:1/24:0)/apolipoprotein A-I,Cer(d18:1/24:0)/apolipoprotein B, Cer(d18:1/24:0)/LDL cholesterol,Cer(d18:1/24:0)/total cholesterol, Cer(d18:1/24:1)/HDL cholesterol,Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/LDL cholesterol, Cer(d18:1/24:1)/total cholesterol andCer(d18:1/24:1)/triglycerides, f) the one or more lipid-clinicalconcentration ratio(s) whose decrease is compared to the control isselected from: Cer(d18:0/22:0)/apolipoprotein B, Cer(d18:0/24:0)/HDLcholesterol and Cer(d18:0/24:0)/LDL cholesterol.
 33. The method of anyone of claims 27-29, wherein the one or more lipids comprise at least 2,at least 3, at least 4, at least 5, at least 6, at least 7, or at least8 lipids, wherein the one or more lipid-lipid ratios comprises at least2, at least 3, at least 4, at least 5, at least 6, at least 7, or atleast 8 lipid-lipid ratios, and wherein the one or more lipid-clinicalratios comprises at least 2, at least 3, at least 4, at least 5, atleast 6, at least 7, or at least 8 lipid-clinical concentration ratios,or combinations thereof.
 34. The method of any one of claims 27-29,wherein a) the CVD is characterized by coronary artery disease,peripheral artery disease, a stroke and/or CVD death; and/or b) the CVDis atherosclerosis-induced; and/or c) the subject has atherosclerosis;or d) the subject does not have atherosclerosis.
 35. The method of anyone of claims 27-29, wherein a) the method further comprises determiningthe serum level of total cholesterol, low-density lipoproteincholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C),Apolipoprotein B (ApoB) and/or Apolipoprotein C-III (ApoC-III) in saidsample; and/or b) the subject does not have elevated serum levels of oneor more of total cholesterol, low-density lipoprotein cholesterol(LDL-C), Apolipoprotein C-III (ApoC-III) or Apolipoprotein B (ApoB), ora decreased serum level of HDL-cholesterol (HDL-C).
 36. The method ofany one of claims 27-29, wherein the subject a) is being or has beentreated with one or more statins and/or any other HMG-CoA reductaseinhibitor; or b) has not yet undergone statin therapy or therapy withany other HMG-CoA reductase inhibitor.
 37. The method of any one ofclaims 27-29, wherein the lipid-lipid ratio(s) or the lipid-clinicalconcentration ratio(s) is (are) determined by using mass spectrometry,nuclear magnetic resonance spectroscopy, fluorescence spectroscopy ordual polarisation interferometry, a high performance separation method,an immunoassay and/or with a binding moiety capable of specificallybinding the analyte.
 38. The method of any one of claims 27-29, whereinthe method is for determining a risk of said patient to develop CVDcomplications including death and myocardial infarction (MI).
 39. Themethod of claim 36, wherein the statin is selected from the groupconsisting of atorvastatin, cerivastatin, fluvastatin, fluvastatin XL,lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. 40.The method of any one of claims 27-29, wherein the subject is at risk todevelop or has suffered from one or more CVD complications.
 41. Themethod of any one of claims 27-29, wherein the control sample is from(a) CAD patient(s) or a group of CAD patients that has/have remainedfree of any major CVD complications, wherein the sample is a bloodsample, or a serum sample.
 42. The method of any one of claims 27-29,wherein the one or more CVD complication(s) is one or more of death,myocardial infarction, acute myocardial infarction, angina pectoris,transient ischemic attack, or stroke.
 43. The method of claim 42,wherein the sample is blood, serum or plasma and wherein the lipid-lipidratio(s) or the lipid-clinical concentration ratio(s) is (are)determined by using mass spectrometry.
 44. The method of claim 28,wherein: a) the one or more lipid(s) whose decrease in concentration iscompared to the control is selected from: Cer(d18:1/16:0),Cer(d18:1/18:0), Cer(d18:1/24:1) and Cer(d18:1/26:1), b) the one or morelipid(s) whose increase in concentration is compared to the control isselected from: Cer(d18:0/22:0) and Cer(d18:0/24:0), c) the one or morelipid-lipid ratio(s) whose decrease is compared to the control isselected from: Cer(d18:1/16:0)/LPC 18:1, Cer(d18:1/18:0)/LPC 16:0,Cer(d18:1/18:0)/LPC 18:1, Cer(d18:1/24:1)/LPC 18:1, Cer(d18:1/24:1)/LPC18:2, Cer(d18:1/18:0)/PC 18:0/20:4 and Cer(d18:1/24:1)/PC 18:0/20:4, d)the one or more lipid-lipid ratio(s) whose increase is compared to thecontrol is selected from: Cer(d18:0/22:0)/Cer(d18:1/22:0),Cer(d18:0/24:0)/Cer(d18:1/16:0), Cer(d18:0/24:0)/Cer(d18:1/20:0), CE18:3/Cer(d18:1/24:1), CE 20:3/Cer(d18:1/24:1), CE 14:0/Cer(d18:1/24:1),CE 18:3/Cer(d18:1/16:0), CE 18:3/Cer(d18:1/18:0), CE16:0/Cer(d18:1/24:1), CE 18:3/Cer(d18:1/24:0), CE 20:4/Cer(d18:1/24:1),CE 20:4/Cer(d18:1/18:0), CE 18:2/Cer(d18:1/24:1), CE16:0/Cer(d18:1/18:0), CE 14:0/Cer(d18:1/18:0), CE 16:1/Cer(d18:1/24:1)and CE 16:1/Cer(d18:1/18:0), e) the one or more lipid-clinicalconcentration ratio(s) whose decrease is compared to the control isselected from: Cer(d18:1/16:0)/apolipoprotein A-I, Cer(d18:1/16:0)/LDLcholesterol, Cer(d18:1/16:0)/triglycerides,Cer(d18:1/18:0)/apolipoprotein B, Cer(d18:1/18:0)/HDL cholesterol,Cer(d18:1/18:0)/total-c/HDL-c, Cer(d18:1/18:0)/total cholesterol,Cer(d18:1/18:0)/triglycerides, Cer(d18:1/24:0)/apolipoprotein A-I,Cer(d18:1/24:0)/apolipoprotein B, Cer(d18:1/24:0)/LDL cholesterol,Cer(d18:1/24:0)/total cholesterol, Cer(d18:1/24:1)/HDL cholesterol,Cer(d18:1/24:1)/LDL-c/HDL-c, Cer(d18:1/24:1)/total-c/HDL-c,Cer(d18:1/24:1)/LDL cholesterol, Cer(d18:1/24:1)/total cholesterol andCer(d18:1/24:1)/triglycerides, f) the one or more lipid-clinicalconcentration ratio(s) whose increase is compared to the control isselected from: Cer(d18:0/22:0)/apolipoprotein B, Cer(d18:0/24:0)/HDLcholesterol and Cer(d18:0/24:0)/LDL cholesterol.
 45. The method of claim28, further comprising adjusting the treatment based on the determiningstep of a), b), and/or c.
 46. The method of claim 29, further comprisingtreating the subject or changing or supplementing an alreadyadministered treatment.
 47. A method of treating or preventingcardiovascular disease (CVD) complications in a subject, the methodcomprising administering to the subject a therapeutically effective doseof a drug capable of modulating one or more of the lipidconcentration(s), lipid-lipid ratio(s) or lipid-clinical concentrationratio(s) according to claim 27, wherein prior to administering the drug,the subject is determined to be at risk to develop one or more CVDcomplications by the method according to claim
 27. 48. The method ofclaim 47, wherein the drug is a statin or any other HMG-CoA reductaseinhibitor, niacin (nicotinic acid); a cholesterol absorption inhibitor;a cholesteryl ester transfer protein (CETP) inhibitor; a bile acidssequestrant; a fibrate; or a phytosterol.
 49. The method of claim 48,wherein the statin is selected from the group consisting ofatorvastatin, cerivastatin, fluvastatin, fluvastatin XL, lovastatin,pitavastatin, pravastatin, rosuvastatin and/or simvastatin.